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ABSTRACT 
Whole exome sequencing (WES) – the targeted sequencing of the subset of the 
human genome that is protein coding – is a powerful and cost-effective new tool for 
dissecting the genetic basis of diseases and traits, some of which have proved to be 
intractable to conventional gene-discovery strategies.  
 
My PhD thesis focuses on the use of whole exome sequencing to dissect the genetic 
aetiologies of families with Mendelian forms of Parkinson’s disease and Dystonia. 
First I present a project where next generation sequencing played an important role 
in the identification of a novel Parkinson’s disease gene (VPS35). I then describe the 
use of WES in i) an autosomal dominant PD kindred, where a novel DCTN1 
mutation was identified; and show a number of examples of successes and failures of 
WES in ii) autosomal recessive Parkinson’s disease and iii) autosomal recessive 
generalised dystonia. 
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CHAPTER 1: INTRODUCTION 
1.1 Specific Aims of this Thesis 
Since 2005, next-generation DNA sequencing (NGS) platforms have become widely 
available, reducing the cost of DNA sequencing by several orders of magnitude 
relative to Sanger sequencing. The development of methods for coupling targeted 
capture and massively parallel DNA sequencing has made it possible to determine 
cost-effectively nearly all of the coding variation present in an individual human 
genome, a process termed ‘whole exome sequencing’ (WES). This technique has 
become a powerful new approach for identifying genes that underlie Mendelian 
disorders in circumstances in which conventional approaches have failed. Even 
where conventional approaches are eventually expected to succeed, for example 
autozygosity mapping, WES provides a method for accelerating discovery.  
 
My thesis is designed to study the use of next-generation sequencing technologies, 
specifically whole-exome sequencing, to try and identify the genetic aetiology of 
families with Mendelian forms of Parkinson’s disease and Dystonia in whom the 
molecular cause has not been determined.   
 
1.2 The Burden of Neurodegenerative diseases and 
Insights from Genetic Analysis 
 
Neurodegenerative diseases represent a significant burden on patients and carers, as 
well to wider society and the economy. As the elderly population increases 
worldwide, this burden is set to increase further. Although treatment options are 
already available for some conditions, these are generally of very limited 
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effectiveness and treat the symptoms rather than preventing onset. Parkinson’s 
disease (PD) is common neurodegenerative disease. It affects >2% of those over the 
age of 75 years.1 In the UK, there are over 100,000 people with the disease and with 
an aging population this is only set to increase. The annual cost in nursing home care 
for PD alone in the UK is estimated to be ~600-800 million.2 The development of new 
therapeutic approaches is therefore essential. In the past dozen years, genes have 
been identified for the familial forms of neurodegenerative disorders, including, 
Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and fronto-
temporal dementia.  
 
Identification of these genes has been important for a number of reasons. Firstly, 
much of the recent progress in our understanding of the pathogenesis of 
neurodegenerative disease has been based on genetic analysis. This is particularly 
true of Parkinson’s Disease (PD), where much of the latest advances in our 
understanding of the pathogenesis of neurodegenerative disease has been based on 
genetic analysis, identification of genes causing Mendelian forms of PD, highlight 
pathways important in the development of PD. PINK1, PARKIN, and DJ-1 map to the 
mitochondrial damage repair pathway, whilst variability at the HLA locus indicates 
that immune response also plays a role. Secondly, these discoveries have given us 
the opportunity to re-create and study the mechanisms of neurodegenerative 
diseases in cell-culture and animal models and to use the findings to point the way 
towards developing pharmacologic and biologic therapies. For example, in 
Parkinson’s disease, a LRRK2 inhibitor is in pre-clinical development for potential 
use. Thirdly, genes identified as causing Mendelian forms of neurodegenerative 
disorders, are good candidates in which genetic variability may contribute to the risk 
of developing the sporadic form of the disease in the general population, for example 
LRRK2 and SNCA in Parkinson’s disease, Lastly, one of the criticisms of trialled 
novel therapeutic agents for Alzheimer’s disease, is that they were not instituted 
early enough. Identifying cohorts of pre-symptomatic genetically defined 
individuals will be important to offer mechanistic therapies, very early in the disease 
course, and also to study such cohorts to identify biomarkers and characterise the 
earliest consequences of disease. 
 
We have DNA from many families with Mendelian neurological disorders at the 
UCL Institute of Neurology, ascertained from the highly specialised clinics at the 
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National Hospital for Neurology and Neurosurgery (NHNN), in whom the causal 
gene has not been identified, either because the families were not suitable for linkage 
analysis or autozygosity mapping has revealed very large regions of homozygosity 
not amenable to Sanger sequencing. This thesis focuses on a new technology, called 
whole-exome sequencing, which can be applied to such families in order to identify 
the molecular cause.  
 
1.3 Next Generation Sequencing Technology 
First described by Sanger in 1977,3 dideoxynucleotide sequencing of DNA has 
evolved into a large-scale production.  Using Sanger sequencing, the cost per 
reaction of DNA sequencing fell in line with Moore’s Law until January 2008, at 
which point, introduction of next-generation sequencing (NGS) resulted in a sudden 
and profound out-pacing of Moore’s law.4 NGS sets itself apart from conventional 
capillary-based sequencing, by the ability to process millions of sequence reads in 
parallel rather than 96 at a time, in a cost-effective manner.  
 
Different NGS technologies share general processing steps, as shown in figure 1.1, 
while differing in specific technical details. UCL in-house exome sequencing uses 
Illumina Truseq capture kit version 3.0 (62 Mb) and sequencing takes place on a 
HiSeq 1000 (Illumina). The first step is to prepare a “library” comprising DNA 
fragments ligated to platform specific oligonucleotide adapters. The DNA is 
fragmented, and terminal overhangs are repaired, following which there is ligation 
to platform specific oligonucleotide adapters.   
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Figure 1.1 Next generation sequencing process steps for platforms requiring clonally 
amplified templates (Illumina, Roche 454 and Life Technologies) 
         
 
Figure 1.1: Next generation sequencing process steps for platforms requiring clonally 
amplified templates (Roche 454, Illumina and life Technologies). Input DNA is 
converted to a sequencing library by fragmentation, end repair, and ligation to 
platform specific oligonucleotide adapters. Individual library fragments are clonally 
amplified by either (1) water in oil bead–based emulsion PCR (Roche 454 and Life 
Technologies) or (2) solid surface bridge amplification (Illumina). Flow cell 
sequencing of clonal templates generates luminescent or fluorescent images that are 
algorithmically processed into sequence reads. Figure adapted from Voelkerding et 
al., Journal of Molecular Diagnostics, 2010, 12: 539-551 (see reference 5) 
 
The next major step is to prepare the “library” for massively parallel sequencing. For 
the Illumina platform, adapter modified library fragments are automatically 
dispensed onto a glass slide flow cell that displays oligonucleotides complementary 
to Illumina adapter sequences.6  Illumina technology then uses a process called 
bridge amplification to generate clonal “clusters” of approximately 1000 identical 
molecules per cluster. Single-stranded, adapter-ligated fragments are bound to the 
surface of the flow cell exposed to reagents for polymerase-based extension. Priming 
occurs as the free/distal end of a ligated fragment “bridges” to a complementary 
oligo on the surface. Repeated denaturation and extension result in localised 
amplification of single molecules in “clusters”. The Illumina sequencing platform, 
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utilises a sequencing-by-synthesis approach, in which all four nucleotides are added 
simultaneously to the flow cell channels, along with DNA polymerase, for 
incorporation into the oligo-primed cluster fragments. The nucleotides carry a base-
unique fluorescent label and the 3’-OH group is chemically blocked, so that each 
incorporation is a unique event. An imaging step follows each base incorporation 
step, during which the flow cell is imaged. Subsequently, the 3’ blocking group is 
chemically removed to prepare each strand for the next incorporation. The cycle is 
repeated, one base at a time, generating a series of images each representing a single 
base extension at a specific cluster (figure 1.2).  
  
 
Above: The Illumina sequencing-by-synthesis approach. Cluster strands created by 
bridge amplification are primed and all four fluorescently labeled, 3′-OH blocked 
nucleotides are added to the flow cell with DNA polymerase. The cluster strands are 
extended by one nucleotide. Following the incorporation step, the unused 
nucleotides and DNA polymerase molecules are washed away, a scan buffer is 
added to the flow cell, and the optics system scans each lane of the flow cell by 
imaging units called tiles. Once imaging is completed, chemicals that effect cleavage 
of the fluorescent labels and the 3′-OH blocking groups are added to the flow cell, 
which prepares the cluster strands for another round of fluorescent nucleotide 
incorporation. Figure adapted from Mardis et al., Annu Rev Genomi Human Genet, 
2008, 9:387-402 (see reference 7) 
 
 
1.4 The Promise of Whole-Exome Sequencing 
Many loci for Mendelian diseases have been identified by positional cloning in the 
past 20 years.8-10 Indeed, all Mendelian forms of PD, up until 2011, were identified 
using this strategy, bar one, mutations in GBA were recognized as a risk factor for PD 
through astute clinical observation. Such approaches usually require large families, 
with affected and unaffected individuals. However, positional cloning methods are 
not suitable for all diseases. Some families may not be genetically informative, being 
small in size, and therefore not suitable for linkage, sometimes because the causal 
mutation is under negative selection, and therefore not transmitted through many 
generations, and therefore not suitable for linkage, or consanguineous families with 
very large regions of homozygosity, make Sanger-sequencing a costly, time 
consuming process. Additionally, mutations under strong negative selection, are 
likely to be de novo events, which cannot be ascertained at all by linkage analysis. Of 
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the nearly 7,000 known or suspected Mendelian disorders identified based on clinical 
features, less than half have been linked to a gene.11 
 
The introduction and widespread use of massively parallel or ‘next generation’ 
sequencing, has made it increasingly practical to generate large amounts of sequence 
data cost-effectively. However, although this has made it possible for individual 
laboratories to sequence a whole human genome, the cost and capacity required are 
still significant, and interpreting variants in the non-protein-coding portion of the 
genome, is extremely challenging. It is estimated that 85% of disease-causing 
mutations are exonic, however, it is likely that this is inflated through ascertainment 
bias, since failed protein-centric disease studies are rarely published. Nevertheless, 
since protein-coding genes constitute approximately 1% of the human genome (the 
‘exome’), and harbor the majority of disease-causing mutations, it was clear that the 
development of viable methods for exome sequencing12 would provide a powerful 
alternative to positional cloning with some notable advantages.  Firstly, because 
potentially causal variants are identified, this method can be applied in families that 
are too small to provide meaningful information using linkage, effectively allowing 
small families and even single probands to be analyzed jointly, irrespective of allelic 
heterogeneity.13 Secondly, this method can be incredibly fast, moving from well-
defined trait to mutation within weeks rather than years.  
 
1.5 Defining the Exome 
A particular challenge for applying exome sequencing has been how to define the set 
of targets that constitute the exome. Considerable uncertainty remains regarding 
which sequences of the human genome are truly protein coding. Initial exome-
capture kits used the CCDS (Consensus Coding Sequence Project) definition,14 which 
is subset of genes determined to be coding with high confidence. However, most 
currently available commercial kits now target, at a minimum, all of the Refseq 
collection of genes and an increasingly large number of hypothetical proteins. In at 
least one example, identification of a novel disease gene would have been missed, if 
the CCDS definition was not expanded to the Refseq database.15 Reflecting this, 
initial exome capture kits had a target of ~30Mb, whilst more recent kits have a 
target up ~62Mb. 
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1.6 Identifying causal alleles 
A key challenge of using exome sequencing to identify novel disease genes for 
Mendelian disorders, is how to identify disease-related alleles among the 
background of non-pathogenic polymorphisms and sequencing errors. Exome 
sequencing on average will identify 24,000 single nucleotide variants (SNVs) in 
African American samples and ~20,000 in European American samples.16  More than 
95% of these variants are already known as polymorphisms in human populations. 
~10,000 variants are non-synonymous (lead to differences in protein sequence) and 
~11,000 are synonymous. A number of variants are likely to have greater functional 
impact: 80-100 nonsense variants (premature stop codons), 40-50 splice site and 200 
inframe indels (see Table 1.1). 
 
 
 
 
 
 
 
 
 
 
Table 1.1: Mean number of coding variant per exome 
Variant Type Mean number of variants 
in African Americans 
Mean number of variants 
in European Americans 
Novel Variants 
Missense 303 192 
Nonsense 5 2 
Synonymous 209 109 
Splice 2 2 
Total 520 307 
Non-novel Variants 
Missense 10,828 9,319 
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Nonsense 98 89 
Splice 36 32 
Total 23,529 19,976 
Total Variants 
Missense 11,131 9,511 
Nonsense 103 93 
Synonymous 12,776 10,645 
Splice 38 34 
Total 24,049 20,283 
 
This table has been published elsewhere.16 This table lists the mean number of coding 
single nucleotide variants from 100 sampled African Americans and 100 European 
Americans.  
 
Strategies for finding causal alleles vary, depending of factors such as the mode of 
inheritance of a trait, the pedigree structure, whether a phenotype arises owing to 
de-novo or inherited variants; and the extent of locus heterogeneity for a trait. Such 
factors also influence the sample size needed to provide adequate power to detect 
trait-associated alleles.  
 
Exome sequencing as a method to find causal mutations has already shown 
considerable promise, particularly in very rare diseases.13, 15, 17, 18 Most of these 
studies have relied on comparisons of exonic variants found in a small number of 
unrelated or closely related affected individuals, to find rare alleles or novel alleles in 
the same gene shared among affected individuals.  
 
1.7 Filtering for Rare Variants 
Novelty of variants is assessed by filtering variants against a set of polymorphisms 
that are available in publically available databases (for example, dbSNP,19 1000 
Genome project20 and Washington Exome Server21). This approach is powerful 
because only a small fraction (2% on average) of the SNVs identified in an individual 
by exome sequencing is novel. Thus sequencing of only a modest number of affected 
individuals, then applying discrete filtering to the data, can be exceptionally 
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powerful for identifying new genes for Mendelian disorders.13  However, this 
filtering approach can be problematic for a number of reasons, publically available 
databases such as dbSNP are ‘contaminated’ with a small but appreciable number of 
pathogenic alleles (e.g. the common p.G2019S mutation in LRRK2 was present in 
dbSNP), filtering of observed alleles in a manner that is independent of their minor 
allele frequency (MAF) runs the risk of eliminating truly pathogenic alleles that are 
segregating in the general population at low but appreciable frequencies. This is 
particularly relevant for recessive disorders, in which the heterozygote state will not 
result in result in a phenotype that might otherwise exclude an individual from a 
‘control’ population.  However, analysis of rare recessive and dominant disorders in 
which one sets the maximum minor allele frequency (MAF) to 1% and 0.1% 
respectively, are still thought to be well powered.16  
 
1.8 Deleteriousness of Variants 
Further stratification of variants can be undertaken based on predictions of their 
deleteriousness. A greater weight may be given to nonsense and frameshift 
mutations, as they are predicted to result in a loss of protein function and are heavily 
enriched among disease-causal variation.15, 22 However, this class of variation is not 
unambiguously deleterious, in some cases allowing functional protein production or 
resulting in loss of a protein that is apparently not harmful.23 Alternatively, 
candidate variants can be stratified using existing biological or functional 
information about a gene: for example, a predicted role in a biological pathway or its 
interactions with genes or proteins that are known to cause a similar phenotype. 
Another approach for stratifying candidate alleles is to use quantitative estimates of 
mammalian evolution at the nucleotide level, which exploit the observation that 
regions of genes and genomes in which mutations are deleterious tend to show high 
sequence conservation as a result of purifying selection, examples of this include 
tools such as phastCONS24, phyloP and Genetic Evolutionary Rate Profiling 
(GERP).25  Several computational tools have been developed to predict the impact of 
a nonsynonymous SNV on protein function and hence distinguish pathogenic from 
neutral variants. These tools include SIFT26, Polyphen227, MutationTaster28 and 
Multivariate Analysis of Protein Polymorphism (MAPP).29  The predictions are 
mostly based on the constraints imposed on amino acid changes in different regions 
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of a protein by checking the extent of sequence conservation across species. Each 
method has an estimated 80-90% sensitivity and 70-85% specificity in distinguishing 
mutations known to be pathogenic from those well-established to have no effects.30, 31 
Particular caution will be needed in late-onset diseases and in families with 
incomplete penetrance, however, as pathogenic variants often do not score highly in 
these programs.  
 
1.9 Inheritance pattern 
The pattern of inheritance of a monogenic disorder influences both the experimental 
design (for example, the number of cases to sequence, and selection of the most 
informative cases for sequencing) and the analytical approach. In recessive disorders, 
fewer cases need to be sequenced, and filtering of variants is likely to leave fewer 
candidate variants than dominant disorders, because the genome of any given 
individuals has around 50-fold fewer genes with two, rather than one, novel protein-
altering alleles per gene. This is also supported by the greater number of genes for 
recessive disorders being identified, through exome sequencing.  
 
1.10 Use of Pedigree Information 
For Mendelian disorders, the use of pedigree information can substantially narrow 
the genomic search space for candidate causal alleles. Exactly which individuals are 
the most informative to sequence depends on the frequency of a disease-causing 
allele and the nature of the relationship between the individuals. For example, two 
first cousins share a rare allele that is identical-by-descent (that is they are inherited 
from a shared common ancestor) in approximately one-eighth of the genome. In the 
absence of mapping data, sequencing the two most distantly related individuals with 
the phenotype of interest can substantially restrict the genomic search space. When 
mapping data is available, the most efficient strategy is to sequence a pair of 
individuals whose overlapping haplotype (a combination of alleles on a single 
chromosome) produces the smallest genomic region. For consanguineous pedigrees 
in which a recessive mode of inheritance is suspected, sequencing the individual 
with the smallest region(s) of homozygosity, as determined by the genome-wide 
genotyping data, should be sufficient. Exome sequencing of parent-child trios is a 
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highly effective approach for identifying de novo coding mutations, as multiple de 
novo events occurring within a specific gene (or within a gene family or pathway) is 
an extremely unlikely event. 32  
 
1.11 How whole-exome sequencing is changing the field 
of Clinical Genetics and Neurogenetics 
Genetic diagnosis and screening.  
Many Mendelian neurological diseases, such as Parkinson’s disease, dystonia, ataxia 
and dementias are genetically heterogeneous. Current screening is often designed to 
detect mutations in common mutational hot-spots. The utilization of WES to 
sequence several genes simultaneously for a genetically heterogeneous condition is 
more cost effective and quicker than by Sanger sequencing. A recent paper showed 
the utility of WES approach in the diagnosis of Mendelian disorders. Yang et al., 
applied WES to the diagnoses of 250 unselected, consecutive patients (80% of 
patients were children with neurological phenotypes) and observed a molecular 
diagnostic yield of 25%, which is higher than the positive rates of other genetic tests 
(karyotype, chromosomal microarray and Sanger sequencing).33    
 
Expanding the phenotype associated with mutations in genes 
WES has provided researchers with a powerful tool to identify mutations in genes 
previously associated to different disease phenotype or pathology. For example 
mutations in the VCP gene, previously linked to Paget’s disease, inclusion body 
myopathy and frontotemporal dementia have been shown also to cause amyotrophic 
lateral sclerosis (ALS) in one of the first studies involving WES in neurodegenerative 
diseases.34  Of note, this group showed that VCP mutations substantially contribute 
to the cause of familial ALS, being responsible for ~2% of cases. This finding 
broadened the clinical and pathological phenotype of VCP mutations to include ALS. 
 
Recently, mutations in ATP13A2, a gene known to cause a form of dystonia-
parkinsonism (Kufor-Rakeb syndrome, KRS), were found in a family with neuronal 
ceroid lipofuscinosis (NCL).35 NCL is part of a heterogeneous group of inherited 
progressive degenerative diseases of the brain and sometimes the retina, that are 
characterized by lysosomal accumulation of auto fluorescent lipopigment. The 
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relationship between the diseases was not obvious, as the clinical features do not 
appear to overlap significantly. KRS typically presents with rigidity, bradykinesia, 
spasticity, supranuclear upgaze paresis and dementia. NCL disease varies according 
to the underlying gene defect and severity of mutation, but typically includes 
seizures, a progressive intellectual and motor deterioration, and in children but 
usually not adult onset cases, visual failure. These results indicate that broadening 
the phenotype associated with mutations provides information on the aetiological 
basis of disorders by uniting what is known about the biological underpinnings of 
apparently unrelated disorders into a single model. This finding shows that KRS is 
indeed linked to the lysosomal pathway, a pathway that was already hypothesized 
for a variety of parkinsonian phenotypes, but was not previously shown for KRS. 
 
Gene identification in Mendelian Disorders 
Large pedigrees are not available in many cases of late onset Neurogenetic disorders, 
in which older generations have died (DNA may not have been stored for all affected 
individuals) and younger generations have not yet reached the age of onset of 
disease onset. Previously, such pedigrees would have been intractable to typical gene 
mapping strategies such as linkage analysis. WES offers a technique that may be able 
to identify the causal variant in such families. One example of this is the discovery 
that recessive mutations in WDR62 are a cause of a wide spectrum of cerebral cortical 
malformations. This study was carried out in a small kindred and would not have 
been amenable to traditional gene identification techniques.18 
 
There have been a number of successes in novel gene discovery for Mendelian 
Neurogenetic conditions. Two groups used WES to identify the p.D620N mutation in 
VPS35, as a cause of autosomal dominant Parkinson’s disease,36, 37 whilst WES was 
used to identify mutations in ANO3 and GNAL as a cause of primary dystonia38, 39 
and PRRT2 as a cause of paroxysmal kinesigenic dyskinesia.40 
 
De novo mutations in Neurological disease 
De novo mutations represent the most extreme form of rare genetic variation: they 
are more deleterious, on average, than inherited variation because they have been 
subjected to less stringent evolutionary selection.41, 42 This makes these mutations 
prime candidates for causing genetic diseases that occur sporadically. Indeed, recent 
WES studies have revealed de novo germline SNVs in single genes as the major 
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cause of rare sporadic malformation syndromes such as Schinzel-Giedion 
syndrome,43 Kabuki syndrome15 and Bohring-Opitz syndrome.44 In addition, WES of 
affected and unaffected tissues has recently revealed de novo somatic SNVs as the 
cause of overgrowth syndromes such as Proteus syndrome.45 Because de novo 
mutations are not rare events collectively it is possible that they are responsible for 
an important fraction of more commonly occurring diseases through disruption of 
any one of a large number of genes. Several pilot studies recently revealed that de 
novo mutations affecting may different genes in different individuals together might 
explain a proportion of common neurodevelopmental diseases such as intellectual 
disability,46 autistic-spectrum disorders47-51 and Schizophrenia.32, 52 The realization 
that de novo mutations are potentially important in complex genetic diseases has 
major implications for our thinking about the causes, mechanisms and preventative 
strategies for these diseases.53  
 
Complex diseases 
In Alzheimer’s Disease (AD), two groups have recently identified a rare variant in 
the TREM2 gene associated with susceptibility to the disease, with a odds ratio of 
~3.54 TREM2 was first nominated as a candidate gene, following the discovery of 
homozygous TREM2 mutations as a cause of Nasu-Hakola disease, a rare recessive 
form of dementia with leukoencephalopathy and bone cysts.55 Researchers generated 
exome sequence data sets and identified the R47H variant, which associated with the 
disease in cohorts from North America and Europe. This work was confirmed by 
researchers at deCODE Genetics,56 who separately identified the R47H variant in a 
GWAS using the Icelandic population and replicated the association with AD in 
North American and European cohorts. TREM2 is an immune phagocytic receptor 
expressed in brain microglia. These studies suggest that reduced function of TREM2 
causes reduced phagocytic clearance of amyloid proteins or cellular debris and thus 
impairs a protective mechanism in the brain, assuming that the risk variants impair 
TREM2 function. 
1.12 Technical and Analytical Limitations 
The most successful reports of the identification of a novel disease gene by exome 
sequencing have relied on discrete filtering, often with the aid of mapping data. 
However, it is difficult to know how often this approach has failed, as negative 
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results are rarely reported. Failure can result for many reasons, most of which can be 
broadly considered as either technical or analytical.  
 
Technical failures 
1. Part or all, of the causative gene is not in the target definition. The probes in 
sequence capture methods are designed based on the sequence information from 
gene annotation databases such as the consensus coding sequence (CCDS) database 
and Refseq database; therefore, unknown or yet-to-annotate exons cannot be 
captured. There may also be a failure in bait design so that an exonic region is not 
captured, for example, in GC-rich regions. Selectively sequencing the exome- which 
is, to our knowledge, the most likely region of the genome to contain pathogenic 
mutations – excludes noncoding regions. The contribution of mutations in non-
coding regions to Mendelian disease has yet to be determined. For example, an 
intronic hexanucleotide repeat in C9orf72 was recently identified as the cause of 
amyotrophic lateral sclerosis and frontotemporal dementia.57, 58 It was missed using 
WES alone, as it was not part of the target definition and even deep resequencing of 
the entire region failed in the first instance. Finally, it is recognized that microRNAs, 
promotors and ultra-conserved elements may be associated with disease, but are not 
fully covered in WES capture kits. 
2. Inadequate coverage of the region that contains a causal variant. A certain minimum 
depth of coverage is required for sufficient accuracy of variant detection; that is, 
positions or regions in the genome of the individual that are different from the 
reference human genome sequence. Typically, a minimum coverage of 8-10 reads per 
base is required for high-confidence detection of a heterozygous single nucleotide 
variant. Regions with repetitive sequences are more poorly characterized, as 
repetitive sequences may have prevented inclusion of a probe, or the reads 
originating from these regions cannot easily be mapped to a single position in the 
reference genome. Additionally probes may be poorly performing in GC rich 
regions. 
3. The causal variant is covered but not accurately called. Frameshift indels in two 
individuals with Kabuki syndrome were undetected by exome sequencing, but were 
successfully identified by Sanger sequencing.15 Mutations in the MUC1 coding 
variable-number tandem repeat sequence in families with medullary cystic kidney 
disease type 1, were missed owing to poor sequence coverage because the region was 
excluded from whole-exome and regional capture probes owing to its low 
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complexity, extreme sequence composition and it was under-represented in quality-
filtered data form the whole-genome sequence, owing to its high GC content and 
homopolymer content. Additionally, exome sequencing is unable to detect structural 
variants or chromosomal rearrangements, which are believed to be important for 
Mendelian disorders. 
4. For analyses across families, true novel variants in the same gene are repeatedly 
identified but only because of the large size of the gene.  
5. False variants in a gene are called because of mismapped reads or errors in the 
alignment or systemic artefacts that are specific to the peculiarities of a production 
pipeline.  
 
Analytical failures  
1. Analytical failures will result if there is analysis across several families/cases and 
there is genetic heterogeneity, or if an individual chosen for exome sequencing is a 
phenocopy. In such cases, detailed phenotyping may aid recognition of more than 
one causal variant.15  
2. Additionally, false-positive calls are frequently observed in segmental duplications 
and processed pseudogenes. For example, repetitive regions and homologous 
sequences may mismap to the reference genome, generating false variants. This is the 
case of the glucosidase, beta, acid gene (GBA), that has a pseudogene with ~96% 
homology in the same genomic region. The existence of this similarity complicates 
the determination of the source of DNA sequenced fragments during alignment. 
Similarly, polyglutamine-type diseases are difficult to study by WES as the 
underlying defect is a repetitive sequence. 
3. Pathogenic mutations may be present in publically available ‘control’ databases, 
and may therefore be erroneously filtered out. Currently, more than 17 million SNPs 
in the human genome have been documented in dbSNP with a false positive rate of 
~15-17%.59 Using an appropriate MAF for the mode of inheritance and the curating 
of databases such as 1000 genomes and Washington exome server will help to reduce 
this type of error.   
 
Improvements in the next-generation sequencing technology and a wider definition 
of the exome will overcome some of these limitations in the future. 
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1.13 Mapping Strategies 
1.13.1 Autozygosity Mapping 
In a landmark paper in 1987, it was proposed that affected children born to 
consanguineous parents offered a powerful approach to disease gene mapping and 
identification.60  This is because in such families, there is a high probability that an 
affected individual has inherited both copies (paternal and maternal) of the mutated 
gene from a common, comparatively recent ancestor. Consequently, the 
chromosomal region surrounding the mutation is expected to be homozygous; such 
a chromosomal region is said to be ‘identical by descent’ (IBD) or ‘autozygous’. Of 
course it could be because a second, independent example of the same allele has 
entered the family at some stage (these alleles can be described as ‘identical by state’ 
IBS). Mathematically, it can be predicted that the longer the segment of 
homozygosity, the lower the probability that the markers tagging that segment have 
the same calls by chance alone.  
 
Autozygosity mapping utilizes the fact that the disease causing mutation is the same 
in affected family members and will be embedded in a region of homozygosity in an 
inbred family. Each child will have multiple homozygous tracts in the genome, but 
only the tract(s) shared by all affected children would be the presumptive location of 
disease causing mutation. Furthermore, regions could be excluded using regions of 
homozygosity (for the same alleles) in unaffected siblings. Figure 1.2 shows a large 
region of homozygosity in chromosome 19 in a patient with generalised dystonia, 
her unaffected siblings are shown to be heterozygous for this region. A homozygous 
mutation in GCDH within this large tract of homozygosity was subsequently 
identified as the cause of dystonia. The patient is described in further detail in 
chapter 6. 
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Figure 1.2: Large tract of homozygosity in chromosome 19 in a patient with a GCDH 
mutation (see chapter 6.5) 
 
 
Initially microsatellites were used for genome-wide genotyping however this was 
very time consuming. The development of high throughput genome-wide SNP 
genotyping revolutionized these projects allowing identification of regions of 
extended homozygosity with high resolution, with essentially complete genomic 
coverage and in a short amount of time. The data lends itself to immediate 
visualisation, with all tracts of disease segregating homozygosity being identified 
and all heterozygous regions/non-segregating homozygous tracts excluded, one can 
be confident that the region harboring the disease causing mutation has been 
identified making the generation of lod scores for these types of analysis effectively 
redundant.61 Furthermore, this technique allows the direct visualisation of structural 
genetic variations, such as genomic deletions or duplications.  
 
Up until recently, after the homozygous regions segregating with the disease have 
been identified, a candidate gene approach was employed. Genes within the 
homozygous regions were prioritised based on putative function, expression 
patterns and other data. Candidate genes were then Sanger-sequenced to pinpoint 
the causal mutation. Sanger sequencing of candidate genes was often the rate-
limiting step in this process. The advent of WES has allowed the process of 
autozygosity mapping to be performed in a timelier manner, particularly in families 
who are highly inbred or have few affected siblings, in both instances this would 
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result in large amounts of autozygous regions, which would not have been amenable 
to a candidate gene approach. 
 
Whether this technique identifies single or multiple regions of interest and the size of 
these regions relies on several factors; the degree of parental consanguinity, the 
number of informative family members, and the relatively stochastic nature of 
recombination. In families where affected family members exhibit a low level of 
inbreeding, or where there is a high degree of separation between affected family 
members, the size of a potential disease-segregating region is likely to be small.   
 
There are however several pitfalls in autozygosity mapping. Although unlikely, it is 
possible for an extended consanguineous family to harbor mutations in two or more 
different genes giving rise to the same phenotype, particularly when the phenotype 
is known to display genetic heterogeneity.62-68 Secondly, apparently shared 
autozygous blocks may in fact be Identical by state (IBS), which is particularly 
problematic when dealing with smaller intervals because the probability of sharing 
two haplotypes by chance is inversely correlated with their lengths. Finally, the 
number of shared autozygous blocks between different members of a given family is 
a function of the randomness of the crossing over events and their frequency. 
Although their randomness may not be predicted, the number of crossing over 
events correlates with number of meiotic events separating the patient from the 
shared parental ancestor.69  Examples of the successful utilization of autozygosity 
mapping in Mendelian forms of parkinsonism include the mapping of PLA2G670, 
SYNJ171, 72 and DNAJC6.73  
 
1.13.2 Genetic Linkage Analysis 
Linkage analysis makes use of the exception to Mendel’s Law of Independent 
Assortment which states that alleles at different genetic loci assort at random during 
meiosis; homologous chromosomes cross over and exchange genetic material during 
recombination, such that 50% of chromosomes will be recombinant, and 50% non-
recombinant for these loci. Loci in close physical proximity on the same 
chromosome, however, tend to be inherited together and are said to be linked and 
alleles on the same small chromosomal segment tend to be transmitted as a block 
through a pedigree as a haplotype. Haplotypes mark chromosomal segments, which 
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can be tracked through pedigrees and through populations. Hence during a genome 
wide search, when DNA markers (with a known location) on the human genetic 
map, co-segregate with the disease (only affected subjects in a pedigree), linkage 
exists, and the DNA marker lies in close proximity to the disease gene.  
 
The proportion of offspring in which two parental alleles are separated by 
recombination is the recombination fraction (θ). Θ is the probability that a parent will 
produce a recombinant offspring. The recombination fraction varies from 0 (for 
adjacent loci) to 0.5 (for distant loci) and may serve as a measure of the distance 
between the loci. For closely linked loci (where θ <0.05-0.1), it is reasonable to assume 
that the probability of more than one recombination occurring between the loci is 
small. In these circumstances the recombination fraction is equal to the genetic map 
distance between the loci, thus two loci showing recombination in 1% of meiosis (θ 
=0.01) are approximately 1 cM apart. Small values of θ are equivalent to the actual 
map distance (w) between loci, and thus recombination fractions are additive over 
small distances. The simplest case relating θ to w occurs when it can be assumed that 
multiple crossovers between two loci do not occur when the distance is very small, 
then θ=w.  
 
Genetic mapping using linkage analysis has essential requirements including 
monogenic mode of inheritance that can be established by segregation analysis, 
correct phenotypic designation of affected and unaffected status. The LOD score 
method, 74 a maximum likelihood analysis, calculates the probability that two loci are 
linked, expressed as a LOD score, which is log10 of the odds ratio favouring linkage. 
Convention dictates that a LOD score >3, which indicates a probability in favour of 
linkage of 1000 to 1, is enough to establish linkage, and conversely a LOD score of -2 
indicating a probability against linkage of 100 to 1 excludes linkage between the two 
loci being tested. Parametric LOD score analysis requires a precise genetic model, 
detailing the mode of inheritance, gene frequencies and penetrance of each genotype. 
The LOD score is calculated for various values of the recombination fraction (θ) 
using computer programs such as Merlin, to obtain the value of θ associated with the 
highest LOD score. This provides an estimate of the genetic distance between the two 
loci studied. Genetic studies of ‘complex traits’ such as PD and Dystonia face 
difficulties arising from uncertainties in diagnosis, disease definition and lack of 
understanding of genetic transmission. In addition in Mendelian disease, especially 
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with autosomal dominant inheritance, linkage analysis can be impaired by 
incomplete penetrance, variable phenotypic expression, genetic heterogeneity, and 
phenocopies.  
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1.14 Genetics of Selected Movement Disorders 
 
1.14.1 Parkinson’s Disease 
Over the last 25 years, genetic findings have profoundly changed our views on the 
aetiology of Parkinson’s disease (PD). Prior to the identification of the α-synuclein 
(SNCA) locus, epidemiologic studies consistently suggested that genes were 
unimportant in disease aetiology. To date, mutations in over 10 genes have been 
shown to cause monogenic forms of PD. Genome-wide association studies (GWAS) 
have provided convincing evidence that low-penetrance variants in at least some of 
these, but also in several other genes, play a direct role in the aetiology of the 
common sporadic form of the disease as well. In addition, rare variants with 
intermediate-effect strengths have been identified as important risk factors. Thus, an 
increasingly complex network of genes contributing in different ways to disease risk 
and progression is emerging. Functional work modeling PD disease-causing 
mutations in cell and animal models has greatly advanced our understanding of PD 
pathogenesis. 
 
Idiopathic PD 
The term parkinsonism defines the combination of two or more of four cardinal 
motor signs: bradykinesia, resting tremor, muscular rigidity, and postural 
instability.75-77 Parkinson’s disease is the most common cause of parkinsonism. The 
modified Queen Square Brain Bank criteria are the most frequently used diagnostic 
criteria, which rely on the presence of three cardinal signs (bradykinesia, rigidity, 
and rest tremor), responsiveness to dopaminergic therapy, and the absence of 
exclusion criteria, which if present, usually mean the diagnosis is that of Parkinson-
plus syndrome or parkinsonism.78 A constellation of non-motor symptoms often 
precede or accompany these features.   
 
The pathological hallmark of PD is a region-specific selective loss of dopaminergic, 
neuromelanin-containing neurons from the pars compacta of the substantia nigra. 
This nerve cell loss is accompanied by three distinctive intraneuronal inclusions: the 
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Lewy body, the pale body, and the Lewy neurite. An abnormal, post-translationally 
modified, and aggregated form of the presynaptic protein, α-synuclein, is the main 
component of Lewy Bodies.79  
 
Idiopathic PD is a common neurodegenerative disease, affecting >2% of those over 
75 years.1 The aetiology of PD is incompletely understood. Similar to other 
neurodegenerative diseases, ageing is the major risk factor. There is a negative 
association between PD and smoking, which is not accounted for by smokers dying 
younger, and therefore being less likely to develop a condition that is more common 
in old age.80 Weak associations between PD and head injury, rural living, middle-age 
obesity, lack of exercise, well-water ingestion, and herbicide and insecticide exposure 
(paraquat, organophosphates, and rotenone) have also been reported.81, 82 
Environmental toxins (e.g. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine MPTP, 
cyanine, carbon disulphide, and toluene) can produce a similar but not identical 
clinical picture.83 
 
Twin studies have been used to estimate the genetic contribution to the pathogenesis 
and several of them showed low concordance rates in monozygotic and dizygotic 
twins.84-86 A major criticism of these studies was that the cross‐ sectional study 
designs used did not exclude the possibility of a later disease onset in unaffected 
siblings. This obstacle has been overcome by using positron emission tomography 
studies (PET), which is sufficiently sensitive to identify pre‐ symptomatic subjects by 
detecting decreased striatal (18F)6‐ fluorodopa as a metric for decreased striatonigral 
dopaminergic function.87, 88 Based on PET scan data, the concordance rate was 
significantly higher for monozygotic twins, than for dizygotic twins (55% versus 
18%), suggesting a substantial genetic contribution to the PD pathogenesis.88  
 
Mendelian Parkinson’s disease and Parkinsonism 
Parkinson’s disease occurs as a sporadic disorder the vast majority of patients. 
However in approximately 5%-10% of cases, the disease occurs as a Mendelian 
disorder. As genes were identified to cause monogenic forms of PD, they were 
assigned PARK loci and numbered in chronological order of their identification. 
However, the PARK loci not only contain genes which cause monogenic forms of PD, 
but also loci identified from genome-wide linkage screens, some of which have not 
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been replicated in subsequent studies. To date, 18 PD-associated loci (PARK1-18) 
have been described (Table 1.2).  
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Table 1.2. PARK-designated Loci 
Symbol Locus Features Inheritance Gene Remarks 
PARK1* 4q21-22 Parkinsonism, dementia, autonomic dysfunction AD SNCA (Missense & 
Multiplications) 
 
PARK2 6q25.2-q27 Juvenile- or young-onset parkinsonism, often with foot dystonia, slow 
progression, good response to L-dopa 
AR Parkin  
PARK5 4p13 Classical PD AD UCHL1 Unconfirmed 
PARK6 1p35-p36 early‐ onset parkinsonism, hyperreflexia, dystonia, slow progression AR PINK1  
PARK7 1p36 early‐ onset parkinsonism, psychiatric features, slow progression AR DJ-1  
PARK8 12q12 mid-late onset parkinsonism, good response to L-dopa AD LRRK2  
PARK9 1p36 Causes Kufor-Rakeb syndrome; juvenile-onset parkinsonism, spasticity, 
hallucinations, dementia, supranuclear gaze, paraparesis 
AR ATP13A2  
PARK13 2p12 L-dopa responsive Parkinson’s disease AD or risk factor HTRA2 Unconfirmed 
PARK14 22q13.1 L‐ dopa responsive dystonia-parkinsonism AR PLA2G6  
PARK15 22q12-13 Early-onset parkinsonian-pyramidal syndrome AR FBX07  
PARK17 16q11.2 mid-late onset parkinsonism, good response to L-dopa AD VPS35  
PARK18 3q27.1 mid-late onset parkinsonism, good response to L-dopa AD EIF4G1 Unconfirmed 
*PARK4 is an erroneous locus, the family was subsequently proven to have a SNCA triplication (i.e. PARK1), AD, autosomal dominant; 
AR, autosomal recessive 
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Autosomal Dominant Parkinson’s Disease Genes/Loci 
 
Alpha synuclein, SNCA Mutations (PARK1) 
In 1996, the mapping and subsequent identification of the first mutations 
responsible for PD indisputably showed that PD may be hereditary.89, 90 The locus 
was mapped to chromosome 4q21-q22 in 1996, in an Italian-American kindred 
originating from Contursi, near Salerno in Southern Italy. This is the largest PD 
kindred characterized to date, with at least sixty affected members spanning four 
generations. A G>A transition at position 209 in exon 4 of the SNCA gene, 
resulting in an alanine to threonine substitution (p.Ala53Thr) was subsequently 
identified as the causative mutation in this kindred.  Overall, point mutations in 
SNCA are rare, two other mutations p.A30P and p.E46K have been identified, in 
one family each.91, 92 
 
Patients with SNCA missense mutations usually have early-onset PD (EOPD, age 
of onset <45 years), with an initially good response to levodopa treatment. 
However, the disease has a rapid progression and may be complicated by 
dementia or rarer features such as central hypoventilation and myoclonus.93 Post-
mortem studies in such patients show the presence of Lewy bodies, with spread 
through the substantia nigra, locus ceruleus, hypothalamus, and cerebral cortex.89  
 
Recently, two additional SNCA point mutations (p.H50Q and p.G51D) have been 
identified. The p.H50Q mutation was reported in two patients of British ancestry, 
both had levodopa responsive, late-onset PD associated with cognitive 
impairment. In one case, there was no family history of the disease.94, 95 The 
p.G51D SNCA mutation has been reported in association with a parkinsonian-
pyramidal phenotype, with early-onset, moderate response to levodopa and 
rapid progression leading to death within a few years of onset.96 
 
Further important insights into the link between SNCA and PD came from the 
discovery of gene multiplications. A triplication of the entire locus containing the 
SNCA gene was identified as a cause of autosomal dominant PD in a family.97 
This finding proved that not only structurally altered α-synuclein, but even the 
wild-type α-synuclein is pathogenic, if overexpressed. Additional families with 
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SNCA triplications and duplications, are described.98  A dose dependence of the 
pathogenic effect has been observed: SNCA duplications lead to late-onset dopa-
responsive parkinsonism resembling typical PD, whereas triplications cause 
earlier disease onset with more severe disease with dementia, rapid progression 
sometimes with additional features such as autonomic instability.99  Penetrance 
of the missense mutations appears to be high (as high as 85% for the p.A53T 
mutation).89 Data from rare kindred’s with SNCA triplications suggests they are 
fully penetrant,100 whereas SNCA duplications are not. 101, 102  
 
The identification of the first SNCA mutations soon led to the discovery that the 
encoded protein (aSYN) is the major fibrillar component of Lewy bodies and 
Lewy neurites,103 the protein aggregates that had long been recognized as the 
pathological hallmark in familial as well as sporadic cases of the disease. The 
SNCA gene has six exons encoding an abundant 140-amino acid cytosolic protein, 
α-synuclein, which is natively unfolded, once bound to phospholipid 
membranes, through its amino-terminal repeats, it adopts structures rich in α-
helical character. All three SNCA missense mutations impair the amino-terminal 
domain, and tend to produce mutant protein, which forms stable β-sheets, and 
thus exacerbate the formation of toxic oligomers, protofibrils, and fibrils.104  
Therefore, it is believed that the missense SNCA mutations cause PD through a 
toxic gain of function, and Lewy bodies may represent the attempt to purge the 
cell of toxic damaged α-synuclein.105  Wild-type α-synuclein is selectively 
translocated into lysosomes for degradation,106 and inhibitors of the lysosomal 
enzyme β-glucocerebrosidase, mutations in which represent a recognized risk 
factor for PD, modulate α-synuclein levels.107  
 
Multiple genome-wide association studies have established that variation at the 
SNCA locus is the most significant genetic risk factor for sporadic PD.108, 109 A 
meta-analysis of this data has found further association 5’ of SNCA, suggesting 
variation in promotor/enhancer regions may modulate expression of SNCA.110 
 
Leucine-rich repeat kinase 2, LRRK2 Mutations (PARK8) 
Mutations in the LRRK2 gene are the most frequent known cause of late-onset 
autosomal dominant and sporadic PD, with a mutation frequency ranging from 
2% to 40% in different populations.111-113 The clinical presentation of most 
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patients with LRRK2 mutations is that of late-onset asymmetric levodopa-
responsive tremor predominant PD, that is clinically indistinguishable from 
idiopathic PD.114, 115 However, early onset and atypical features such as 
autonomic dysfunction, motor neuron disease and choreoathetosis and 
pyramidal tract signs are reported.116, 117,118, 119 
 
 
LRRK2 is a large gene that consists of 51 exons. It encodes the 2527-amino acid 
cytoplasmic protein leucine-rich repeat kinase 2 (LRRK2) that consists of a 
leucine-rich repeat toward the amino terminus of the protein and a kinase 
domain toward the carboxyl terminus with various conserved domains in-
between.120  There are more than 100 LRRK2 variants have been reported in 
association with PD (http://www.molgen.vib-ua.be/PDMutDB),120, 121 however 
of these only 7 are unequivocally pathogenic based on co-segregation with 
disease in families and absence in controls: p.R1441G,122 p.R1441C,118 
p.R1441H,123 p.Y1699C,118, 122 p.G2019S,124, 125 p.I2020T,118 and p.N1437H.126  
Several pathogenic LRRK2 mutations cluster in functionally important domains 
and have been shown to alter their function: p.R1441C, p.R1441G and p.R1441H 
reduce the proteins GTPase activity, whilst the p.G2019S and p.I2020T mutations 
in the kinase domain have been shown to increase its activity and are thus a 
highly attractive therapeutic target (see 127  for review).  
 
LRRK2 mutations are found in ~10% of autosomal dominant PD kindreds.114 By 
far the most frequent and best-studied mutation is c.6055G>A (p.G2019S) that 
accounts for as many as 40% of cases of PD in Arab descent,112 about 20% of 
Ashkenazi Jewish patients113 and 1-7% of PD patients of European origin128, 129. 
Owing to a founder effect, the p.R1441G is very frequent in Basques130 and 
p.I2020T in Japanese patients.131 An incomplete, age-related penetrance (ranging 
from approximately 30%-70% by the age of 80 years in different studies) has been 
estimated for the G2019S mutation.115, 132-134 
 
Patients with LRRK2 mutations show pleiomorphic pathologies, which overlap 
with other neurodegenerative diseases. The commonest pathology is Lewy 
bodies with dopaminergic cell loss and gliosis in the substantia nigra. However, a 
minority of cases demonstrate nigral loss without Lewy bodies,118, 135-138 whilst 
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others cases have been reported with neurofibrillary tangle pathology,139 glial 
cytoplasmic inclusions similar to those seen in MSA140 and some with anterior 
horn cell degeneration associated with axonal spheroids.118  
 
A variety of functions and mechanisms have been ascribed to LRRK2 including 
neurite outgrowth,141 protein translation through regulation of microRNA 
processing142 and vesicle storage and mobilization within the recycling pool.143 
The physiological and pathological functions of LRRK2 have not yet been fully 
characterized.  
 
 
Vacuolar protein sorting-35, VPS35 Mutations (PARK17) 
Mutations in VPS35 as a cause of familial PD were identified by exome 
sequencing by 2 independent groups, demonstrating the utility of this 
technique.36, 37 To date, only 1 pathogenic mutation has been identified: p.D620N 
and it accounts for ~1% of familial PD cases, across several populations.144, 145 146, 
147  To-date the clinical phenotype associated with VPS35 mutations closely 
resembles that of idiopathic PD. Reduced penetrance has been observed.146, 147 
Dementia although reported is not a prominent feature of presentation, the age of 
onset varies with some patients presenting with early onset PD.144, 146, 147  So far, 
very little is known about the specific role of VPS35 in PD, except that is a highly-
conserved component of the retromer, a heteromeric complex that mediates 
retrograde transport of the transmembrane cargo from endosomes back to the 
trans-Golgi network.148, 149  The pathology associated with mutations in VPS35 
has not been reported. 
 
Ubiquitin carboxyl-terminal hydrolase L1, UCH-L1 Mutations (PARK5) 
Using a candidate gene approach, Leroy et al. described a small German 
autosomal dominant PD kindred, with a disease‐ segregating missense mutation 
(p.I93M) in ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1). Subsequent 
replication efforts have failed to confirm UCH-L1 as a disease‐ causing gene in 
familial PD.150, 151 The small size of the original family and the lack of replication 
indicate that this UCH-L1 mutation is either a rare cause of PD or is not a 
disease‐ causing mutation.  
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Eukaryotic translation initiation factor 4 gamma 1, EIF4G Mutations (PARK18) 
Mutations in EIF4G were described in a French family with autosomal dominant 
PD and Lewy body pathology. Linkage analysis showed a lod score of 3.01 for a 
region on 3q26-q28, a mutation in EIF4G was the only novel variant segregating 
in 10 affected family members. Several other variants in EIF4G were identified in 
other individuals with PD, but none came from large enough families to 
demonstrate segregation.152 However, subsequent studies have not been able to 
convincingly replicate the association of autosomal dominant PD and EIF4G 
mutations, additionally, reportedly pathogenic variants have been identified in 
controls.153-157 EIF4G is the core scaffold of a multisubunit translation initiation 
complex that regulates the translation initiation of mRNAs encoding 
mitochondrial, cell survival and growth genes in response to different stresses.158, 
159  
 
Dynactin 1, DCTN1  
Mutations in DCTN1 cause Perry Syndrome, an autosomal dominant, rapidly 
progressive form of parkinsonism associated with depression, weight loss and 
hypoventilation. Dynactin is a multisubunit protein complex that is required for 
most, if not all, long-distance trafficking of protein complexes and membrane 
organelles.  All reported mutations cluster in exon 2, the P150glued highly 
conserved N-terminal cytoskeleton-associated protein, glycine-rich (CAP-Gly) 
domain, which serves as a parking brake of the dynein motor. It is a very rare 
cause of familial parkinsonism with only 6 missense mutations reported (p.G67D, 
p.G71A/E/R, p.T72P, and p.Q74P) reported in 12 families worldwide.160-171 
Histology shows severe neuronal loss in the substantia nigra without Lewy 
bodies and a unique distribution of TDP-43-positive pathology in neurons and 
glial cells in a pallidonigral distribution.172    
 
 
Autosomal Recessive Parkinson’s Disease: Genes and Loci 
Parkin Mutations (PARK2) 
Autosomal recessive early-onset PD with linkage to chromosome 6q was first 
recognized in Japanese families and subsequently mutations in parkin were 
identified by positional cloning.173, 174 The disease usually starts in the third or 
fourth decade of the patient’s life, and is usually slowly progressive with an 
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excellent response to dopaminergic treatment. However, some Parkin-mutation 
carriers have onset in childhood, and homozygous Parkin mutations are the most 
frequent cause of juvenile PD (age of onset <21years). Reported post-mortem 
examinations indicate that the substantia nigra shows neuronal loss and gliosis, 
however, it is frequently lacking Lewy bodies.175, 176 Mutations in parkin explain 
up to 50% of cases with a clinical diagnosis of familial PD compatible with 
recessive inheritance and disease onset before the age of 45 years, and also ~15% 
of sporadic cases with onset before 45 years.177  The Parkin protein functions as 
an E3 ubiquitin ligase in the process of ubiquitination, a form of posttranslational 
modification that conjugates ubiquitin proteins(s) to lysine residue(s) of target 
proteins, which in turn, determines their cellular fate. Disturbed elimination of 
damaged mitochondria, which is an important cellular process called mitophagy, 
appears to be one of the most important mechanisms for neuronal death in 
parkin deficiency. Parkin and PINK1 (see below) appear to act together in this 
pathway178, 179. Parkin is recruited to damaged mitochondria, characterized by 
their low membrane potential and mediates the engulfment of mitochondria by 
autophagosomes, leading to their elimination.180 Intact PINK1 seems to be 
necessary for this translocation of parkin.180 
 
Phosphatase and tensin homolog (PTEN)-induced putative kinase 1, PINK1, 
(PARK6) 
Mutations in PINK1 are the second commonest cause of autosomal recessive 
early onset PD. The frequency of PINK1 mutations is in the range of 1-9%, with 
considerable variation across difference ethnic groups.181-184 An exception is in the 
Philippines, where one founder mutation has a high carrier frequency.184 
Interestingly, in contrast to Parkin, the majority of PINK1 mutations reported are 
either missense or nonsense mutations, and to date only families with whole-
exon deletions have been reported.185-187 The pathology of PINK1-linked PD has 
been reported in a single patient and was characterized by neuronal loss in the 
substantia nigra pars compacta, Lewy bodies and sparing of the locus ceruleus.188 
PINK1 is a 581 amino acid ubiquitously expressed protein kinase. It consists of an 
amino-terminal 34 amino acid mitochondrial targeting motif, a conserved serine-
theonine kinase domain (amino acids 156-509; exons 2-8), and a carboxy-terminal 
autoregulatory domain. Two-thirds of the reported mutations in PINK1 are loss-
of-function mutations affected the kinase domain, demonstrating the importance 
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of PINK1’s enzymatic activity in the pathogenesis of PD. PINK1 and Parkin 
function in a common pathway for sensing and selectively eliminating damaged 
mitochondria from the mitochondrial network. PINK1 is stabilized on 
mitochondria with lower membrane potential and recruits Parkin from the 
cytosol. Once recruited to mitochondria, Parkin becomes enzymatically active 
and initiates the autophagic clearance of mitochondria by lysosomes. i.e., 
mitophagy.189 
 
Oncogene DJ-1, DJ-1 Mutations (PARK7) 
DJ-1 is the third gene associated with autosomal recessive PD, and it is mutated 
in about 1-2% of EOPD cases.190 About 10 different point mutations and exonic 
deletions have been described, in both the compound heterozygous and 
homozygous state. The seven coding exons of the DJ-1 gene code for a 189-amino 
acid-long protein that is ubiquitously expressed and functions as a cellular sensor 
of oxidative stress. 191, 192 The DJ-1 protein forms a dimeric structure under 
physiological conditions,193 and some of the pathogenic missense mutations, 
particularly p.L166P prevent dimerization and lead to the degradation of 
protein.194  No neuropathological examination of a patient with a homozygous 
pathogenic DJ-1 mutation has been reported, and so it is not clear whether this is 
a Lewy body disorder. One possible hint that the disease caused by DJ-1 
mutations is not a Lewy body disease is the fact that, in patients with DJ-1 related 
PD (as with Parkin-related PD) there is no olfactory involvement.  Atypical 
phenotypes have been reported, including one family with early-onset 
parkinsonism, dementia and amyotrophic lateral sclerosis.195  
 
 
Complex forms of Autosomal Recessive Parkinsonism 
 
ATPase 13A2, ATP13A2 Mutations (PARK9) 
ATP13A2 mutations underlie the autosomal recessive neurodegenerative 
disorder Kufor-Rakeb syndrome, a rare, juvenile-onset disorder characterized by 
parkinsonism, dementia, pyramidal tract signs, myoclonus and supranuclear 
gaze palsy.196 Brain imaging often reveals moderate cerebral and cerebellar 
atrophy sometimes with iron deposition in the basal ganglia.197  ATP13A2 is a 
large gene, comprised of 29 exons coding for an 1180-amino acid protein. The 
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ATP13A2 protein is normally located in the lysosomal membrane and has 10 
transmembrane domains and an ATPase domain.196 Most mutations produce 
truncated proteins that are unstable and are retained in the endoplasmic 
reticulum and subsequently degraded by the proteasome. No disease causing 
copy number variants have been described. Mutations in ATP13A2 are likely to 
have a role in lysosomal degradation based on the putative gene function, sural 
nerve pathology and the recent identification of a homozygous ATP13A2 
mutation in a kindred with a clinical and pathological diagnosis of Neuronal 
Ceroid Lipofuscinosis (NCL)35 and that ATP13A2 mutations cause a form of 
canine NCL.198, 199  
 
F-box only protein, FBXO7, (PARK15) 
Mutations in FBXO7 present with juvenile-onset, severe levodopa-responsive 
parkinsonism and pyramidal signs.200  The pathological features of this condition 
are not currently known. Recently, FBXO7 was shown to act in a common 
pathway with Parkin and PINK1 to induce mitophagy in response to 
mitochondrial depolarisation and that disease-associated mutations in FBXO7 
interfere with this pathway.201 
 
Phospholipase A2, group VI (cytosolic, calcium-independent), PLA2G6 
Mutations (PARK14) 
Recessive mutations in the phospholipase A2, group VI (PLA2G6) gene were 
initially described in as the cause of infantile neuroaxonal dystrophy and 
neurodegeneration associated with brain iron accumulation. However, PLA2G6 
mutations were later identified in patients with a different phenotype, consisting 
of dystonia predominant parkinsonism often accompanied by cognitive decline, 
eyelid opening apraxia, and supranuclear gaze palsy.70 Brain MRI may show iron 
accumulation in the globus pallidus, substantia nigra and/or striatum.  
Pathologically, both early infantile and late onset PLA2G6 is characterized by 
Lewy bodies and synuclein-positive dystrophic neuritis in the substantia nigra 
and cortex as well as tau immunoreactive cortical neurofibrillary tangles.202 
 
Synaptojanin 1, SYNJ1 
A homozygous mutation in SYNJ1 (p.R258Q) was recently identified by exome 
sequencing, in two unrelated consanguineous kindred’s, as a cause of a complex 
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autosomal recessive parkinsonian syndrome.71, 72 The clinical phenotype includes 
early-onset, rapidly progressive parkinsonism with severe levodopa-induced 
dystonia. Additional features may be present, including: generalized seizures, 
cognitive decline, dysarthria, eyelid apraxia and supranuclear gaze palsy. Brain 
MRI demonstrated diffuse cortical atrophy with T2 hyperintensities. 
Synaptojanin 1 is a phosphoinositide phosphatase protein involved in clathrin-
mediated endocytosis in the adult brain.203  
 
Auxilin, DNAJC6 
Recently, two recessive pathogenic mutations (splicing mutation c.801 -2 A>G 
and p.Q734X) have been reported in DNAJC6 in association with juvenile onset 
parkinsonism with rapid progression to dependence 10-15 years after onset. In 
one family the parkinsonism was not levodopa responsive. Associated features, 
which may be present, include dysarthria, generalised seizures and brain atrophy 
on MRI.73, 204  DNAJC6 encodes auxilin, which is a clathrin-associated protein 
enriched in nerve terminals and may play a role in synaptic vesicle recycling.205  
 
 
Identification of further multiplex kindreds with DNAJC6 and SYNJ1 mutations 
will confirm these as PD genes. 
 
High Risk Susceptibility Loci for PD 
Glucocerebrosidase, GBA 
The astute clinical observation that patients and relatives of patients with 
Gaucher’s disease, seem to present with PD more often than expected, led to 
studies which confirmed mutations in GBA are a risk factor for PD.206-210 The odds 
ratio for developing PD with a single GBA mutation is estimated to be 5.4 (largely 
reflecting the common N370S mutation), with mutations in 15% of Ashkenazi 
Jewish patients and 3% of non-Ashkenazi Jewish patients, compared to 3% and 
<1% of matched controls.211 Recently, mutations in GBA have also been 
confirmed as a significant risk factor for dementia with Lewy bodies (estimated 
odds ratio of 8.28) and PD with dementia (estimated odds ratio 6.48), confirming 
that PD, PD-dementia and Lewy body dementia form a continuum within the 
spectrum of Lewy body diseases.212 Evidence suggests that impairment of the 
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aging lysosome, enhanced by deficient or mutant glucocerebrosidase, can affect 
α-synuclein degradation.213  Functional loss of glucocerebrosidase causes 
accumulation and aggregation of α-synuclein, which in turn inhibits the 
trafficking and lysosomal activity of glucocerebrosidase leading to a self-
propagating disease.214 
 
Genome Wide Association Study (GWAS) identified Risk Factors For PD 
Candidate gene association studies have been used to try and find loci in which 
common variability contributes to the risk of disease. Out of such studies genetic 
variability at the SNCA,215 and the MAPT (microtubule-associated protein tau) 
locus,216 were shown to contribute to the risk of disease. Over the last few years, 
there has been a revolution in the power of association studies through the 
development of platforms that allow the assessment of genetic variability on the 
order of 500,000 to 1 million variants (usually single-nucleotide polymorphisms) 
across the genome with the disease.217 These analyses have consistently 
confirmed association of SNCA and MAPT. 109, 110, 218-220 Additional loci have been 
more recently identified and replicated, including: HLA-DRB5, BST1, LRRK2, 
GAK.108-110, 218, 220-222 Imputation and a recent meta-analysis identified ten new loci, 
the nearest gene to these loci being ACMSD, MCCC1/LAMP3, SYT11, and 
CCDC62/HIP1R222 and PARK16/1q32, STX1B, FGF20, STBD1, and GPNMB.223  
 
Variability in both in the promotor and 3’ end of SNCA are the most consistently 
reported associations with PD. The REP1 microsatellite in SNCA, located ~10Kb 
upstream of the translational start of SNCA, has been linked to PD, and its 
pathological effect has been suggested to be mediated by gene expression. 
Interestingly, it is in linkage disequilibrium with PD associated 3’ 
polymorphisms ascertained using GWAS studies. This supports the notion that 
rare familial disease is aetiologically related to typical sporadic PD and suggests 
that genes that contain common risk variants are excellent candidates to also 
contain rare disease-causing mutations. It is more surprising that genetic 
variability in the MAPT locus, is associated with PD. Predictably, a number of 
tauopathies are associated with common or rare variants in MAPT, including 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and 
frontotemporal dementia with parkinsonism linked to chromosome 17.224-226  
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MAPT is part of a large conserved region on the long arm of chromosome 17.  
Two main extended haplotypes (H1 and H2) that diverged about 3 million years 
ago and stretch about 900kb in size have been described at this locus. These two 
haplotypes are inverted relative to each other and do not recombine.227, 228 The H1 
haplotype, confers risk with an odds ratio (OR) of 1.5. It is most likely that 
variants in MAPT act to increase expression.222 A recent analysis, using only 
neuropathologically proven PD, shows that the MAPT association is not a result 
of unrecognized contamination of PD case cohorts with PSP.229 
 
Currently known PD risk alleles each confer only a ~1.3 fold increase in risk. 
Even when considering cumulative risk burden for those in the highest quintile 
of disease risk versus the lowest quintile, the odds ratio is estimated to be 2.5.222 
 
1.14.2 Genetics of Dystonia 
The dystonias are a heterogeneous group of hyperkinetic movement disorders, 
characterized by involuntary sustained muscle contractions that lead to abnormal 
postures of the affected body part.  Three basic parallel approaches are used to 
classify dystonia: age of onset, distribution of affected body parts, and cause. 
Clinically the most useful way to categorize dystonia is by aetiology: 
 Primary Dystonia: dystonia +/- tremor without a secondary cause and no 
neurodegeneration 
 Dystonia-plus syndromes: dystonia occurs with other clinical signs, 
however there is no secondary cause or neurodegeneration 
 Secondary Dystonia: results from a secondary cause e.g. brain injury 
 Heredo-degenerative dystonia: dystonia occurs in the context of a wider 
neurodegenerative syndrome 
 Paroxysmal Dystonia: episodic attacks of dystonia 
 Psychogenic Dystonia 
 
The pathogenesis of primary dystonia is poorly understood, although family 
studies have led to the identification of 14 disease genes, no association studies 
for dystonia have been published. 
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Primary Torsion Dystonia 
TOR1A Mutations (DYT1) 
A 3bp (CAG) deletion in exon 5 of the TOR1A gene, is a major cause of early 
onset, generalized dystonia. The delGAG mutation removes glutamic acid form 
the C-terminal region of the encoded protein, torsin A. Two further pathogenic 
variants have been described: an 18bp deletion,230 and a 4bp deletion.231 DYT1 
dystonia is inherited in an autosomal dominant fashion, but has a markedly 
reduced penetrance: of 30%.232  The delGAG mutation is present across 
ethnicities, however, because of a founder mutation, it accounts for 80% of early 
onset dystonia in the Ashkenazi Jewish population. Penetrance is lower (~3%) in 
those with histidine at amino acid 216 of torsin A, suggesting that this single 
nucleotide polymorphism acts as a genetic modifier of DYT1.233 Torsin A is a 
member of the AAA+ superfamily (ATPases associated with a variety of cellular 
activities). This family of proteins has many functions that are critical to 
assembly, disassembly, and operation of protein complexes. Torsin A is widely 
distributed in the brain; it is restricted to neurons, and normally associated with 
the endoplasmic reticulum (ER). In cellular models, mutated torsin A relocates 
from the ER to the nuclear envelope.234 Its aberrant localization and interactions 
may result in stress-induced abnormalities, including impaired dopamine 
release. 235, 236 It has also been shown that mutant torsin A interferes with 
cytoskeletal events, which may affect development or neuronal pathways in the 
brain.237 
 
Thanatos-associated protein domain-containing apoptosis-associated protein 1, 
THAP1 (DYT6) 
Mutations in THAP1 cause autosomal dominant dystonia with reduced 
penetrance (~ 60%), typically involving cranial or cervical muscles; laryngeal 
involvement is also frequent.238 THAP1 is a member of a family of cellular factors 
sharing a highly conserved THAP DNA binding domain, which is an atypical 
zinc finger.239 The mechanism by which mutant THAP1 protein causes dystonia 
is unclear, although recent work shows that THAP1 is a transcription factor and 
that mutant THAP1 leads to altered transcription of TOR1A, implying a linked 
mechanism.240, 241 
 
CDKN1A Interacting Zinc Finger Protein, CIZ1  
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Linkage analysis combined with exome sequencing were recently used to 
identify a mutation in CIZ1 (c.790A>G p.S264G) as the likely causal variant in a 
large Caucasian kindred with primary cervical dystonia inherited as an 
autosomal dominant trait. CIZ1 is a p21Cip1/Waf1-interacting zinc finger protein, 
expressed in brain and involved in DNA synthesis and cell-cycle control. The 
c.790A>G mutation is thought to alter splicing and subnuclear localization of 
CIZ1. Screening in a cohort of patients with adult-onset dystonia identified 2 
additional missense mutations (p.P47S and p.R672M), however these were not 
found in multiplex kindred so segregation analysis was not possible. To date 
mutations in CIZ1 have not been replicated as a cause of autosomal dominant 
cervical dystonia. 
 
Anoctamin 3, ANO3 (DYT23) 
Mutations in ANO3 as a cause of autosomal dominant cranio-cervical dystonia 
were identified as a result of WES and linkage analysis.38 To date 3 mutations 
have been shown to segregated with the disease in unrelated kindreds 
(p.Arg494Trp, p.Trp490Cys and p.Ser685Gly). The phenotype is characterized by 
focal or segmental dystonia, variably affecting the cranio-cervical, laryngeal or 
brachial regions. There was often dystonic tremor with a jerky quality affecting 
the head, voice, or upper limbs. The age of onset ranges between childhood and 
40 years. Little is known about the protein anoctamin 3 other than it is very 
highly expressed in the striatum. Functional work in patient fibroblasts with the 
p.trp490Cys mutation showed evidence of a potential defect in endoplasmic 
reticulum related Ca2+ handling. It is believed that Ca2+-activated chloride 
channels have a role to play in the modulation of neuronal excitability.242, 243 Since 
ANO3 is highly expressed in the striatum it is possible that mutations lead to 
abnormal excitability of striatal neurons.  
 
Guanine Nucleotide Binding Protein (G Protein), Alpha Activating Activity 
Polypeptide, Olfactory Type, GNAL  
A combination of WES and linkage analysis was also used to identify mutations 
in GNAL as a cause of autosomal dominant dystonia.39 More than 8 mutations 
have been reported. Patients predominately have cranio-cervical onset of 
dystonia with generalisation in ~10%.  GNAL encodes Gαolf, the alpha subunit of 
trihetrometric G protein Golf, which is involved in dopamine signalling. There is 
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evidence to show that Gαolf is mostly responsible for the coupling of D1 receptors 
to adenylyl cylase in striatal neurons and that Gαolf is required for D1-mediated 
behaviour and biochemical effects.244-246  
 
Tubulin beta 4A class IVa, TUBB4A (DYT4) 
Mutations in TUBB4A were identified as a cause of autosomal dominant 
inherited ‘whispering dysphonia’ and generalised dystonia with a peculiar 
‘hobby horse’ gait using a combination of WES and linkage analysis in a very 
large pedigree, independently by two groups.247, 248 The gene is expressed 
throughout the brain, but most highly in the cerebellum, which has been linked 
to dystonia.247 The mutation identified in the family (p.Arg2Gly) occurs at a 
highly conserved residue in the autoregulatory MREI (methionine-arginine-
glutamic acid-isoleucine) domain. Mutations in this domain abrogate the 
autoregulatory capability of TUBB4A, which may affect the balance of tubulin 
subunits and interfere with proper assembly.249 The findings suggest a role for 
the cytoskeleton in dystonia pathogenesis.  
 
Dystonia Plus Disorders 
TAF1 RNA Polymerase II, TATA Box Binding Protein (TBP)-Associated Factor, 
TAF1 (DYT3) 
DYT3 related dystonia is primarily found in Filipino males, due to a founder 
mutation, and is inherited in an X-linked recessive fashion. It is due to a 2.6kb 
retrotransposon insertion in intron 32 of TATA box-binding protein-associated factor 
1 (TAF1),250 which appears to reduce neuron-specific expression of TAF1 and the 
dopamine receptor D2 gene in the caudate nucleus.250, 251 Symptoms start as focal 
dystonia and progress to multifocal/generalized dystonia, sometimes with 
parkinsonism. Neuronal degeneration on postmortem analysis is described in 
association with DYT3.252, 253 
 
GTP cyclohydrolase I, GCH1, (DYT5a) 
Mutations in GCH1 lead to autosomal dominantly inherited, L‐ DOPA‐
responsive dystonia (DRD). Typically, it presents in childhood, with limb onset 
dystonia, and a dramatic response to L-dopa. Parkinsonism may occur in the 
later stages of the disease.  There is a female preponderance, which may be 
explained by a higher GCH1 enzyme activity in males.254 
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Tyrosine Hydroxylase, TH (DYT5b) 
Dopa-responsive dystonia can also be inherited as an autosomal recessive 
disorder associated with mutations in TH. Typically this presents with a more 
severe disease, reflecting deficiencies of serotonin and norephinephrine as well as 
dopamine, with onset of parkinsonism, ptosis, myoclonic jerks, seizures and 
truncal hypotonia in infancy. 
 
ATPase, Na+/K+ Transporting, Alpha 3 Polypeptide, ATP1A3 (DYT12) 
Mutations in ATP1A3 cause rapid onset dystonia with parkinsonism, which is 
inherited in an autosomal dominant trait with reduced penetrance (90%). The 
phenotype is characterized by abrupt onset and typically follows a rostro-caudal 
gradient of spread. 255 ATP1A3 encodes the catalytic unit of the sodium pump 
that uses ATP hydrolysis to exchange Na+ and K+ across the cell membrane to 
maintain ionic gradients.  
 
Dystonia Plus Myoclonus 
Sarcoglycan, Epsilon, SGCE (DYT11) 
Myoclonus-dystonia usually begins in childhood and is characterized by a 
combination of brief lightning-like myoclonic jerks most often affecting the neck, 
trunk and upper limbs, and focal or segmental dystonia in the neck or arms in 
about half of the cases.256 Inheritance is autosomal dominant, and caused by 
mutations in the epsilon-sarcoglycan gene, penetrance is reduced and related to 
maternal imprinting.257 SGCE is a member of the sarcoglycan gene family. In the 
brain SGCE mutations are thought to lead to mislocalisation from the plasma 
membrane to the endoplasmic reticulum and to promotion of its degradation by 
the proteasome.258 
 
Paroxysmal Dystonia 
Myofibrillogenesis Regulator 1, MR-1 (DYT8) 
Symptoms of paroxysmal non-kinesigenic dyskinesia (PNKD) typically begin in 
childhood or adolescence and include dystonic and choreatic dyskinesias, lasting 
from minutes to hours with a frequency of 20 per day to twice per year, often 
precipitated by alcohol or caffeine.259 It results from mutations in the 
myofibrillogenesis regulator (MR-1) gene and is inherited as an autosomal 
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dominant trait.  The function of MR-1 is not fully understood, but it is 
homologous to glyoxalase hydroxyacylglutathione hydrolase, known to detoxify 
methylglyoxal, a compound found in coffee and alcohol, and a by-product of 
oxidative stress.260 
 
Proline-Rich Transmembrane Protein 2, PRRT2  (DYT10) 
Mutations in PRRT2 cause paroxysmal kinesigenic dyskinesia. Affected 
individuals have short (seconds to minutes), frequent (up to 100 times per day) 
attacks of dystonic or choreiform movements, precipitated by sudden 
unexpected movements or startle, which are responsive to anticonvulsant 
therapy and usually begin in childhood. PRRT2 is highly expressed in the 
developing nervous system and truncating mutations, produce a protein, lacking 
the transmembrane domain, resulting in altered subcellular localization.40 
 
Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1, SLC2A1 
(DYT18) 
Mutations in the SLC2A1 gene encoding the glucose transporter GLUT1 cause 
paroxysmal exercise-induced dyskinesia (PED), which is characterized by attacks 
of combined chorea, athetosis, and dystonia in excessively exercised body 
regions which last from a few minutes to an hour.261 The disease usually begins 
in childhood and can have other disease manifestations, including epilepsy and 
haemolytic anemia.262, 263 GLUT1 is the main glucose transporter in the brain and 
PED is thought to be caused by reduced glucose transport into the brain, 
particularly when energy demand is high after prolonged exercise. The 
symptoms improve with intravenously administered glucose and with 
permanent ketogenic diet. 
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CHAPTER 2. MATERIALS AND 
METHODS 
2.1 DNA EXTRACTION  
2.1.1 DNA extraction from saliva 
Genomic DNA was extracted from saliva samples using the Oragene© DNA kit 
according to the manufacturers instructions. Essentially, the saliva sample and 
Oragene solution was incubated at 50°C in an air incubator for 2 hours. Then, 
500μl of the solution was transferred to a 1.5mL microcentrifuge tube. 20μl of 
Oragene DNA purifier was added and the tube was vortexed for a few seconds. 
The sample was then incubated on ice for 10 minutes. Next, the sample was 
centrifuged at room temperature for 15 minutes at 13,000 rpm. The clear 
supernatant was transferred into a fresh microcentrifuge tube. The pellet 
containing impurities was discarded. 500μl of 100% ethanol was added to the 
solution and inverted 10 times. The sample was left at room temperature for 10 
minutes allowing the DNA to fully precipitate. The sample was then centrifuged 
at room temperature for 2 minutes at 13,000 rpm. The supernatant was removed 
and discarded. 250μl of 70% ethanol was added. The sample was allowed to 
stand at room temperature for 1 minute. The ethanol was then removed, taking 
care not to disturb the pellet. 100μl of DNA buffer was then added to dissolve the 
DNA pellet.   
 
2.1.2 DNA extraction from blood 
Blood from families was taken in EDTA (ethylenediaminetetraacetic acid) bottles 
and genomic DNA was extracted from whole blood in the Diagnostic Genetics 
Laboratory in the UCL Institute of Neurology using a FlexiGene© kit (Quiagen) 
according to manufacturers instructions. In brief, 300ul of whole blood is mixed 
with 750ul of buffer (FG1), which lyses the cells. The sample is centrifuged for 20 
seconds at 10,000xg. The supernatant is discarded leaving only the pellet. 150ul of 
Buffer (FG2 – which contains a protease) is added and the tube vortexed until the 
pellet is homogenized.  The sample is centrifuged for 5 seconds and then placed 
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in a heating block at 65°C for 5 minutes. 150ul of isopropanolol (100%) is then 
added and the tube inverted several times. This step precipitates the DNA. The 
sample is centrifuged for 3 minutes at 10,000xg. The supernatant is discarded. 
150ul of 70% ethanol is added and the sample vortexed for 5 seconds and 
centrifuged for 3 minutes at 10,000xg. The supernatant is discarded and the pellet 
air dried. 200ul of Buffer (FG3) is added and the sample vortexed at 5 seconds. 
The DNA is then dissolved by heating the sample at 65°C in a heating block. 
 
2.2 DNA Quantification 
Genomic DNA is measured using the NanoDrop Spectrophotometer equipped 
with the software ND-1000. Absorbance measurements will measure any 
molecules absorbing at a specific wavelength, DNA will absorb at 260nm and 
will contribute to the total absorbance. For quality control, the ratios of 
absorbance at 260/280 nm and 260/230nm are used to assess the purity of DNA. 
Ratios of 260/280 + ~1.8 and 260/230 = 2.0-2.2 denote pure DNA. Ratios 
significantly lower than expected may indicate the presence of contaminants. The 
NanoDrop spectrophotometer is loaded with 1μl of solution and reads the DNA 
concentration that will be expressed in ng/μl. 
 
2.3 Polymerase chain reaction (PCR) 
PCR is performed using Roche Faststart PCR Master (400RXN/10ml) (Roche 
Applied Sciences), primers designed by ExonPrimer 
(http://ihg.gsf.de/ihg/ExonPrimer.html) or Primer 3 software 
(http://primer3.ut.ee/) at a dilution of 10 pmol/μl and genomic DNA is added 
to the reaction at a final concentration of 15-20ng. PCR amplification is performed 
using a program that has been shown to optimally amplify the product.  
 
2.4 Agarose gel electrophoresis  
10x TBE (tris-borate-EDTA solution) solution was prepared using 121.1g of 
Trizma base (Sigma), 61.8g Boric Acid (Sigma), 7.4g of 
Ethylenediaminetetraacetic acid (EDTA) (Sigma) and dissolved in 1 litre of 
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distilled water. Agarose gel electrophoresis is used to verify the quality and size 
of PCR amplification product. A 1.5% gel is prepared using Ultrapure Agarose 
(Invitrogen) and TBE 1X buffer and stained with gel red (Cambridge bioscience). 
3μl of PCR product and 3μl of X6 Orange DNA loading dye (Thermo scientific) 
was loaded into each gel well. A DNA ladder (Midrange 100-2000 bp) (Qiagen) 
was run alongside the samples and a run at 100 mV for 30 minutes. DNA 
fragments are visualized using UV transilluminator. 
 
2.5 PCR Cleanup  
PCR cleanup can be performed either using an enzymatic or filtration method. 
 
2.5.1 Enzymatic method 
The enzymatic cleanup solution is a mixture of Fast-Alkaline phosphatase 
(Thermo scientific), which removes unused dNTPs, and Exonuclease I (Thermo 
scientific), which removes ssDNA from PCR products. The enzyme mix is 
prepared 1ml at a time, to minimize freeze thaw, into an eppendorf tube 
combining: 50μl Exonuclease I, 200μl Fast-Alkaline phosphatase and 750μl of 
purified water. This enzymatic cleanup solution is stored at -20°C.  
 
5μl of PCR product is added to 2μl of the enzymatic cleanup solution. It is then 
run on a thermal cycler at 37°C for 30 minutes followed by 80°C for 15 minutes.  
 
2.5.2 Filtration method 
Alternatively, PCR product can be purified using a filtration method using 96 
wells PCR filter plates (Millipore, Co. Cork, Ireland). 80μl of distilled/purified 
water was added to the PCR product. It was then transferred to the PCR filter 
plate and was placed on the vacuum for ~5 minutes until the membrane was dry. 
Subsequently PCR product is re-suspended in 25μl of distilled/purified water 
and shaken on the thermo-shaker (Eppendorf, Hauppauge, NY, USA) at room 
temperature at 300 rpm for 25 minutes. Purified PCR product is used for 
sequencing reaction. 
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2.6 Sequencing reaction 
Sequencing Reaction is performed by means of 0.6μl BigDye Terminator v3.1, 2μl 
5X Sequencing Buffer (Applied Biosystems), 0.6μl forward or reverse primers at 
10 pmol/μl and purified PCR product (3.8μl of PCR product purified by filtration 
method or 3μl of PCR product purified by enzymatic cleanup) and 2.15μl of PCR 
grade water. The standard program recommended by Applied Biosystems is 
used to run the Sequencing reaction in the thermo-cycler.  
 
2.7 Sequencing purification 
Sequencing purification was performed via a filtration method using Millipore 
filtration plates or Sephadex plates. 
 
2.7.1 Filtration method 
Sequencing product can be purified using a filtering method using 96 wells PCR 
filter plates (Millipore, Co. Cork, Ireland). 80μl of distilled/purified water was 
added to the PCR product. It was then transferred to the PCR filter plate and was 
placed on the vacuum for ~5 minutes until the membrane was dry. Subsequently, 
the sequencing product is re-suspended in 25μl of distilled/purified water and 
shaken on the thermo-shaker (Eppendorf, Hauppauge, NY, USA) at room 
temperature at 300 rpm for 25 minutes. 
 
2.7.2 Sephadex purification 
A hydrated solution of Sephadex was prepared using 2.9 grams of Sephadex G-
50 powder (Sigma-Aldrich) and 40ml of autoclaved water. It was mixed well and 
allowed to hydrate for at least 30 minutes at room temperature. Next, 350μl of the 
well-mixed Sephadex solution was transferred to each well of a Corning 
FiltrEXTM 96 well filter plates (0.66 mm glass fibre filter). The Corning FiltrEXTM 
filter plate was placed on top of an empty collection plate and centrifuged for 3 
minutes at 700xg. The Corning FiltrEXTM was then placed on top of a new plate. 
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The entire contents of the sequencing reaction were pipetted onto the Sephadex 
columns. The plates were then centrifuged for 5 minutes at 910xg.  
 
2.8 Sanger sequencing and analysis 
Sanger sequencing was performed on a 3730 DNA analyser (Applied Biosystems, 
Foster City, CA, USA) and electropherograms were visualised using Sequencher 
software (Gene Codes Corporation, MI, USA, version 5.0.1). 
  
2.9 DNA array SNP analysis 
Two types of DNA array SNP beadchips were used for mapping in conjunction 
with WES data. Human CytoSNP beadchips (Illumina) have ~220,000 markers 
and were used for whole genome linkage analysis. HumanOmniExpress 
(Illumina) beadchips have ~715,000 markers and were utilized in families where 
autozygosity mapping was performed. Samples were processed, hybridized and 
scanned in accordance with the manufacturers instructions at UCL Genomics. 
Clustering, normalization and genotype calls were performed using Genome 
Studio 2010.3 Genotyping module (Illumina).  
 
2.10 Autozygosity Mapping 
Autozygosity mapping was performed using the Homozygosity Detector plug-in 
software within the BeadStudio suite. Regions of shared homozygosity over 
0.5Mb, that segregated with disease, were visually identified using the Illumina 
Genome Viewer tool with the Beadstudio suite.  
 
2.11 Genome wide Parametric Linkage Analysis 
Individuals from kindred’s that were analysed by parametric linkage analysis 
were run on Human CytoSNP beadchips (Illumina). Clustering, normalization 
and genotype calls were performed using Genome Studio 2010.3 Genotyping 
module (Illumina). Plink output files were created in Genome Studio using the 
Plink report plug-in.  Plink (http://pngu.mgh.harvard.edu/~purcell/plink/) 
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was then used to removed SNPs that have low call rates (<90%) and 
monomorphic SNPs (MAF <0.5%) using the commands –-maf 0.05 –-geno 0.1. A 
subset of markers were extracted to use for linkage analysis typically in the 
region of 5,000 using the command –-thin.  The .ped, .dat, .map and .model files 
were then created as per instructions on the Merlin website 
(http://www.sph.umich.edu/csg/abecasis/merlin/tour/linkage.html).264  
 
For the .ped file, affection status was indicated by a number: 1=unaffected and 
2=affected 0=unknown, the sex of the individual was indicated: 1=male, 
2=female. The structure of the pedigree was indicated by assigning every 
individual a unique number. In the model file the mode of inheritance was 
specified together with the estimated disease allele frequency and penetrance.  
 
A program called Pedstats 
(http://www.sph.umich.edu/csg/abecasis/PedStats/download/) was used to 
check the input formats and pedigree consistency and genotyping errors using 
the command: pedstats –d file.dat –p file.ped.  
 
Merlin was then used to perform genome wide parametric linkage analysis using 
the command: merlin –d file.dat –p file.ped –m file.map –model file.model –
markernames –-pdf –-tabulate. This created output files of LOD scores by marker 
and a PDF graphical representation of the results. Linkage analysis was 
performed on at least 3 different randomly generated marker sets.  
 
2.12 Whole exome sequencing 
WES was either performed at UCL Institute of Neurology or at AROS Applied 
Biotechnology using the Truseq Exome Enrichment Kit, which targets 62Mb of 
exonic sequence and run on an Illumina Hiseq 2000. The Illumina truseq kit has 
more than 90% coverage of the exons or genes in the latest version of the CCDS 
and Refseq database. All sequencing reads were aligned to the hg19 build of the 
human genome. The bioinformatics pipeline for data analysis is described below. 
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2.13 Bioinformatic pipeline for next generation 
sequencing data 
The schematic representation of WES data analysis is represented in figure 3.1. 
The whole exome sequencing data for the families described in this thesis was 
run through a bioinformatics pipeline, utilizing various programs, made by Dr. 
Vincent Plagnol. The components of the tools used to perform various steps of 
the data analysis are described below. 
 
Figure 2.1: Analytical pipeline for WES.  
Left panel indicates program used for each step. Middle panel indicates analysis 
steps. Right panel indicates data formats. 
 
 
1. Quality control 
The sequenced data generated by the HiSeq 2000 is stored in a FASTQ file, a text-
based format for storing nucleotide sequence and it’s corresponding quality 
scores. The certainty of each base call is recorded as a ‘Phred’ quality score, 
which measures the probability that a base is called incorrectly. The quality score 
of a given base, Q, is defined by the equation: Q=-10log10(e) where ‘e’ is the 
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estimated probability of the base call being wrong. Thus, a higher quality score 
indicates a smaller probability of error. A Q20 value, for example, corresponds to 
a 1 in 100 error probability, and a Q30 value to a 1 in 1000 error rate (see table 
2.1). NGS platforms have different error profiles and thus, quality values need to 
be derived accordingly.  
 
 
Table 2.1: Phred quality scores 
Quality Score Probability of Incorrect 
Base Call 
Inferred Base Call 
Accuracy 
10 (Q10) 1 in 10 90% 
20 (Q20) 1 in 100 99% 
30 (Q30) 1 in 1000 99.9% 
 
In Illumina technology the per-base quality score is determined by background 
noise during imaging265. In reality, Phred scores over 40 are uncommon and a 
cut-off Phred score of 20 is commonly used.266 
 
Raw reads were analysed using FastQC program 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). FastQC runs a 
series of tests on a fastq file to generate a comprehensive quality control report. 
FastQC assesses data quality by evaluating: read length, per base quality score, 
per sequence quality scores, GC content, nucleotide content, sequence 
duplication and overrepresented sequences. 
 
2. Alignment/Mapping 
The first and arguably most crucial step of most NGS analysis pipelines is to map 
reads to sequences to the reference genome. The HiSeq 2000 can produce up to 6 
billion paired-end reads, with a maximum read length of 2x100bp, equivalent to 
a maximum of 600Gb of data. Because of the large volume of reads and the huge 
size of the whole reference genome, alignment algorithms have been optimized 
for speed and memory usage. Therefore different alignment tools are designed 
with different approaches to trading off speed and accuracy to optimize detection 
of different types of variations in donor genomes. Alignment algorithms usually 
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follow a multistep procedure to map a sequence. First they quickly identify a 
small set of places in the reference sequence where the sequence is most likely to 
accurately align to. Then slower and more accurate alignment algorithms are run 
on the limited subset of possible mapping location identified in the first step. To 
speed up the process most alignment algorithms construct auxiliary data 
structures, called indices, for the reference sequence and/or read sequences. In 
addition to the selection of the alignment program, three issues are noteworthy. 
First, to overcome the problem of ambiguity when mapping short reads to a 
reference genome, paired-end reads have proven to be a valuable solution and 
are highly recommended, if not a requirement for WES.267  Second, reads that can 
only be mapped with many mismatches should not be considered and as a 
consequence, mutations that are only backed by such reads should be discarded 
from further analysis. Thirdly, as current NGS technologies incorporate PCR 
steps in their library preparations, multiple reads originating from only one 
template might be sequenced, thereby interfering with variant calling statistics. 
For that reason, it is common practice to remove PCR duplicates after alignment 
in WES studies.  
 
The analytical pipeline utilizes Novoalign (www.novocraft.com), an aligner 
designed for single and paired-end reads. The reference assembly (downloaded 
from UCSC: http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/) was 
indexed; then the paired-end reads were aligned to the indexed set of reference 
sequence. Novoalign finds global optimum alignments using an index called fast-
hashing Needleman-Wunsch algorithm, and uses affine gap penalties to allow 
consecutive run of spaces in a single string of a given alignment. Novoalign 
allows gaps up to 7bp on single end reads, even longer on paired end reads. 
Novoalign also supports paired-end mapping: it first finds the positions of all the 
good hits, sorts them according to the chromosomal coordinates and then does a 
scan through all the potential hits to pair the two ends. The expected size 
distribution for these sequencing runs were on average 300 base pairs as 
determined in the library preparation. Importantly, Novoalign calculates a 
mapping quality score, which is Phred-scaled probability of the alignment for the 
whole read being incorrect. This probability depends on the length of alignment, 
on the number of mismatches and gaps and on the uniqueness of the aligned 
region on the genome. It is important in the downstream analysis to distinguish 
 71 
the real SNPs from the mismatches between, for instance repeated homologous 
genomic regions. 
 
3. PCR duplicate removal; Samtools and Picard 
Samtools (http://samtools.sourceforge.net/) is a suite of tools designed primarily 
to manipulate SAM files and the binary transformed BAM files, in preparation 
for downstream analysis. The SAM format was created in 2009268 to define a 
generic nucleotide alignment format that described the alignment of large 
nucleotide sequences to a reference sequence. SAM files are tab-delimitated text 
files that contain an header section, which carries information on the project and 
the genome, and an alignment section, that contain alignment information such 
as such as mapping position and information on mismatches. This information is 
used for downstream analysis. Samtools was used for converting SAM and BAM 
files, for sorting (arranging the file according to left-most coordinates) and 
indexing (generating a complementary file ‘.bai’ which aids fast access to BAM 
file) the alignment files generated by Novoalign. Samtools was also used for 
calling SNPs and short indel variants (see paragraph on SNP calling).  
 
One technical artifact of capture-sequencing procedures is the generation of 
duplicate DNA sequencing reads (defined as reads with the same start point and 
direction) that are due to PCR-induced duplication. They share the same 
sequence and have the same alignment position.  It is essential to identify and 
‘mark’ duplicate reads so that they do not influence variant calling. PCR artifacts 
were removed with Picard (http://sourceforge.net/projects/picard/), which 
comprises Java-based command-line utilities that manipulate SAM or BAM files. 
Picard removes all read pairs with identical coordinates, only retaining the pair 
with the highest mapping quality. Picard examines aligned records in the 
supplied SAM file to locate duplicate molecules and generates a SAM output file 
that includes all aligned reads, without the duplicate records. Picard also 
generates a file that contains information on the percentage of PCR duplicates 
found in the original aligned file. 
 
4.SNP Calling 
Once an alignment is generated, SNP calling can be performed by comparing the 
aligned SAM/BAM file to the reference genome. The end result of a SNP calling 
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analysis is a collection of SNPs, each associated to a Phred-like quality score that 
takes into account base calling as well as mapping scores. A standard file has 
been created to hold these SNPs and related information, the Variant Call Format 
(VCF). BCF is the binary version of VCF: it keeps the same information in VCF, 
while much more efficient to process especially for many samples. The analytical 
pipeline utilizes Samtools and VCFtools for SNP calling,269 a software suite that 
implements various utilities for processing VCF files, including validation, 
merging and comparing. Samtools collects summary information in the input 
BAMs, such as the number of different reads that share a mismatch from the 
reference, the cloning process artifacts (e.g. PCR induced mutations), the error 
rate associated with the sequence reads (e.g. the Phred score associated to every 
base in the read), the error rate associated with the mapping (mapping quality) 
and computes the likelihood of data given each possible genotype; then it stores 
the likelihoods in the BCF format. Bcftools performs the actual SNP calling. Then 
the .bcf was converted to .vcf, and only the SNPs on the set of exons targeted by 
Nimblegen (i.e., CCDS) were included. Lastly, the varFilter script was used to 
rule out error-prone variant calls. 
 
5.Indels Calling  
The analytical pipeline utilizes Dindel,270 a program specifically designed for 
calling small indels from next-generation sequence data by realigning reads to 
candidate haplotypes. Dindel considers all candidate indels in a BAM file, and 
tests whether each of these is a real indel or a sequencing error or mapping error. 
In stage I) Dindel extracts all indels from the read-alignments in the BAM file. 
These indels are the candidate indels around which the reads will be realigned in 
stage III). In this stage, Dindel also infers the library insert size distributions. 
These will be used in stage III) for paired-end reads. In stage II) the candidate 
indels obtained in stage I) are grouped into windows of ∼ 120 bp, into a realign-
window-file. In stage III) for every window, Dindel generates candidate 
haplotypes from the candidate indels it detects in the BAM file, and realign the 
reads to these candidate haplotypes. Realignment is the computationally most 
intensive step. In stage IV) indel calls and qualities are produced in the VCF4 
format. This step integrates the results from all windows into a single VCF4 file. 
 
6. Annotation 
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The ANNOVAR tool271 is a command-line tool for up to date functional 
annotation of various genomes, supporting SNPs, INDELs, block substitutions as 
well as CNVs. It provides a wide variety of different annotation techniques, 
organized in the categories gene-based, region-based and filter-based annotation. 
The tool relies on several databases, which need to be downloaded individually. 
This approach ensures that the correct database version is used and the 
download of large unnecessary data sets is avoided. ANNOVAR uses six 
different scores to estimate deleterious impact: GERP++,272 LRT,273 
MutationTaster,28 PolyPhen,27 PhyloP conservation,274 and SIFT.26 
 
2.13.1 Copy Number Variant Analytical Pipeline for Next 
Generation Sequencing Data 
A custom package called Exome Depth275 was used to examine copy number 
variants in next generation sequencing data. This package used a read depth 
analysis approach to identifying copy number variants276-278, i.e., it compares the 
number of reads mapping to a chromosomal window with an expectation under 
a statistical model. Deviations from this expectation are indicative of CNV calls. 
Reference samples will be those samples run on the same Illumina Hiseq run.  
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CHAPTER 3. VPS35 SCREENING IN A 
PARKINSON’S DISEASE COHORT 
 
3.1 STATEMENT OF CONTRIBUTION TO THIS 
RESEARCH 
Dr. Gavin Charlesworth and I both performed Sanger sequencing of VPS35 in a 
large series of PD patients. I collected the clinical data relating to the family with 
the VPS35 c.1858G>A; p.Asp620Asn mutation. Dr Laura Moriyama performed 
and interpreted the olfactory testing. Dr. Gavin Charlesworth and I jointly wrote 
the manuscript detailing this work, which is published in Neurobiology of 
aging.144  
 
3.2 BACKGROUND 
In 2011, using an whole-exome sequencing approach, two independent groups 
identified a missense mutation in vacuolar protein sorting 35 homolog 
(VPS35 c.1858G>A; p.Asp620Asn) as the cause of autosomal dominant late-onset 
PD in a number of kindreds.36 Pathogenicity is supported by segregation, 
evolutionary conservation at that base, and software predictions that the variant 
is likely to be damaging. However, at the time of this work, no other pathogenic 
mutations had been identified with certainty in VPS35, and the c.1858G>A 
mutation, had only been found in Caucasian individuals.  
 
In this study, we screened a large series of Parkinson’s disease patients for 
variants in VPS35, both in order to estimate the frequency of the published 
mutations and in order to search for novel mutations that may be disease-
causing. 
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3.3 MATERIALS AND METHODS 
3.3.1 Samples 
The series included 160 familial PD cases, 175 young-onset PD cases, and 262 
sporadic, neuropathologically confirmed PD cases (total number screened, 501). 
Neuropathologically confirmed cases were selected from the Queen Square and 
Parkinson's UK brain bank. The study was approved by the East Central London 
Research Ethics Committee 1 and informed consent was obtained as per its 
guidelines. 
 
All living patients fulfilled criteria for clinical diagnosis of PD at the time of the 
study with at least 2 of 3 cardinal signs of tremor, rigidity, and bradykinesia, as 
well as a positive response to levodopa therapy. Familial cases were defined as 
those reporting 1 or more first degree relatives with PD with a pedigree 
consistent with autosomal dominant inheritance, who had tested negative for 
mutations in SNCA and LRRK2. Early-onset PD cases were defined as those who 
had developed their first signs of the disease at age 45 or younger (mean age of 
onset in young-onset PD was 37 ± 6, range 14–45 with a male to female ratio of 
1.63:1). A family history of PD (first or second degree relative) was noted in 31 
early-onset PD cases (17.7%). The neuropathological diagnosis for brain bank 
cases was made by an experienced neuropathologist and based on accepted 
morphological criteria.279  This group included 166 males and 96 females, with an 
average age at onset of 64 ± 11 years (range, 29–85) and a family history recorded 
in 7.6% of cases. 
 
3.3.2 PCR and Sanger sequencing 
PCR and sequencing of the 17 coding exons of VPS35 was performed as 
described in the Materials and Methods (chapter 2). PCR and sequencing 
purification was performed using the filtration method. To amplify exon 9 and 
10, we added 1ul of 5% dimethylsulfoxide (DMSO; American Bioanalytical, MA, 
and USA) to the PCR mix.  
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All 17 exons and exon-intron boundaries of VPS35 were sequenced in 96 familial 
PD cases (FPD), and exon 15 (in which the c.1858G>A; p.Asp620Asn mutation is 
found) in an additional 64 familial PD cases, 175 young-onset PD cases, and 262 
sporadic, neuropathologically confirmed PD cases (total number screened, 501). 
 
3.3.3 Variant Definitions 
Any deviation from the reference sequence, ENST00000299138, was called a 
variant or a mutation. Variants were described as novel, if they were absent from 
dbSNP and 1000genomes data.  
 
3.3.4 Clinical Characterisation of VPS35-related PD 
Clinical details were collated were possible from living family members for those 
affected relatives that were deceased. Where possible affected individuals were 
clinical examined and olfactory testing undertaken using UPSIT.280 
 
3.4 RESULTS 
3.4.1 Sanger sequencing 
Sanger sequencing revealed a single case from our familial PD series who 
harboured the previously described p.Asp620Asn mutation. No other 
nonsynonymous variants were detected in any other exon of any sample. In 
addition to this we observed 7 other sequence variants, including 2 novel and 5 
previously described variants (Table 3.1) 
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Table 3.1: Summary of Variants found in VPS35.  
This table has been published elsewhere (see reference 144). 
 
 
Variant Nucleotide 
change 
Amino Acid 
Change 
Rs Number Exon Number of 
Cases 
Coding 
Non-
synonymous 
c.1858G>A p.Asp620Asn Recently 
published 
15 1 
Synonymous c.231T>C 
 
p.Leu77Leu 
 
rs11550462 
 
4 1 
 c.1842T>C 
 
p.Tyr615Tyr 
 
Novel 
 
15 1 
 c.1938C>T p.His646His rs168745 
 
15 1 
Non-coding 
UTR c.1-34G>A  rs3743928  1 
Intronic 
 
c.3+25A>G  
 
 Novel 1 1 
 c.1524+42G>C 
 
 rs4966616 
 
12 27 (2 hom) 
 c.1648-26G>A  rs2304492 14 58 (10 hom) 
 
3.4.2 Clinical Characterisation of VPS35-related PD 
In order to determine whether the p.Asp620Asn mutation segregated with PD in 
the family of the individual from our FPD series, we contacted other affected 
family members: a sister, and two cousins, they subsequently were found also to 
have the p.Asp620Asn mutation. The family is of European ancestry, the 
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pedigree (figure 3.1) is consistent with autosomal dominant mode of inheritance 
and revealed 9 further affected individuals across 3 generations, all of whom are 
deceased. 
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 Figure 3.1: Pedigree of a family showing autosomal dominant inheritance of Parkinson's disease.  
 
Age of onset (O:) and age at death (D:) are indicated where known for all descendants of I-1 and I-2. The p.Asp620Asn mutation 
in VPS35 was confirmed by Sanger sequencing in the 3 living individuals affected by the disease. 
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The index case (IV-7) noticed his first symptoms in 1993 at the age of 40, consisting 
of stiffness in the left arm on waking followed, a few months later, by gradually 
worsening stiffness in the left leg. He was diagnosed as suffering from PD in 1995. 
At that time, examination showed unilateral bradykinesia and reduced arm swing. 
L-dopa was commenced with a good response, although he continued to gradually 
worsen. He began to notice a mild intermittent tremor of the left upper limb 13 
years after his initial symptoms, followed by the spread of the stiffness to his right 
upper limb. Dyskinesias started after 9 years of L-dopa therapy, but were not 
severe. He complains of difficulty with balance, but has not had any falls. There is 
no history of mood disturbance or other psychiatric features, including visual 
hallucinations. Cognitively, he feels that his concentration has deteriorated 
somewhat over the years, but he has only recently retired from a demanding job. A 
Mini Mental State Examination (MMSE) performed 18 years into the disease 
revealed a score of 28/30. He has recently had deep brain stimulation, which has 
significantly improved his symptoms. Olfactory testing was undertaken 18 years 
into the disease, using the 40-item University of Pennsylvania Smell Identification 
Test (UPSIT)280 and results were interpreted in comparison with 55 control subjects 
(27 males and 28 females) and 46 PD patients (30 males and 16 females) who had 
been previously tested for a study about olfaction in the UK.281 The patient 
correctly identified 29/40 items of the UPSIT, scoring on the 37th percentile of 55 
controls aged between 55 and 65 from the UK, and the 87th percentile of 46 PD 
subjects aged between 55 and 65 from the UK. His sibling (IV-8) developed 
symptoms aged 52 years of age and was formally diagnosed 2 years later. Initial 
symptoms included cramping in the left foot and tripping when walking. Within 6 
months she developed a unilateral leg tremor. Further symptoms included 
micrographia, and freezing. Dopamine agonists were tried initially but within 3 
years she required L-dopa. She has not developed any dyskinesias. She does not 
report any cognitive symptoms and a Mini Mental State Examination was 30/30. 
Olfactory testing was undertaken 11 years into the disease as described above with 
the patient also identifying 29/40 items of the UPSIT. Individual IV-5 presented 
with a stiffness and rigidity of the left leg at the age, followed by walking 
difficulties, bradykinesia, loss of postural reflexes and micrographia aged 47. There 
was no rest tremor. He was diagnosed shortly afterward. He responded well to L-
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dopa, but developed dyskinesias after 10 to 15 years of treatment and has now had 
a deep brain stimulator implanted to good effect. There have been no 
hallucinations or psychiatric complications. The clinical history for individual IV-6, 
was provided by her brother. She developed PD at the age of 41 with noticeable 
tremor and generalized bradykinesia and rigidity. She responded well to L-dopa, 
developing only mild dyskinesias after a reasonable period of treatment. She 
underwent a pallidotomy at around 60 years of age and died at age 66 as a 
consequence of a nosocomial infection after a hip replacement operation. 
Limited information is available for other affected family members. Individual II-1 
presented with akinetic-rigid parkinsonism in her late fourth decade, family 
members noted that she never developed tremor, but suffered with depression late 
in the disease course. She died aged 66 years. Individuals II-3 and II-5 developed 
parkinsonism in their seventh decade and died in their eighth decade. II-4 
developed tremor-predominant Parkinson's disease aged 35 years and had a 
slowly progressive disease course, dying at the age of 69. Individuals II-9 and II-10 
are known to have been affected with parkinsonism, but ages of onset are not 
known. They died in their sixth and fourth decade respectively. Individual III-7 
developed parkinsonism at age 37. Medical records and family members indicate 
left-sided rigidity, bradykinesia, hypomimia, falls, and freezing. Tremor was not 
recorded. Surgical interventions, including pallidotomy (right then left) and 
thalamotomy, were performed before L-dopa was commenced. No dyskinesias 
developed despite 10 years of treatment and she died at age 62. Individual III-9 
developed parkinsonism aged 47 years presenting with a unilateral rest tremor. 
Family members report early severe muscular spasms, difficulty walking, and falls. 
Later in the disease, she developed depression and cognitive impairment. She died 
aged 57 years. 
 
3.5 DISCUSSION 
Two independent research groups used WES to identified a single c.1858G>A 
mutation in VPS35 as the cause of Parkinson's disease in several kindreds. This 
study was an attempt to estimate the frequency of the published mutations and in 
order to search for novel mutations that may be disease-causing. We included PD 
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patients with a positive family history, as well as those with early onset and late-
onset sporadic disease in order to maximize our chances of identifying mutations. 
 
We identified one individual with the published disease-causing mutation 
(c.1858G>A; p.Asp620Asn). This individual had a family history consistent with 
highly penetrant, autosomal dominant Parkinson's disease. Based on clinical 
examination, clinical records and family reports, the disease in this family appears 
clinically similar to idiopathic PD. Onset was generally unilateral, with slow 
progression and variable tremor. Cognitive or psychiatric features are not 
prominent. Response to L-dopa was generally good and was not associated with 
early or unusually severe dyskinesias. The 2 patients in which olfaction was tested 
here show mild to moderate olfactory dysfunction when compared with controls in 
the UK, but still performed better than the vast majority of PD patients. Olfaction 
has been demonstrated to be unimpaired in homozygous and compound 
heterozygous carriers of Parkin mutations282, 283 but impaired 
in LRRK2 parkinsonian carriers,115, 284-286 although not to the same extent as in 
sporadic PD. The most notable feature of our kindred is the relatively early age at 
onset. Six individuals developed PD in their third or fourth decades, of which 4 
were younger than the age of 45. No other potentially disease-causing mutations 
were found in exon 15 (597 cases screened) or in any other exon (96 cases 
screened). We concluded that the c.1858G>A VPS35 mutation, is not a common 
cause of PD, at least in our series of patients.  
 
To date, robust evidence for pathogenicity has only been found for the c.1858G>A; 
p.Asp620Asn VPS35 mutation. This mutation is located in the C-terminal region of 
the VPS35 protein, suggesting that subtle structural changes might influence the 
disease pathogenesis.36 Subsequent to our screening study, a much larger multi-
centre screening study also found that the c.1858G>A; p.Asp620Asn VPS35 
mutation was a rare cause of PD.146 In this study 8,870 PD patients were screened 
for mutations in VPS35. Seven patients were found to have the c.1858G>A; 
p.Asp620Asn mutation in VPS35. Two of these patients were of Asian descent (the 
remainder were Caucasian) thus confirming a pathogenic relevance for this 
mutation in different populations. Two patients with this mutation did not have a 
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family history of PD confirming that this mutation is not likely to be fully 
penetrant.146  
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CHAPTER 4. WHOLE EXOME 
SEQUENCING IN AUTOSOMAL 
DOMINANT PARKINSONISM  
 
4.1 STATEMENT OF CONTRIBUTION TO THIS 
RESEARCH 
I examined affected and unaffected living family members and gathered medical 
records and DNA on deceased individuals. I analysed the clinical and WES data 
and performed the confirmatory Sanger sequencing. Prof. Tamas Revesz 
performed the histological examination of brain tissue from an affected family 
member. 
 
4.2 BACKGROUND 
We identified a large UK Caucasian family with atypical autosomal dominant 
Parkinson’s disease (see Figure 4.1 for pedigree) through the Neurogenetics clinic 
at the National Hospital of Neurology and Neurosurgery. The index case (III:14) 
had been extensively investigated in multiple hospitals, including genetic testing 
for PD. 
 
The family were keen to pursue genetic research studies to try and identify the 
molecular cause as family members wished to have predictive genetic testing and 
make reproductive decisions. DNA from four affected individuals was available at 
the beginning of the study, however two samples had only a very small amount of 
DNA (enough for a couple of PCR reactions), therefore precluding linkage 
analysis. In view of the limited samples available a WES approach was taken 
without linkage analysis to try and identify the causal variant. 
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Figure 4.1: A truncated pedigree of the family with atypical autosomal dominant parkinsonism. 
 
 
 
 
Above: An arrow indicates those individuals for whom DNA was available. Individual IV:10 only became clinically affected after the causal 
variant was identified in the family. Individuals IV:9 and III:14 were selected for whole exome sequencing.
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4.3 MATERIALS AND METHODS 
4.3.1 Samples 
DNA samples were available from 3 affected deceased individuals (III:8, III:10 
and IV:9), 1 affected living individual (III:14) and 1 unaffected individual who 
had passed the age at onset of the disease (III:5). Participants or their named 
next of kin gave written informed consent. The local ethics board approved the 
study. 
 
4.3.2 Exome Sequencing  
Two individuals (individuals IV:9 and III:14) were selected for WES using 
Illumina’s TruSeq (62Mb) DNA Sample Prep Kit and Exome Enrichment Kit, 
based on the fact that they were distantly related and sufficient DNA was 
available for WES. 
 
4.3.3 PCR and Sanger Sequencing 
This was performed as described in Materials and Methods (chapter 2). 
 
4.4 RESULTS 
4.4.1 Phenotypic Characterization  
Clinical features for affected individuals are summarized in table 4.1. 
 
II:1 Medical records are not available for individual II:1, but the family report 
she developed Parkinsonism in her 30’s, and died age 37 years.  
 
II:3 developed parkinsonism aged 65 years according to her family and died 7 
years later. No further information is available as medical records are not 
available. 
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III:5 This individual was examined by myself at the age of 80 years. She had no 
neurological symptoms and her clinical examination was normal. She had 4 
children who were in their 50’s and 60’s, none had neurological abnormalities. 
For the purposes of this study, given that the disease appeared to be highly 
penetrant in this family, I assumed this individual was unaffected. 
 
III:8 presented aged 49 years with tremulous parkinsonism and cognitive 
decline. Over 4 years she developed a supranuclear gaze palsy, bulbar palsy and 
diffuse muscle wasting, weakness in all four limbs and a severe peripheral 
neuropathy. She had an initial good clinical response to low-dose levodopa. 
Electrophysiology indicated mild denervation changes distally in the right 
lower limb and a severe mixed demyelinating/axonal sensory motor peripheral 
neuropathy.  III:8 died aged 53 years.  
 
III:10 presented aged 66 years with bradykinesia which was quickly followed by 
recurrent falls, memory problems, weight loss, hearing problems, depression 
and social withdrawal. Reversal of the sleep-wake cycle and frequent episodes 
of urinary and faecal incontinence were noted. The patient had several ‘vacant’ 
episodes, lasting 1-2 minutes, with no recall of the event. Motor symptoms 
improved with low-dose levodopa. Medical records documented hypophonia, 
hypomimia, slow horizontal saccades and a fine rest tremor of the hands. 
Reflexes were pathologically brisk but with flexor plantar responses. MMSE 
aged 68 years was 24/30. Formal neuropsychometry showed global cognitive 
dysfunction, with a frontotemporal predominance. An EEG was not performed. 
The patient died aged 68 years of ischaemic heart disease. 
 
III:14 presented with a more slowly progressive form of the disease. Aged 52 
years she presented with 3 stone weight loss. Investigations revealed a renal 
carcinoma and following a curative resection her weight stabilized. Aged 54, she 
developed tremulous parkinsonism, and was noted to be apathetic, irritable, 
depressed and required prompting to carry out activities of daily living. III:14 
started shoplifting and developed obsessional tendencies and a preference for 
sweet foods. She developed daily episodes of urinary and faecal incontinence, 
for which no secondary cause was identified. Aged 59 years she had several 
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unprovoked generalised seizures. Treatment with low dose levodopa improved 
both motor and behavioral symptoms. Examination revealed frontalis over 
activity, hypomimia, restriction of upgaze, and slow, hypometric saccades 
particularly in the vertical plane. The jaw jerk was brisk and a left palmomental 
reflex was present. There was moderate bradykinesia without cogwheeling or 
rigidity. There was moderate spasticity in all limbs and mild pyramidal 
weakness in the legs. Reflexes were pathologically brisk. Plantar responses were 
extensor on the right and flexor on the left. Arm swing was reduced bilaterally 
with loss of postural reflexes. MRI brain showed small vessel disease but no 
atrophy. Interictal EEG was normal. Cognitive assessment demonstrated 
impaired visual memory, executive function, cognitive speed and poor 
attention, indicating fronto-temporal compromise, more marked in the 
dominant hemisphere and with subcortical features. Vital capacity was normal.  
 
III:17 is affected with parkinsonism, however no further details are known as he 
declined to participate in the research study. 
 
IV:6 presented aged 51 with one month history of shortness of breath, nocturnal 
dyspnoea, recurrent chest infections and weight loss. He required intubation for 
type 1 respiratory failure and frequent nocturnal dyspnoeic episodes. On 
examination he had generalised wasting with a mild akinetic-rigid parkinsonian 
syndrome, vertical gaze palsy, hypometric saccades, pathologically brisk 
reflexes and frontal disinhibition. Despite nasogastric feeding he continued to 
lose weight and died of aspiration pneumonia five months after admission. 
 
IV:9  presented aged 43 years with personality change. He had lost confidence at 
work and was prone to aggressive outbursts, emotional lability and reported 
motor and cognitive slowing. Over the ensuing year he developed tremulous 
parkinsonism. Lower limb reflexes were diminished. He responded well to low-
dose levodopa. He had severe recurrent chest infections and died aged 46 years 
of aspiration pneumonia. An MRI brain showed an incidental venous 
abnormality but no atrophy. 
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IV:10 developed rapidly progressive symptoms including dramatic weight loss, 
memory problems and tremor aged 56 years. Within a few months she 
developed recurrent apnoeic episodes. Examination revealed a fine rest and 
postural tremor of the upper limbs with cogwheeling. Reflexes were 
pathologically brisk with equivocal plantar responses, brisk jaw jerk and grasp 
reflex. Dysdiadochokinesis was present in the upper limbs. Gait was narrow 
based. MMSE was 22/30.  
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Table 4.1: Summary of clinical features of affected family members (see pedigree figure 4.1) 
Individual II:1 II:3 III:3 III:8 III:10 III:14 III:17 IV:6 IV:9 IV:10 
Age at onset ~35 ~65 n/k 49 66 52 nk 51 43 56 
Duration (yrs) 7 7 n/k 4 2  nk 0.4 3  
Age at death ~42 72 53 53 68 alive alive 51 46 alive 
Cause of death nk nk Respiratory 
failure 
Bronchial 
pneumonia 
Ischaemic 
heart disease 
n/a n/a Aspiration 
pneumonia 
Aspiration pneumonia n/a 
Presenting clinical 
symptom 
Parkinsonism Parkinson-
ism 
Parkinsonism Parkinsonism Parkinson-
ism 
bvFTD  Parkinson-
ism 
Respiratory 
failure 
Personality change Parkinsonism 
Parkinsonism + + + + + + + + + + 
Hypo-ventilation nk nk + + - - nk + + + 
Psychiatric 
Symptoms 
nk nk nk - Depression, 
social 
withdrawal 
Apathy, 
depression, 
obsessions 
nk Frontal 
disinhibition 
Apathy 
Frontal disinhibition 
Aggression 
- 
Weight loss nk nk nk - + + nk + - + 
Response to 
Levodopa 
nk nk nk + + + nk Not tried + + 
Cognitive decline nk nk nk + Fronto-
temporal 
compromise 
Fronto-
temporal 
compromise 
nk - + + 
Spasticity nk nk nk - - + nk - - - 
 
Hyperreflexia 
 
nk 
 
nk 
 
nk 
 
- 
 
+ 
 
+ 
 
nk 
 
+ 
 
- 
 
+ 
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Extensor plantar 
responses 
nk nk nk - - + nk + - Equivocal 
Eye movement 
abnormality 
nk nk nk Supranuclear 
gaze palsy 
Slow 
horizontal 
saccades 
Restricted 
upgaze, 
hypometric 
saccades 
nk Supranuclear 
gaze palsy, 
hypometric 
saccades 
Normal Normal 
Bulbar palsy nk nk nk + - - nk - - - 
Peripheral 
neuropathy 
nk nk nk Severe 
demyelinating 
& axonal 
sensory motor 
neuropathy 
- - nk - Possibly – LL reflexes 
diminished 
- 
Urinary and faecal 
incontinence 
nk nk nk - + + nk - - - 
Muscle wasting nk nk nk + - - nk + - - 
Muscle weakness nk nk nk + - Pyramidal 
weakness LL 
nk - - - 
Seizures nk nk nk - Possible 
seizures 
Several GTC 
seizures 
nk - - - 
MRI Brain nk nk nk nk Generalised 
atrophy / 
SVD 
SVD nk Normal Normal Normal 
Key: bvFTD=behavioural variant frontotemporal dementia, SVD=small vessel disease, nk=not known, n/a not applicable,  
         += present, -= absent, GTC generalised tonic-clonic, LL=lower limb 
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4.4.2 Pathological examination in an affected family member 
A brain post mortem was performed on III:8 in 1991. It showed generalised 
atrophy, with slight preponderance of the temporal lobes and depigmentation of 
the substantia nigra with occasional neurons containing lewy bodies. Studies of the 
median nerve showed axonopathy. 
 
4.4.3 Candidate gene screening 
Mutations in SNCA, LRRK2, VPS35, MAPT, GRN and repeat expansions causing 
spinocerebellar ataxia and Huntington’s disease had been excluded in III:14. 
 
4.4.4 Whole exome sequencing 
Alignment metrics on both individuals WES data showed good coverage in both 
individuals (Table 4.2).  
 
Table 4.2: summary of metrics of WES in individual III:16 and IV:9 
 III:14  IV:9  
Total number of reads 136,078,746 127,297,302 
Non-duplicated reads 106,855,818 97,105,484 
Reads aligned to target 92,043,322 83,578,035 
Mean Target Coverage 88.123837 79.879976 
% Target covered by 2 reads 96 96 
% Target covered by 10 reads 92 92 
% Target covered by 20 reads 87 86 
Total number of variants 22,308 22,566 
 
4.4.5 Variant filtering 
I assumed that both III:14 and IV:9 had the same genetic cause of disease and that 
the mode of inheritance was autosomal dominant. Based on these assumptions 
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synonymous and homozygous variants were excluded. Next, variants were 
removed if they were present in publically available databases (National Heart, 
Lung, and Blood Institute (NHLBI) Exome Variant Server (EVS), 1000 genomes and 
dbSNP) at a frequency above 0.1%. Variants were also filtered out if they were 
present in an in-house set of exomes (from an unrelated non-neurological disease) 
more than 3 times. After filtering, 12 variants remained (Table 4.3). 
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Table 4.3 Rare shared variants between III:14 and IV:9 after variant filtering. 
 
Gene Full Gene 
Name 
Variant 
Annotation 
Variant Type Frequency 
in public 
databases 
Sift 
Score 
Poly 
phen 2 
score 
GERP 
Score 
Comment 
ARHGEF19 Rho guanine 
nucleotide 
exchange 
factor 19 
ARHGEF19 
ENST000002707
47.3 exon10 
c.A1616G 
p.D539G 
nonsynonymous 
SNV 
Novel 0.16 0.99431 3.07 Acts as guanine nucleotide exchange factor 
for RhoA GTPase 
DCTN1 dynactin 1 DCTN1 
ENST000003618
74.3 exon2 
c.A202G p.K68E 
nonsynonymous 
SNV 
Novel 0 0.95502 3.97 Required for the cytoplasmic dynein-driven 
retrograde movement of vesicles and 
organelles along microtubules. Dynein-
dynactin interaction is a key component of 
the mechanism of axonal transport of vesicles 
and organelles. DCTN1 mutations cause 
Perry Syndrome, a rare autosomal dominant 
form of parkinsonism 
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VARS valyl-tRNA 
synthetase 2, 
mitochondrial  
VARS 
ENST000003756
63.3 exon2 
c.C136G p.P46A 
nonsynonymous 
SNV 
Novel 0.03 0.99708 3.71 Aminoacyl-tRNA synthetases catalyze the 
aminoacylation of tRNA by their cognate 
amino acid 
MOB3B MOB kinase 
activator 3B 
MOB3B 
ENST000002622
44.5 exon2 
c.C253T p.R85W 
nonsynonymous 
SNV 
Novel 0.01 0.97534 1.84 May regulate the activity of kinases 
ZNF485 zinc finger 
protein 485 
ZNF485 
ENST000003744
37.2 exon3 
c.669_670insT 
p.I223fs 
frameshift 
insertion 
Novel N/A N/A N/A May be involved in transcriptional regulation 
VWA2 von 
Willebrand 
factor A 
domain 
containing 2 
VWA2 
ENST000002987
15.4 exon12 
c.G1711A 
p.G571S 
nonsynonymous 
SNV 
Novel 0.02 0.99945 4.96 The encoded protein is localized to the 
extracellular matrix and may serve as a 
structural component in basement 
membranes or in anchoring structures on 
scaffolds of collagen VII or fibrillin.  
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C10orf82 chromosome 
10 open 
reading frame 
82 
C10orf82 
ENST000003692
10.3 exon3 
c.A247C 
p.N83H 
nonsynonymous 
SNV 
Novel 0.55 0.01972 -2.12 Function unknown. Poorly conserved 
therefore unlikely to be candidate variant 
MAP1A microtubule-
associated 
protein 1A 
MAP1A 
ENST000003002
31.5 exon4 
c.C4257G 
p.D1419E 
nonsynonymous 
SNV 
Novel 0.28 0.19407 -2.5 Structural protein involved in the 
filamentous cross-bridging between 
microtubules and other skeletal elements. 
Poorly conserved therefore unlikely to be 
candidate variant 
LRRC8E leucine rich 
repeat 
containing 8 
family, 
member E 
LRRC8E 
ENST000003067
08.5 exon3 
c.2113delG 
p.A705fs 
frameshift 
deletion 
Novel N/A N/A N/A This gene encodes a member of a small, 
conserved family of proteins with similar 
structure, including a string of extracellular 
leucine-rich repeats. A related protein was 
shown to be involved in B-cell development.  
EML2 triggering 
receptor 
expressed on 
myeloid cells-
like 2 
EML2 
ENST000002459
25.2 exon9 
c.C803T 
p.T268M 
nonsynonymous 
SNV 
Novel 0 0.99859 3.74 May modify the assembly dynamics of 
microtubules, such that microtubules are 
slightly longer, but more dynamic 
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CEP250 centrosomal 
protein 
250kDa 
CEP250 
ENST000003425
80.4 exon34 
c.G7001A 
p.S2334N 
nonsynonymous 
SNV 
Novel 0.29 0.98298 2.71 Probably plays an important role in 
centrosome cohesion during interphase 
TSHZ2 teashirt zinc 
finger 
homeobox 2 
TSHZ2 
ENST000003296
13.5 exon2 
c.73_75del 
p.25_25del 
nonframeshift 
deletion 
Novel N/A N/A N/A Probable transcriptional regulator involved 
in developmental processes. May act as a 
transcriptional 
repressor  
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The variant in the DCTN1 gene (Ensemble transcript ID ENST000003618750 
c.A202G p.K68E), was of immediate interest as mutations in this gene are an 
extremely rare cause of atypical autosomal dominant parkinsonism. The variant 
occurred at a residue that was highly conserved (GERP score 3.97), and was highly 
likely to be deleterious (SIFT score 0; Polyphen2 score 0.955). The mutation was 
confirmed by Sanger sequencing in all affected individuals for whom DNA was 
available (III:8, III:10, III:14, IV:9 and IV:10). It was absent in one unaffected family 
member who is 82 years old (III:5) (figure 4.2). 
 
Figure 4.2: Chromatograms showing the novel heterozygous DCTN1 mutation 
 
 
 
 
 
Subsequently, a further family member (IV:10) developed symptoms consistent 
with the phenotype in the family. Sanger sequencing also confirmed this 
individual had the DCTN1 p.K68E variant. 
 
4.4.6 Re-examination of the brain histopathology for individual 
III:8 
At this point in the study it seemed likely that the variant in DCTN1 was causal. 
DCTN1 mutations are known to cause a rare autosomal dominant Parkinson 
syndrome with clinical features that overlap with those seen in this family. 
Secondly, the putative causal variant segregates with disease in family members 
Left: wild type sequence (III:5) 
Left: chromatogram for individual III:14 
showing c.A151G:pK68E in exon 2 of DCTN1. 
Individuals III:8, III:10, III:14, and IV:9 were also 
found to have the same mutation. 
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for whom DNA was available. However in the absence of genetic linkage data, 
further evidence would be needed to determine whether this variant was 
pathogenic. Brain tissue in Perry Syndrome has been described in association with 
positive TDP-43 immunohistochemical staining.172  Brain tissue of III:8 was re-
examined in 2013 by Prof Tamas Revesz. This demonstrated abnormal TDP-43 
immunohistochemistry, abnormal neurites and axonal swellings in the globus 
pallidus and midbrain tegmentum. There were no TDP-43 positive neuronal 
cytoplasmic inclusions in the substantia nigra, however, tissue was not available 
for review from all of the nigra. It is likely that the cell loss in the nigra was very 
severe, which may explain the absence of TDP-43 positive neuronal cytoplasmic 
inclusions in the nigra. No neocortical plaques, tau or alpha-synuclein staining was 
detected. Overall, these histopathological findings were felt to be highly supportive 
of a diagnosis of Perry Syndrome. 
 
4.5 DISCUSSION 
Mutations in DCTN1 cause Perry Syndrome,160 which has traditionally been 
described as an autosomal dominant, rapidly progressive form of parkinsonism 
associated with depression, weight loss, and hypoventilation. It is an extremely 
rare form of familial parkinsonism with only six mutations (p.G67D, p.G71A/E/R, 
p.T72P, and p.Q74P) reported in 12 families worldwide.161-171 All mutations are 
located within the p150glued highly conserved N-terminal cytoskeleton-associated 
protein, glycine-rich (CAP-Gly) domain within a hydrophobic pocket upon the 
surface. p150glued is the major subunit of the dynactin protein complex, which plays 
a crucial role in retrograde axonal and cytoplasmic transport of various cargoes.  
The CAP-Gly domain is critical for microtubule binding and in vitro assays have 
shown mutations result in a reduced affinity of dynactin for microtubules.160 287, 288 
 
In this family, WES of two distantly affected family members, without linkage 
analysis, has identified a novel missense mutation (p.K68E) in DCTN1 as the cause 
of disease. There is strong evidence to support its causality. The mutation is absent 
from publically available databases, it is located in the CAP-Gly domain, where all 
reported mutations, which cause Perry Syndrome occur. The mutation segregates 
 101 
with disease in the family, it is present in 5 affected family members and is absent 
from 1 unaffected family member, who is past the age of onset of the disease. The 
mutation is predicted to be highly damaging using in-silico prediction software 
(SIFT score 0,289 Polyphen2 score 0.955289) and occurs at a highly conserved residue 
(GERP score of 3.97). Furthermore, the diagnosis of Perry Syndrome is supported 
by the detection of TDP-43 positive inclusions, predominantly in a pallidonigral 
distribution and nigral cell loss in an affected individual. 
 
For individuals whom medical records were available, the average age at onset 
was 52 years (range 35-66 years) and average duration of disease was 3 years 9 
months (range 5 months-7 years). To-date, clinical features of Perry Syndrome are 
relatively consistent between families. Notable exceptions include a family who 
did not have weight loss or hypoventilation290 and a patient with a vertical gaze 
palsy and features of behavioural variant frontotemporal dementia (bvFTD).162 
Clinical and pathological criteria have been proposed for the diagnosis of Perry 
Syndrome. A ‘definite’ diagnosis requires the presence of five cardinal features 
(autosomal dominant inheritance, hypoventilation, parkinsonism, weight loss and 
psychiatric features) and characteristic pathological findings of severe substantia 
nigra neuronal loss and few or no Lewy bodies.290 
 
The commonest presenting symptom in this family was parkinsonism, however 
atypical presentations included bvFTD, personality change and fulminant type 1 
respiratory failure. Only one individual had all five cardinal features required for a 
definite diagnosis of Perry syndrome (autosomal dominant, hypoventilation, 
parkinsonism, weight loss and psychiatric features), suggesting these criteria may 
not identify all patients with Perry syndrome.  
 
Unusually, several individuals had upper or lower motor neuron signs or 
frontotemporal compromise, features more commonly seen in FTD/Amyotrophic 
lateral sclerosis. Upper motor neuron signs observed in affected individuals 
included pathologically brisk reflexes, extensor plantar responses and pyramidal 
pattern of weakness. One patient had a bulbar palsy. A frontotemporal pattern of 
cognitive impairment and frontal disinhibition was prominent in several 
individuals. Motor neuron involvement has not been described in association with 
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Perry syndrome, however the p.G59S DCTN1 mutation, which is buried within the 
center of the CAP-Gly domain, has been identified in a family with distal 
hereditary motor neuropathy with vocal cord paresis.291 TDP-43 pathology is 
common to Perry Syndrome, amyotrophic lateral sclerosis and some forms of 
frontotemporal lobar degeneration, indicating pathological overlap between these 
conditions. Four individuals had eye movement abnormalities (slow saccadic eye 
movements, restricted vertical gaze and supranuclear gaze palsy), confirming this 
as a clinical manifestation of Perry Syndrome. Additionally, incontinence, seizures 
and peripheral neuropathy may be part of the extended phenotype. Epileptiform 
discharges on EEG and neuropathy have previously been described in a single 
patient each.167, 292  
 
Perry Syndrome is probably under diagnosed, as it is rarely tested for. It is likely 
that the phenotype is broader than that described in the literature to date and will 
continue to widen with identification of additional families. In view of the fact that 
this family widen the phenotypic spectrum of disease associated with mutations in 
DCTN1, we suggest genetic testing for Perry Syndrome be considered in any 
patient with autosomal dominant parkinsonism and one other of the cardinal 
features as in the proposed diagnostic criteria290 (hypoventilation, weight loss and 
psychiatric features), keeping in mind that a eye movement abnormalities, 
neuropathy, upper or lower motor neuron features, frontotemporal cognitive 
impairment, urinary and faecal incontinence, may be prominent features of the 
clinical presentation. 
 
The rapid identification of a novel DCTN1 mutation in this family demonstrates 
the utility of next-generation sequencing technologies applied to families with 
undiagnosed neurological disorders, in whom linkage analysis is not possible. This 
is a common scenario facing clinicians, particularly those families with late-onset 
neurodegenerative disorders, where DNA samples may not be available for the 
preceding generations. 
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CHAPTER 5. WHOLE EXOME 
SEQUENCING IN AUTOSOMAL 
RECESSIVE PARKINSONISM 
DISORDERS 
 
5.1 STATEMENT OF CONTRIBUTION TO THIS 
RESEARCH 
Unless otherwise indicated I performed autozygosity mapping and analysed the 
WES data. I performed confirmatory Sanger sequencing and segregation analysis. I 
examined all family members apart from family 2, who were examined by Dr. 
Uday Muthane and Prof Kailash Bhatia. 
 
5.2 BACKGROUND 
Large scale screening studies have shown that of patients with autosomal 
recessive, early-onset (<45 years) typical parkinsonism, ~50% of patients will have 
mutations in Parkin,177 ~1-8% will have mutations in PINK1,293 and ~1% will have 
mutations in DJ-1.294  This suggests that there are further autosomal recessive 
Parkinson’s disease genes yet to be identified. The NHNN Neurogenetics database 
contains a large number of samples from patients with suspected genetic forms of 
Parkinson’s disease. A search of this database revealed several families with 
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suspected autosomal recessive parkinsonism in whom the genetic cause had not 
been identified. 
 
Where parental consanguinity is present in the context of a suspected autosomal 
recessive disorder, the initial assumption is that the disease is likely to be caused 
by a homozygous variant inherited from both parents (identical by descent) and 
this variant resides within a large stretch of homozygosity. Such families are 
suitable for autozygosity mapping, which will reduce the proportion of the 
genome which needs to be considered. Homozygous variants which lie in large 
homozygous regions in affected family members only can therefore be prioritized. 
The use of autozygosity mapping and WES reduces the amount of variants for 
follow-up and WES data is only required from a single affected individual, 
reducing costs. 
 
This chapter details the work done on 3 families with suspected autosomal 
recessive Parkinsonism in whom the genetic cause was not known. 
 
 
5.3 FAMILY 1: WHOLE EXOME SEQUENCING AND 
AUTOZYGOSITY MAPPING IN AUTOSOMAL 
RECESSIVE EARLY-ONSET PARKINSON’S 
DISEASE 
 
Family 1 is a consanguineous Pakistani family with four offspring, two of whom 
were affected with young-onset parkinsonism. The parents were first cousins 
(figure 5.1). In this family a genetic approach of WES and autozygosity mapping 
resulted in a candidate variant list. However, the causal variant could not be 
identified as none of the candidate variants were found in a series of early-onset 
PD. There are many reports in the literature where a candidate variant for a 
Mendelian disorder has been identified from exome sequencing data and then 
confirmed as pathogenic after identification of the same variant or a different 
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variant in the same gene in a ‘replication cohort’ of individuals with the same 
disease. Demonstrating that the variant segregates with disease in the family of the 
patient from the ‘replication cohort’ provides further evidence for pathogenicity.38  
15, 36, 37 
 
 
 
 
Figure 5.1: Pedigree of family 1 
 
 
5.3.1 MATERIALS AND METHODS 
5.3.1.1 Samples 
Genomic DNA samples were obtained from peripheral blood lymphocytes, for 
individuals III:1, III;2, IV:1, IV:2 and IV:3. Individual IV:4 was not available for 
participation. Participants gave written consent and the study met with the local 
ethic boards approval.  
 
5.3.1.2 Whole exome sequencing 
Individual IV:2 was selected for WES using Illumina Truseq kit. This was 
performed as described in the Materials and Methods chapter (chapter 2).  
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5.3.1.3 Autozygosity Mapping 
Autozygosity mapping was performed in individuals IV:1, IV:2 and IV:3 as per 
Materials and Methods chapter 2. Regions of homozygosity larger than 0.5Mb 
shared by the affected individuals (IV:2 and IV:3) were identified. 
 
5.3.1.4 Variant Filtering 
Variants within the regions of homozygosity, only shared by the affected 
individuals were selected. Heterozygous variants, synonymous variants and those 
above a frequency of above 1% were filtered out. 
 
5.3.1.5 PCR and Sanger Sequencing 
This was performed as described in the materials and methods (chapter 2) for rare 
variants that remained in the autozygous regions. 
 
5.3.1.6’ Replication cohort’ of PD patients for screening candidate variants 
The exon in which a candidate variant was found was screened in a series of early-
onset PD cases (age of onset <45 years), which was collected through specialized 
Neurogenetics and Movements disorder clinics at the National Hospital of 
Neurology and Neurosurgery (NHNN). This series totaled 364 patients with early-
onset PD, 70% had a family history of PD. Patients in this cohort were known to be 
negative for the common SNCA mutations, the p.G2019S LRRK2 mutation and 
mutations in Parkin and PINK1.  
5.3.2 RESULTS 
5.3.2.1 Clinical Phenotyping of affected individuals 
The index case (IV:2) presented at the age of 31 years with a right sided thumb 
tremor and right arm bradykinesia. Shortly after a diagnosis of Parkinson’s disease 
was confirmed. He was commenced on Rasagiline, which provided no clinical 
benefit. Ropinirole was withdrawn due to gambling behavior. He had a good 
clinical response to Trihexyphenidyl and Sinemet. Examination aged 34 years 
revealed hypomimia and mild hypophonia. Eye movements were normal. He had 
a severe tremor at rest in the right arms and leg with more moderate tremor 
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affecting the left side. He had increased tone in all four limbs and bradykinesia and 
loss of postural reflexes. He has not subjectively noticed any change in his sense of 
smell. 
 
IV:2 has been extensively investigated. A DATScan showed bilateral (worse on the 
left) pre-synaptic dopaminergic deficit. Diagnostic genetic testing was negative for 
the p.G2019S mutation in LRRK2. Sanger sequencing and MLPA (for copy number 
variants) of Parkin and PINK1 was also negative. Furthermore sequencing of DJ-1 
and selected exonic MLPA for this gene was also negative. Screening for Wilson’s 
disease was negative and included formal ophthalmology, 24-hour urinary copper 
studies and serum ceruloplasmin. Formal neuropsychometry revealed dysfunction 
in anterior and sub-cortical regions, with some involvement of the dominant 
temporal lobe.  
 
IV:3 was clinically assessed aged 33 years old. Subjectively she had no symptoms 
however there was evidence of hypomimia, left-sided bradykinesia and reduced 
arm-swing on the left. Postural reflexes were retained.  
 
IV:1 was clinically assessed aged 38 years and had an entirely normal neurological 
examination. III:1 and III:2 were examined, both had normal neurological 
examinations. IV:4 not available to participate in the study as he lived abroad and 
was not contactable. He was reported by the family to have no symptoms of PD.  
 
Autosomal recessive inheritance was felt to be the most likely mode of inheritance 
firstly, because of parental consanguinity and due to the young age of onset of 
symptoms in IV:2. 
 
5.3.2.2 Autozygosity Mapping 
Only the two affected siblings were used to derive the regions of homozygosity as 
it was felt that IV:1 could yet develop the disease. 23 homozygous regions were 
identified that were >0.5Mb and shared between IV:2 and IV:3 (table 5.1) 
encompassing >133Mb.  
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Table 5.1: Homozygous regions >0.5Mb in individual IV:2 and IV:3.  
Chromosome Position from  Position To Size (bp) 
1 8,168,564 8,960,153 791,589 
1 23,145,239 23,902,416 757,177 
1 35,268,368 45,035,621 9,767,253 
1 46,954,587 55,136,529 8,181,942 
1 73,227,348 74,170,796 943,448 
1 84,058,458 89,459,475 5,401,017 
1 224,021,459 224,794,237 772,778 
3 0 9,836,386 9,836,386 
3 74,831,395 75,974,251 1,142,856 
3 82,602,965 83,558,368 955,403 
3 100,864,107 101,712,255 848,148 
3 159,686,068 160,398,885 712,817 
4 33,628,239 34,910,052 1,281,813 
5 36,678,275 37,671,746 993,471 
5 136,972,187 138,668,704 1,696,517 
7 138,742,981 142,041,961 3,298,980 
8 0 1,469,213 1,469,213 
10 74,482,123 75,669,319 1,187,196 
12 63,158,162 116,977,528 53,819,366 
14 62,366,843 72,334,903 9,968,060 
15 38,030,147 54,353,991 16,323,844 
19 3,278,206 5,841,356 2,563,150 
20 13,559,616 14,337,539 777,923 
 
5.3.2.3 Exome Sequencing 
WES summary metrics for exome sequencing results for individual IV:2 indicated 
good coverage (see table 5.2).  
 
Table 5.2: Showing coverage statistics for the WES in individual IV:2 
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 IV:2  Family 1 
Total number of reads 104,750,902 
Non-duplicated reads 85,652771 
Reads aligned to target 74,665,663 
Mean Target Coverage  71 
% Target covered by 2 reads 96 
% Target covered by 10 reads 91 
% Target covered by 20 reads 85 
Total number of variants 22,521 
 
5.3.2.4 Variant Filtering 
5 novel or rare variants were present in the homozygous regions shared between 
the two affected individuals (table 5.3). All the variants were confirmed with 
Sanger-sequencing, which demonstrated that both parents were heterozygous 
carriers, and that both siblings with PD were homozygous for the variants, but the 
unaffected sibling was not. 
 
In order to try and investigate these candidate variants further I Sanger sequenced 
the exon in which the variant occurred, in a ‘replication cohort’ of early-onset PD 
patients, hoping to find another patient with a rare/novel variant in that exon also. 
I prioritised the variants so that only the best candidate variants would be tested in 
the replication cohort, as discussed in chapter 1. All of the variants occurred at 
highly conserved amino acids, so it was not possibly to exclude variants on this 
basis. Instead I focused on the functional class of variant, putative gene function 
and expression patterns. I did not rely heavily on the in-silico prediction of 
deleteriousness as this is not highly specific or sensitive.30, 31 
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Table 5.3: Variants within the regions of homozygosity shared between IV:2 and IV:3 
Gene Full Gene 
Name 
Variant 
annotation 
Variant Type Frequency 
in 
publically 
available 
databases 
Sift 
score 
Polyphe
n 2 score 
GERP 
score 
Comment 
ECHDC2 enoyl CoA 
hydratase 
domain 
containing 2 
ECHDC2 
ENST000003583
58.5 exon5 
c.C398Tp.T133M 
nonsynonymous 
SNV 
Novel 0.02 0.999 2.31 Fatty acid metabolic process. Likely located in the 
mitochondria. Widely expressed. Most highly 
expressed in the liver. Expressed in brain, most 
highly in the cerebellum 
SUMF1 sulfatase 
modifying 
factor 1 
SUMF1 
ENST000002729
02.5 exon2 
c.C287T p.A96V 
nonsynonymous 
SNV 
Novel 0 0.209 4.59 Encodes an enzyme that catalyzes the hydrolysis of 
sulfate esters by oxidizing a cysteine residue in the 
substrate sulfatase to an active site 3-oxoalanine 
residue. Mutations cause multiple sulfatase 
deficiency, an infantile onset autosomal recessive 
fatal lysosomal storage disorder characterised by 
coarsened facial features, deafness, icthyosis, 
organomegaly and skeletal abnormalities.  
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HAL histidine 
ammonia-
lyase 
HAL 
ENST000005419
29.1 exon12 
c.G469A 
p.A157T 
nonsynonymous 
SNV 
Novel 0 0.997 4.06 Histidine ammonia-lyase is a cytosolic enzyme 
catalyzing the first reaction in histidine catabolism, 
the nonoxidative deamination of L-histidine to 
trans-urocanic acid. Histidine ammonia-lyase 
defects cause histidinemia, which is characterized 
by increased histidine and histamine and decreased 
urocanic acid in body fluids. Although 
histidinaemia was reported initially in association 
with speech difficulties and/or mental retardation, 
more recently it is suggested that histidinemia does 
not cause central nervous abnormalities or other 
forms of disease. Low brain expression profile.  
THBS1 thrombospon
din 1 
THBS1 
ENST000003975
93.3 exon3 
c.C166A 
p.H56N 
nonsynonymous 
SNV 
Novel 0.02 0.92 5.21 Adhesive glycoprotein that mediates cell-to-cell 
and cell-to-matrix interactions. Binds heparin. May 
play a role in dentinogenesis and/or maintenance 
of dentin and dental pulp, platelet aggregation, 
angiogenesis, and tumorigenesis. Highly expressed 
in blood, bone and smooth muscle. Minimal brain 
expression. 
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TMBIM4 Transmembra
ne BAX 
Inhibitor 
Motif 
Containing 4 
TMBIM4 
ENST000003582
30.3 exon2 
c.113delT 
p.V38fs 
frameshift 
deletion 
Novel NA NA NA Anti-apoptotic protein which can inhibit apoptosis 
induced by intrinsic and extrinsic apoptotic stimuli. 
Can modulate both capacitative Ca2+ entry and 
inositol 1,4,5-trisphosphate (IP3)-mediated Ca2+ 
release. Widely expressed. 
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THBS1, Thrombospondin-1 
Thrombospondin-1 is a matricellular, calcium-binding protein that participates in 
cellular responses to growth factors, cytokines and injury. It regulates cell 
proliferation, migration and apoptosis in a variety of physiological and 
pathological settings, including wound healing, inflammation, angiogenesis and 
neoplasia. These processes involve the formation of multi-protein complexes on the 
cell surface and the clustering of receptors that initiate signal transduction. 
Thrombospondin-1 dictates the composition of these multi-protein complexes 
through specific interactions with growth factors, cytokines, other matrix 
components and membrane proteins.295 In the central nervous system THBS1 
secreted by astrocytes promotes synaptogenesis and neurite outgrowth.296, 297 
Thrombospondin-1 is expressed in many tissues during embryonic development 
but has limited expression in the healthy adult. THBS1 is the most abundant 
protein in alpha granules of platelets. Expression in other cell types is induced by 
wounding, during tissue remodeling, in atherosclerotic lesions, rheumatoid 
synovium, glomerulosclerosis, and in stroma of many tumours. THBS1 null mice 
have impaired wound repair, increased retinal angiogenesis, and are hyper-
responsive to several inflammatory stimuli. THBS1 has been implicated in 
myocardial infarction,298 stroke299 and tumours invasive behavior, tumour 
neovascularization and metastasis.300, 301 Both SIFT and Polyphen2 scores predict 
the variant in THBS1 to be damaging. 
 
The variant in THBS1 was prioritised for screening in the ‘replication cohort’ of PD 
patients because of its role in synaptogenesis in the central nervous system. 
However, factors suggesting that it may not be causal include the fact it is not 
highly expressed in the adult human brain.  
 
HAL, Histidine ammonia-lyase 
Histidine ammonia-lyase is a cytosolic enzyme catalyzing the first reaction in 
histidine catabolism, the nonoxidative deamination of L-histidine to trans-urocanic 
acid. Histidine is an α-amino acid with a imidazole functional group. It is one of 
the amino acids that are precursors to proteins. Histidine ammonia-lyase enzyme is 
expressed in a tissue-specific manner in the liver and epidermis in the rat.302 
Histidinaemia results from histidine ammonia-lyase deficiency.303 It is inherited as 
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an autosomal recessive disorder that affects the liver,304 with several mutations 
identified. It was thought to be associated with mental retardation, infantile 
spasms, epilepsy, speech defects, and motor incoordination.305 However, the long-
term outcome of patients diagnosed by newborn screening in the north-west of 
England between 1966 and 1990 showed that in most cases the disorder is benign: 
IQ did not correlate with plasma histidine at diagnosis or with the mean plasma 
histidine throughout life.306 Growth has been normal in all patients. In contrast to 
some earlier studies, there was no excess of clinical symptoms. It has been 
concluded that histidinaemia in the typical form (due to impairment of histidine 
ammonia-lyase activity) is not a disease in humans, because retrospective and 
prospective studies together indicate that the prevalence of disadaptive 
phenotypes (e.g., impaired intellectual or speech development, seizures, 
behavioural or learning disabilities) in histidinaemia population is not higher than 
the frequency of these functional disorders in the nonhistidinaemia population. 
The possibility remains that histidinaemia is a risk factor for development of an 
unfavourable central nervous system phenotype, in particular in individuals under 
specific circumstances.  Both SIFT and Polyphen2 scores predict the variant in HAL 
to be damaging. 
 
I did not prioritise the variant in HAL for screening in the replication cohort of 
early-onset PD as it is not highly expressed in human brain and loss of activity has 
been investigated in epidemiological studies and has not been shown to be 
associated with a neurological phenotype. 
 
ECHDC2, enoyl CoA hydratase domain containing 2 
Little is known about the function of ECHDC2. It is thought to be a mitochondrion 
protein and is known to be highly expressed in the liver. It is thought to be 
involved in fatty acid and lipid metabolism. Enoyl-CoA hydratases are enzymes 
that hydrate the double bond between the second and third carbons on acyl-CoA. 
They are essential in metabolizing fatty acids to produce acetyl CoA and energy. 
Many inborn errors of metabolism are due to defects in mitochondrial fatty acid 
oxidation (e.g., Medium-chain acyl-coenzyme A dehydrogenase deficiency MCAD 
deficiency) and very long chain fatty acids (e.g., Refsums disease) and many of 
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these disorders have neurological problems as part of their phenotype. Both SIFT 
and Polyphen2 scores predict the variant in ECHDC2 to be damaging. 
 
The variant in ECHDC2 was prioritised as it is expressed in brain, involved in 
processes in which defects can result in human disease. Of note it is a 
mitochondrial protein and four autosomal recessive PD disorders caused by 
mutations in PINK1, PARKIN, DJ-1 and FBXO7 are linked to mitochondrial 
maintenance.  
 
SUMF1, sulfatase modifying factor 1 
SUMF1 encodes the enzyme sulfatase modifying factor 1, which is highly 
conserved among eukaryotes and localised in the lumen of the endoplasmic 
reticulum. The profound deficiency but not complete absence of all known 
sulfatase activities of sulfatase modifying factor 1 results in ‘multiple sulfatase 
deficiency’ (MSD), which is an autosomal recessive lysosomal disorder with 
storage of sulphated lipids and sulphated glycans and a profound deficiency of all 
lysosomal and nonlysosomal sulfatases.307-309 Deletions, nonsense and missense 
mutations have been described in association with MSD. The clinical symptoms of 
MSD represent a composite of the symptoms found in disorders caused by 
deficiency of single sulfatases such as metachromatic leukodystrophy, 
mucopolysaccharidosis, chondrodysplasia punctate, hydrocephalus, ichthyosis, 
neurological deterioration and developmental delay. The leukodystrophy-like 
(deficiency of arylsulfatase A) and mucopolysaccharidosis-like (deficiency of 
glycosaminoglycan degrading sulfatases) features prevail in MSD. The variant 
p.A96V has not been reported in association with MSD previously, there are no 
mutations in adjacent codons which cause MSD. Mutations in SUMF1 causing 
MSD are spread throughout the length of the gene.  
 
SUMF1 was also prioritised, as mutations in this gene are known to cause a 
lysosomal storage disorder: multiple sulfatase deficiency. Lysosomal storage 
disorders are linked to the pathogenesis of PD as either compound heterozygous 
or homozygous mutations in GBA cause the storage disorder Gaucher’s disease in 
which parkinsonism can be a feature and heterozygous mutations in GBA are a risk 
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factor for developing PD. SIFT but not Polyphen2 predicts the variant in SUMF1 to 
be damaging. 
 
 
 
TMBIM4, Transmembrane BAX Inhibitor Motif Containing 4 
TMBIM4 is a novel regulator of cell death that is highly conserved in eukaryotes 
and present in some poxviruses. Its predominant localization is in the Golgi and it 
is known to be able to suppress apoptosis.310 TMBIM’s are highly conserved in a 
broad range of organisms including human, orangutan, dog, mouse, rat, Xenopus 
laevis and zebrafish, and related proteins are present in Drosophila and Arabidopsis. 
Human TMBIM4 is expressed ubiquitously in human tissues. Stable expression of 
human TMBIM4 is associated with suppression of cell death induced by a broad 
variety of intrinsic and extrinsic apoptotic stimuli. Conversely, knockdown of 
TMBIM4 in tissue culture cells by siRNA resulted in cell death. Alterations in the 
finely tuned intracellular Ca2+ homeostasis and compartmentalization contribute to 
the induction of apoptosis. The switch from the control of physiological functions 
to the involvement in apopotosis most likely entails changes in the tightly 
regulated spatiotemporal Ca2+ signaling pattern affecting cytosolic effector proteins 
and effort organelles.311 Ca2+ signaling between storage organelles and 
mitochondria plays an important role in sensitizing cells to apoptosis.312 TMBIM4 
has been shown to modulate both capacitive Ca2+ entry and inositol-1,4,5-
trisphosphate-mediated Ca2+ release, suggesting it has an important role in the 
cross-talk between the intracellular Ca2+ stores, the cytosol and the mitochondria, 
and this may explain how it plays a decisive role in regulating cell death by 
apoptosis.  
 
TMBIM4 was prioritised as it is a frameshift deletion and therefore predicted to 
result in loss of protein function and this type of mutation is enriched among 
known disease-causing variation.22 TMBIM4 function in anti-apoptosis and calcium 
signaling in apoptosis and could therefore link in with known functions of 
PARKIN and PINK1 in mitochondrial biogenesis and destruction by autophagy.  
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5.3.2.5 Sanger sequencing of candidate variants in a replication cohort of EOPD 
THBS1, SUMF1, ECHDC2, TMBIM4 were selected as potential disease causing 
candidate variants. The exon in which the candidate variant in each of these genes 
was Sanger sequenced in a cohort of 364 early-onset PD patients. However, no 
variants were found in the exon in which they occurred in the cohort of early-onset 
PD patients (table 5.4). 
 
Table 5.4: Sanger Sequencing of potential causal variants in the replication cohort 
Gene Transcript and exon Sanger 
sequenced  
Sanger sequencing result in 
364 EOPD patients 
 
THBS1 ENST00000397593 exon 3 No variants in this gene were 
found 
SUMF1 ENST00000272902 exon 2 No variants in this gene were 
found 
ECHDC2 ENST00000358358 Exon 5 No variants in this gene were 
found  
TMBIM4 ENST00000358230 Exon 2 No variants in this gene were 
found 
 
5.3.3 DISCUSSION 
In this small consanguineous family with two affected individuals with early onset 
PD, WES and autozygosity mapping was used to try and identify the causal 
variant. Five homozygous, rare variants occurred at codons that are highly 
conserved. Of these, the exon in which 4 variants occurred was selected for Sanger 
sequencing in a cohort of early-onset PD patients (n=364). No variants were found 
in the exon in which the candidate variants occurred in this cohort of patients. 
Consequently, it is not possible to assign causality to any of the variants that 
remain in the candidate list of variants.  
 
There are two possibilities regarding the candidate variants. Firstly, the causal 
variant may be one of the candidate variants listed in table 5.3, however this form 
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of early-onset PD is very rare and a much larger sequencing project needs to be 
performed in order to identify a second patient with a mutation in that gene. Such 
a sequencing project might include many more patients and sequence all exons of 
all the candidate genes. Due to the cost of Sanger-sequencing, such a project would 
be better performed by a targeted next generation sequencing panel of candidate 
genes. Data sharing between PD research groups of WES data from EOPD patients 
may also be of help in determining if any of the candidate variants are pathogenic, 
particularly if co-segregation can be shown in another multiplex kindred. 
Secondly, the causal variant may not be present in the candidate list of disease 
causing variants due to the technical or analytic limitations of WES: 
 
Technical Limitations: 
1. Part or all, of the causative gene is not in the target definition (for example, 
it is not a known gene, or there is a failure in the bait design). The probes in 
sequence capture methods are designed based on the sequence information from 
gene annotation databases such as the consensus coding sequence (CCDS) 
database and Refseq database; therefore, unknown or yet-to-annotate exons cannot 
be captured. There may also be a failure in bait design so that an exonic region is 
not captured. Selectively sequencing the exome- which is, to our knowledge, the 
most likely region of the genome to contain pathogenic mutations – also excludes 
noncoding regions. The contribution of mutations in non-coding regions to 
Mendelian disease has yet to be determined. MicroRNAs, promotors and ultra-
conserved elements may be associated with disease, however these are not fully 
covered in current exome capture kits.  
2. Inadequate coverage of the region that contains a causal variant. A certain 
minimum depth of coverage is required for sufficient accuracy of variant detection; 
that is, positions or regions in the genome of the individual that are different from 
the reference human genome sequence. Regions with repetitive sequences are 
more poorly characterized, as repetitive sequences may have prevented inclusion 
of a probe, or the reads originating from these regions cannot easily be mapped to 
a single position in the reference genome. Additionally probes may be poorly 
performing in GC rich regions. The causal variant may be covered but not 
accurately called (for example, in the presence of a small indel) 
 119 
3. The causal variant is covered but not accurately called, for example, in the 
presence of a small but complex indel. WES is unable to detect structural variants 
or chromosomal rearrangements, which are believed to be important for 
Mendelian disorders.   
 
Analytical Limitations: 
4. The mode of inheritance was assumed to be autosomal recessive in this 
kindred, as there was an early age at onset of symptoms and parental 
consanguinity. It is possible that the mode of inheritance is autosomal dominant 
with reduced penetrance in either III:1 or III:2.  
5. Pathogenic mutations may be present in publically available ‘control’ 
databases, and may therefore be erroneously filtered out. Currently, more than 17 
million SNPs in the human genome have been documented in dbSNP with a false 
positive rate of ~15-17%.59 Using an appropriate MAF for the mode of inheritance 
and the curating of databases such as 1000 genomes and Washington exome server 
will help to reduce this type of error.  Alternatively, the causal variant could be 
synonymous and have been excluded in the variant filtering process. 
 
 
5.4 FAMILY 2: WHOLE EXOME SEQUENCING AND 
AUTOZYGOSITY MAPPING IN A SINGLETON 
CASE WITH COMPLICATED PARKINSONISM 
5.4.1 STATEMENT OF CONTRIBUTION TO THIS RESEARCH 
I performed autozygosity mapping, WES analysis and confirmatory Sanger 
sequencing. 
 
5.4.2 BACKGROUND 
This patient was brought to my attention by Prof. Kailash Bhatia who is a 
movement disorders specialist at the National hospital for Neurology and 
 120 
Neurosurgery and Dr. Uday Muthane who is a movement disorders specialist in 
Bangalore, India. The pedigree of the family is shown in figure 5.2. Parental 
consanguinity suggested a genetic aetiology with an autosomal recessive mode of 
inheritance. However, the patient had been treated with antipsychotic drugs, a 
recognized side effect of which is drug-induced parkinsonism, leading to 
diagnostic uncertainty.  
 
In family 2, an approach of WES and autozygosity mapping in a single individual 
identified a novel homozygous missense mutation: c.T2525C p.L842P in the 
hydrolase domain of the ATP13A2 gene confirming the diagnosis of Kufor-Rakeb 
Syndrome. 
 
Figure 5.2: Pedigree of family 2 
               
 
5.4.3 MATERIALS AND METHODS 
5.4.3.1 Samples 
The DNA samples for the index case (IV:1) and the parents (II:1 and III:1) were 
collected by Dr. Uday Muthane at the Movement disorders Clinic, Bangalore, 
India. All participants gave written informed consent. The study was approved by 
the local ethics committee. 
 
5.4.3.2 Phenotypic characterization 
The index case (Figure 1: IV:1) is a 34 year old Indian gentleman, the only child 
born to consanguineous parents (uncle-niece relationship) with a juvenile 
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complicated parkinsonian syndrome. His first symptoms were at the age of 13 
years with falls and dysarthria. A Neurologist formally assessed him at the age of 
22; he was found to have signs of parkinsonism and was commenced on half a 
tablet twice a day of controlled release Carbidopa/Levodopa, 250 mg (Syndopa® 
CR). Four years later he developed L-Dopa induced dyskinesias. At this point 
Syndopa® was stopped and Ropinirole was commenced. One year later, aged 27 
years, he developed acute psychosis with both visual and auditory hallucinations. 
Initially, he was treated with Olanzapine and later Risperidone and Levosulpiride. 
However, these led to a worsening of his parkinsonism. Recently the patient has 
been restarted on Syndopa® and the aforementioned antipsychotic medications 
have been discontinued and substituted with Quetiapine, which has resulted in 
some improvement in the patients parkinsonism. The patient is now 34 years of 
age, he is wheelchair bound, has bowel and bladder incontinence, cognitive 
impairment and dependent for all his activities of daily living. There is no family 
history of parkinsonism.  
 
Examination of the patient’s parents was entirely normal. Clinical examination of 
IV:1 revealed normal pursuit eye movements but impaired saccadic eye 
movements with a supranuclear gaze palsy. His mouth was partially open due to 
jaw opening dystonia and his speech was dysarthric. Tongue movements were 
normal. He had intermittent myoclonic jerks at rest in both hands and an intention 
tremor in the left hand. Finger-nose testing was normal. During rapid alternate 
movements of the hands, the jaw opening dystonia and laterocollis and eversion of 
the lower lip became more apparent. There was asymmetrical bradykinesia present 
in all four limbs. There was mild weakness of left hand grip, plantar and 
dorsiflexor weakness of both feet. There was spasticity in the lower limbs. Reflexes 
were pathologically brisk in the upper limbs and at the knee but plantar responses 
were flexor. Bedside examination revealed significant cognitive impairment.  
 
MRI brain age 32 years showed pontine, midbrain and caudate atrophy with no 
cerebellar atrophy. No iron deposition was seen on T2* images. A peripheral blood 
smear for acanthocytes, axillary skin biopsy for adult polyglucosan body disease 
and neuronal ceroid lipofuscinosis, nerve conduction studies and genetic testing 
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for Huntington’s disease and Dentatorubro Pallido-Luysian Atrophy (DRPLA) 
were all normal or negative. 
 
There was diagnostic uncertainty in this case as it was initially suspected that the 
patient had drug-induced parkinsonism. However, parental consanguinity 
suggested the possibility of autosomal recessive PD. WES and autozygosity 
mapping was used to investigate the possibility of an autosomal recessive juvenile 
parkinsonian syndrome.  
5.4.4 METHODS 
5.4.4.1 Autozygosity Mapping  
Autozygosity mapping was performed as described in chapter 2 identifying 
homozygous regions in IV:1 (figure 5.2) larger than 0.5Mb.  
5.4.4.2 Whole Exome Sequencing 
WES was performed in IV:1 (figure 5.2) as described in the Materials and methods 
chapter (chapter 2). 
5.4.4.3 Variant Filtering 
Only variants within regions of homozygosity were used for filtering. Synonymous 
variants and any variant present at a global minor allele frequency of more than 
1% in a range of publically available databases of sequence variation (1000 
Genomes, Complete Genomic 69 Database and NHLBI Exome Sequencing Project 
database) was filtered out, as well as those found in our in-house exomes from 
individuals (n=200) with unrelated diseases. 
5.4.4.4 Sanger Sequencing  
Sanger Sequencing was used to confirm the variant in ATP13A2 in the index case 
(IV:1) and both parents (II:1 and III:1). 
 
5.4.5 RESULTS 
5.4.5.1 Whole exome sequencing 
WES metrics revealed good coverage of the WES in individual IV:1 (Table 5.5). 
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Table 5.5: WES metrics of individual IV:1 (family 2) 
 
 Family 2  IV:1 
Total number of reads 43,413,599 
Reads aligned to target 34,945,383 
Mean Target Coverage 33 
% Target covered by 2 reads 94% 
% Target covered by 10 reads 85% 
% Target covered by 20 reads 68% 
Total number of variants 21,308 
 
5.4.5.2 Variant filtering 
Following variant filtering, 29 homozygous, rare, variants remained (Table 5.6). Of 
immediate interest was the homozygous missense variant in the ATP13A2 gene. 
Homozygous or compound heterozygous mutations in ATP13A2 are associated 
with a juvenile onset complicated parkinsonian syndrome: Kufor-Rakeb 
Syndrome.196 The residue at which the mutation occurs is highly conserved, with a 
GERP (Genomic Evolutionary Rate Profiling) score of 3.46, and is predicted with a 
high probability to be deleterious using in-silico prediction software (SIFT score of 
0, and a Polyphen2 score of 0.96).  
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5.4.5.3 Sanger sequencing 
Sanger sequencing confirmed the index case (IV:1) was homozygous for the 
c.T2525C p.L842P mutation in ATP13A2, both parents (II:1 and III:1) were also 
confirmed to be heterozygous carriers of this mutation.  
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Table 5.6: Homozygous Variants Remaining in Regions of Homozygosity Following Exome Filtering  
Gene Full Gene Name Annotation Exonic Function Call Present in 
publically 
available 
databases 
SIFT 
Score 
Poly 
Phen2 
GERP 
Score 
ATP13A2 ATPase type 13A2 ATP13A2:uc001bac.2:exon23:
c.T2525C:p.L842P 
nonsynonymous 
SNV 
hom Novel 0 0.965088 3.46 
CASZ1 castor zinc finger 1 CASZ1:uc009vmx.2:exon9:c.
C2639T:p.P880L 
nonsynonymous 
SNV 
hom Novel 0 0.651 3.85 
NECAP2 NECAP 
endocytosis 
associated 2 
NECAP2:uc001ayo.3:exon6:c.
A502G:p.K168E 
nonsynonymous 
SNV 
hom Novel 0 0.791 5.33 
GJB3 gap junction 
protein, beta 3, 
31kDa 
GJB3:uc001bxz.4:exon1:c.342
delC:p.A114fs 
frameshift deletion hom Novel NA NA NA 
RPL5 ribosomal protein 
L5 
RPL5:uc001dpd.3:exon2:c.A1
04G:p.D35G 
nonsynonymous 
SNV 
hom Novel 0.11 0.616 5.01 
DPH5 DPH5 homolog (S. 
cerevisiae) 
DPH5:uc001dty.2:exon4:c.G1
08A:p.M36I 
nonsynonymous 
SNV 
 
hom Novel 0.01 0.128 4.03 
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LCE1F late cornified 
envelope 1F 
LCE1F:uc010pdv.2:exon1:c.19
1_197GCTGCTGCAGCTCTG
GGGGTGGTGG 
nonframeshift 
substitution 
hom Novel NA NA NA 
KCNN3 potassium 
intermediate/small 
conductance 
calcium-activated 
channel, subfamily 
N, member 3 
KCNN3:uc001ffp.3:exon1:c.1
99_200insCAGCAGCAGCA
GCAG:p.Q67delinsQQQQQ
Q 
nonframeshift 
insertion 
hom Novel NA NA NA 
EFNA4 ephrin-A4 EFNA4:uc001fhd.3:exon4:c.T
590C:p.L197P 
nonsynonymous 
SNV 
hom Novel 0 0.570624 4.76 
PCNXL2 pecanex-like 2 
(Drosophila) 
PCNXL2:uc001hvk.1:exon2:c.
G226T:p.D76Y 
nonsynonymous 
SNV 
hom Novel 0.1 NA NA 
LYST lysosomal 
trafficking 
regulator 
LYST:uc001hxi.2:exon15:c.G2
140A:p.G714R 
nonsynonymous 
SNV 
hom 9.30E-05 0.19 0.889 5.53 
SMEK2 SMEK homolog 2, 
suppressor of 
mek1 
(Dictyostelium) 
SMEK2:uc002rzb.3:exon13:c.
G1838A:p.R613H 
nonsynonymous 
SNV 
hom Novel 0.31 0 5.1 
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TMEM131 transmembrane 
protein 131 
TMEM131:uc002syh.4:exon5:
c.C419T:p.T140M 
nonsynonymous 
SNV 
hom Novel 0 NA NA 
RFX8 regulatory factor X, 
8 
RFX8:uc010yvx.1:exon8:c.C64
7T:p.A216V 
nonsynonymous 
SNV 
hom Novel 0.06 NA NA 
FOXL2 forkhead box L2 FOXL2:uc003esw.3:exon1:c.C
668A:p.A223D 
nonsynonymous 
SNV 
hom Novel 0.01 0.509 2.94 
MCCC1 methylcrotonoyl-
CoA carboxylase 1 
(alpha) 
MCCC1:uc003flf.3:exon9:c.G9
11A:p.R304Q 
nonsynonymous 
SNV 
hom Novel 0.03 0.666 5.1 
G3BP2 GTPase activating 
protein binding 
protein 2 
G3BP2:uc003hit.3:exon9:c.A8
71G:p.I291V 
nonsynonymous 
SNV 
hom Novel 0.55 0.001 4.5 
SEMA5A sema domain, 
seven 
thrombospondin 
repeats (type 1 and 
type 1-like), 
transmembrane 
domain (TM) and 
short cytoplasmic 
SEMA5A:uc003jek.2:exon9:c.
G824A:p.R275H 
nonsynonymous 
SNV 
hom Novel 0 0.986 5.25 
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domain 5A 
REV3L REV3-like, catalytic 
subunit of DNA 
polymerase zeta 
(yeast) 
REV3L:uc003puy.4:exon13:c.
G2704A:p.G902R 
nonsynonymous 
SNV 
hom Novel 0 0.995 5.32 
TTYH3 tweety homolog 3 
(Drosophila) 
TTYH3:uc003smp.3:exon2:c.
C278A:p.A93D 
nonsynonymous 
SNV 
hom Novel 0 0.668 4.61 
RPA3 replication protein 
A3, 14kDa 
RPA3:uc003sri.3:exon6:c.C11
0A:p.T37N 
nonsynonymous 
SNV 
hom Novel 0.25 0.039 3.37 
PCSK5 proprotein 
convertase 
subtilisin/kexin 
type 5 
PCSK5:uc004ajy.2:exon14:c.2
008_2017del:p.670_673del 
frameshift deletion hom Novel NA NA NA 
PTRH1 peptidyl-tRNA 
hydrolase 1 
homolog  
PTRH1:uc004bro.3:exon2:c.17
6delG:p.R59fs 
frameshift deletion hom Novel NA NA NA 
ANXA11 annexin A11 ANXA11:uc010qlx.1:exon6:c. nonsynonymous hom 0.000186 0 1 4.19 
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G1205A:p.R402H SNV 
SYT4 synaptotagmin IV SYT4:uc002law.3:exon2:c.G50
5A:p.A169T,SYT4:uc010xcm.
2:exon2:c.G451A:p.A151T 
nonsynonymous 
SNV 
hom 0.0005 0.05 0.045 3.11 
MYLK2 myosin light chain 
kinase 2 
MYLK2:uc002wws.2:exon4:c.
C298A:p.L100M 
nonsynonymous 
SNV 
hom Novel 0.04 0 3.12 
CTNNBL1 catenin, beta like 1 CTNNBL1:uc002xhj.3:exon7:c
.C694T:p.R232W 
nonsynonymous 
SNV 
hom Novel 0 0.998 4.93 
BC112340 NA BC112340:uc002zoc.3:exon1:c.
C329T:p.T110I 
nonsynonymous 
SNV 
hom Novel 0 NA NA 
FER1L4 NA FER1L4:uc002xcx.3:exon5:c.C
622T:p.R208X 
stopgain SNV hom Novel 1 NA NA 
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5.4.6 DISCUSSION 
Exome sequencing and autozygosity mapping in this family has revealed a novel 
homozygous missense mutation in ATP13A2 (c.T2525C p.L842P) supporting a 
diagnosis of Kufor-Rakeb Syndrome in this patient.  Kufor-Rakeb syndrome (KRS) 
(MIM: 606693) was originally reported in a consanguineous family originating 
from Kufor-Rakeb in Jordan.313 KRS is an autosomal recessive inherited juvenile 
Parkinsonian syndrome caused by mutations in the ATP13A2 gene.196  The clinical 
features comprise akinetic-rigid parkinsonism, supranuclear gaze palsy, oculogyric 
dystonic spasms, facial-faucial-finger mini-myoclonus, and spasticity in some. 
Dementia and visual hallucinations are also recognised cognitive features. Brain 
imaging often reveals moderate cerebral and cerebellar atrophy sometimes with 
iron deposition in the basal ganglia.197  Individual IV:1 (family 2) has a clinical 
presentation in keeping with that recognised with KRS, with juvenile onset 
symptoms including: parkinsonism, pyramidal tract signs, dystonia, eye 
movement abnormalities, supranuclear gaze palsy, cognitive impairment and 
myoclonus. IV:1 developed L-dopa-induced dyskinesias early in the course of the 
disease, as has been reported in other KRS cases.314, 315  To date, only nine KRS 
families have been reported in the literature and they carry 11 different 
mutations.196, 197, 314, 316-322 The patient (IV:1) is the second patient of Asian ancestry 
in the literature to be reported with KRS, confirming a relevance for this condition 
in this population.322 Recently, a homozygous missense mutation in ATP13A2 was 
identified in a family with pathologically confirmed neuronal ceroid-
lipofuscinosis.35 This finding suggests that KRS is linked to the lysosomal pathway, 
a pathway that was already hypothesized for a variety of parkinsonian 
phenotypes, but was not previously shown for KRS.  
 
This novel ATP13A2 mutation c.T2525C p.L842P, resides in the hydrolase domain 
of the protein, a domain in which other pathogenic frameshift and missense 
mutations have already been described.196, 314, 316, 319, 320, 323-327 To-date, only three 
other homozygous missense variants have been reported in association with 
KRS,314, 316, 321 the vast majority being frameshift and splice-site mutations.  The 
mechanism(s) through which missense mutations cause KRS are not fully 
understood at present, however a recent study implicates that another missense 
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mutation in the hydrolase domain results in (p.G877R) impaired protein stability 
and enhanced degradation by the proteasome. Other missense mutations resulted 
in mislocalization of ATP13A2 to the endoplasmic reticulum.328  
 
Family 2 demonstrate the utility of WES and autozygosity mapping as a cost-
effective, timely way of simultaneous screening of several genes that can cause 
juvenile onset, complex parkinsonian syndromes, even in a singleton case.  
 
 
5.5 FAMILY 3: EXOME SEQUENCING AND 
LINKAGE ANALYSIS IN A NON-
CONSANGUINEOUS PARKINSONISM-DYSTONIA 
FAMILY 
 
5.5.1 STATEMENT OF CONTRIBUTION TO THIS 
RESEARCH 
I examined all family members. I performed parts of the genome-wide linkage 
analysis. I analysed the WES data and performed confirmatory Sanger sequencing 
and segregation analysis. 
 
5.5.2 BACKGROUND 
Dr. Nin Bajaj (a movements disorders expert in Birmingham, UK) identified this 
interesting family (figure 5.3) in whom there is no known parental consanguinity. 
In order to try and identify the causative variant in this family a combination of 
linkage analysis and exome sequencing was performed. The mode of inheritance 
was assumed to be autosomal recessive with a penetrance of 90%. Analysis of WES 
variants did not reveal any homozygous or compound heterozygous variants in 
the linkage regions. However, a novel, highly conserved variant was identified in 
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the LRRK2 gene, a gene in which mutations are known to cause autosomal 
dominant PD. The variant segregates with PD in this family.  
 
Figure 5.3: Pedigree of family 3. An arrow indicates the individuals selected for 
exome sequencing 
 
 
 
 
 
 
Above: Full pedigree for family 3.  
 
5.5.3 METHODS 
5.5.3.1 Samples 
DNA samples from II:1-II:5 were collected by myself. II:1-II:5 were examined by 
both Dr. Nin Bajaj and myself. Individuals I:1 and I:2 are deceased, DNA is not 
available on them, nor were they formally clinically examined. The wider family 
were not available to participate in the study.  
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5.5.3.2 Genome wide Linkage Analysis 
Genome-wide multipoint parametric linkage utilizing ~30,000 equally spaced 
markers was performed using the computer program Allegro. This work was 
performed by Prof Robert Kleta, Dr. Dr. Horia Stanescu and Mehmet Tekman at 
UCL.  
 
5.5.3.4 Whole Exome Sequencing 
Individuals II:1 and II:5 were selected for WES. This was carried out as described in 
the materials and methods section (chapter 2). 
 
5.5.3.5 Variant filtering 
Only variants within regions of linkage were used for filtering. Synonymous 
variants and any variant present in a range of publically available databases of 
sequence variation (dbSNP, 1000 Genomes, Complete Genomic 69 Database and 
NHLBI Exome Sequencing Project database) with a frequency more than 1% were 
filtered out.  
5.5.3.6 Sanger sequencing 
The variant in the LRRK2 gene was confirmed by Sanger Sequencing as described 
in Chapter 2). 
 
5.5.4 RESULTS 
5.5.4.1 Phenotypic Characterisation of patients 
II:1 is a 49 years old gentleman who developed a tremor from very early 
childhood. He had learning difficulties and attended a specialist school. He had 
poor motor skills and struggled with sports at school.  He also had many falls as a 
child. He left school aged 16 without any qualifications. He became aware of an 
arm tremor and dysarthria aged 28 years of age. He has a tendency to fall 
backwards.  
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Investigations showed normal copper and ceruloplasmin. Genetic testing was 
negative for DRPLA, Freidreich’s ataxia and the common Spinocerebellar ataxias. 
DATscan showed a presynaptic dopaminergic deficit. 
 
Examination revealed cognitive impairment especially in the frontal domain. He 
had a mild right-sided torticollis. Pursuit eye movements were broken. There was a 
right-sided rest tremor with a dystonic postural tremor and hyperextension of the 
thumb. Cogwheel rigidity and bradykinesia were present bilaterally but worse on 
the right. Gait examination revealed bilaterally reduced arms swing and dragging 
of the right leg. Postural reflexes were impaired. The patient is L-dopa responsive 
and on a low dose of Madopar twice daily. In summary there is evidence of 
learning disability, dystonia and parkinsonism.  
 
II:2 developed a bilateral hand tremor as a child. He had normal motor skills as a 
child and excelled in sport at school. He developed psychiatric problems aged 25 
years and was treated with neuroleptics including Dosulepin, Chlorpromazine and 
Olanzapine. He had a dystonic reaction to one of these drugs necessitating 
treatment with Chlorpromazine. He developed falls aged 35 years. He also has 
dysphagia and constipation, which has required hospital admission. A DATscan 
was positive indicating that the parkinsonism was not drug induced but due to a 
primary dopaminergic deficit. His parkinsonism symptoms respond to a low dose 
of Madopar. 
 
His examination showed cogwheel rigidity, which was asymmetric being worse on 
the right, together with some axial rigidity. There was no rest or postural tremor. 
His gait was shuffling with reduced arm swing. He had retained postural reflexes.  
 
II:3 has a normal examination.  
 
II:4 also developed a bilateral arm tremor in the first decade of life, which has 
progressively become worse. Her mobility is not affected. She has no REM sleep 
behavioral disturbances or anosmia. She was found to have signs of parkinsonism 
incidentally on examining her as part of this study aged 46 years. Neurological 
examination reveals mild facial hypomimia with a bilateral rest tremor worse on 
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the right with an emergent postural tremor and dystonic posturing of the right 
hand. There was mild right torticollis. Repetitive movements showed bradykinesia 
more on the right. There was also bilateral cogwheel rigidity. Gait examination 
showed reduced arm swing on the right. There was also a mild degree of 
micrographia. The patient was L-dopa responsive and had a severe type III 
abnormality on DAT scan.  
 
II:5 developed an arm tremor aged 26 years. Over the years this has worsened and 
her mobility has become affected resulting in her becoming wheelchair bound aged 
48 years. There is no history of REM sleep disorder or anosmia. Memory is not 
impaired. Past medical history includes childhood polio affecting the left arm and 
leg and diabetes. Examination showed a bilateral rest and postural tremor. There 
was thumb hyperextension bilaterally indicating dystonic posturing. There was 
marked bradykinesia and cog-wheeling bilaterally.  
 
Clinical examination for the wider family was not available as they were 
unavailable to participate in the research study, however none had a diagnosis of 
PD. 
 
5.5.4.2 Clinical summary  
This is a non-consanguineous family originating from Pakistan. 4 of the 5 siblings 
are affected by varying degrees of parkinsonism-dystonia which is confirmed on 
DAT scan. An autosomal recessive inheritance is most likely for a number of 
reasons. 1. There is an early age of onset with several siblings developing an arm 
tremor in the first decade. 2. Neither parent was known to be affected, they lived 
into their late 50’s. 3. None of the affected sibling’s children have developed 
symptoms, despite the early age of onset, some of the children are now in their 
20’s. However, there is a possibility that this is an early-onset autosomal dominant 
disorder, most likely inherited through the maternal side of the family. Their 
mother may not have been symptomatic due to reduced penetrance, or because she 
died before the disease onset. Transmission of the disorder via the maternal side of 
the family may be masked by the fact the mother has no siblings.  
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5.5.4.2 Genome Wide Parametric Linkage Analysis 
Multipoint parametric linkage analysis resulted in a total of ~134Mb of linked 
regions (table 5.7), narrowing the region in which the candidate variant(s) are most 
likely to be found to 4.5% of the total genome.  
 
Table 5.7: Linked regions for family 3 
Chromosome Position From Position To Lod Score 
chr4 4,826,875 5,116,247 1.9311 
chr4 5,576,140 5,827,079 1.9311 
chr5 8,791,745 56,733,883 1.9311 
chr5 150,760,282 151,351,067 0.9993 
chr7 47,898,734 68,549,573 1.9311 
chr9 93,874,879 109,989,135 1.846 
chr10 1,948,064 2,394,389 1.5551 
chr10 105,328,241 105,817,891 1.7334 
chr11 86,093,568 86,621,300 1.9311 
chr11 93,281,716 94,902,171 1.9311 
chr11 110,023,164 110,833,266 1.0272 
chr12 7,645,777 22,263,219 1.9311 
chr12 30,938,922 50,306,148 1.9311 
chr12 51,585,335 53,210,145 1.6074 
chr12 67,880,042 68,485,984 1.0808 
chr13 113,530,199 114,056,524 1.9311 
chr15 22,916,162 23,877,411 1.9311 
chr15 45,934,869 46,845,278 1.5562 
chr19 2,032,148 2,930,806 1.9311 
chr20 2,978,928 6,836,952 1.9311 
chr21 16,139,324 16,576,783 1.5031 
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5.5.4.3 Whole Exome Sequencing  
WES metrics indicated good coverage in both II:2 and II:5 (table 5.8) 
 
Table 5.8: WES metrics 
 II:1 Family 3  II:5 Family 3 
Total number of reads 70,225,472 150,593,410 
Non-duplicated reads 43,796,142 130,413,440 
Reads aligned to target 85% 85% 
Mean Target Coverage 35 87 
% Target covered by 2 reads 91% 96% 
% Target covered by 10 reads 81% 94% 
% Target covered by 20 reads 67% 91% 
Total number of variants 21,025 23,555 
 
5.5.4.4 Variant Filtering 
Tables 5.9 and 5.10 show the variants remaining after variant filtering as described 
above in individuals II:2 and II:5.
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Table 5.9: Variants remaining after filtering in linkage regions in individual II:1 
 
Gene  Gene Name Amino acid 
change 
Exonic Function Call Highest 
Frequency 
in 
Publically 
Available 
databases 
SIFT 
Score 
Poly 
phen2 
Score 
GERP 
Score 
Comment 
AGXT2 alanine-
glyoxylate 
aminotransferase 
2 
ENST0000023142
0.6  exon12 
c.T1269G 
p.D423E 
nonsynonymous 
SNV 
het 7.70E-05 0.15 0.122 2.67 Class III pyridoxal-phosphate-
dependent mitochondrial 
aminotransferase. Catalyzes 
conversion of glyoxylate to 
glycine.  
ATF7IP activating 
transcription 
factor 7 
interacting 
protein 
ENST0000054079
3.1  exon1 
c.C1505T p.S502L 
nonsynonymous 
SNV 
het 0.003695 0.25 0.673 4.5 Protein that can act as a 
transcriptional 
coactivator or corepressor 
depending upon its binding 
partners 
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CARD6 caspase 
recruitment 
domain family, 
member 6 
ENST0000025469
1.5  exon3 
c.C1016T p.T339I 
nonsynonymous 
SNV 
het Novel 0 0.988 2.79 Microtubule-associated protein 
that interacts with receptor-
interacting protein kinases and 
positively modulate signal 
transduction pathways 
converging on activation of the 
inducible transcription factor 
NF-kB. May be involved in 
apoptosis 
CDKN1B cyclin-dependent 
kinase inhibitor 
1B  
ENST0000022887
2.4 exon1 c.C277T 
p.R93W 
nonsynonymous 
SNV 
het 5.00E-04 0 1 5.05 Important regulator of cell 
cycle progression. Involved in 
G1 arrest. 
CLEC4E C-type lectin 
domain family 4, 
member E 
ENST0000029966
3.3 exon2 c.G83T 
p.G28V 
nonsynonymous 
SNV 
het 7.70E-05 0.28 0.861 2.23 C-type lectin that functions as 
cell-surface receptor for a wide 
variety of ligands such as 
damaged cells, fungi and 
mycobacteria. 
DNAJC22 DnaJ homolog, 
subfamily C, 
member 22 
ENST0000039506
9.2 exon2 
c.G742A p.G248R 
nonsynonymous 
SNV 
het 0.000769 0 0.995 3.52 May function as a co-
chaperone 
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GZMK granzyme K  ENST0000023100
9.2 exon2  
c.G212A 
p.R71QGZMK;G
ZMK 
Splicing het Novel 0.27 0.137 -3.56 Serine proteases from the 
cytoplasmic granules of 
cytotoxic lymphocyte. Poorly 
conserved. 
LRRK2 leucine-rich 
repeat kinase 2 
ENST0000029891
0.7 exon47  
c.C6974T 
p.S2325F 
nonsynonymous 
SNV 
het Novel 0 0.544 5.38 Gene in which mutations are 
known to cause autosomal 
dominant Parkinson's disease 
NANOGP1 Nanog 
Homeobox 
Pseudogene 1 
ENST0000053098
9.1 exon3  
c.T305C p.L102P 
nonsynonymous 
SNV 
het 0.007 0.26 NA NA Probable transcriptional 
regulator 
OR13C2 olfactory 
receptor, family 
13, subfamily C, 
member 2 
ENST0000054219
6.1 exon1  c.C88G 
p.L30V 
nonsynonymous 
SNV 
het Novel 0.11 0 2.66 Odorant receptor 
PKP2 plakophilin 2 ENST0000034081
1.4 exon11  
c.A2233G p.I745V 
nonsynonymous 
SNV 
het Novel 0.29 0.022 2.64 May play a role in junctional 
plaques 
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PLEKHA5 pleckstrin 
homology 
domain 
containing, 
family A member 
5 
ENST0000042426
8.1 exon8  
c.G791A p.S264N 
nonsynonymous 
SNV 
het Novel 0.77 0 2.55 Unknown function  
RAI14 retinoic acid 
induced 14 
ENST0000039744
9.1 exon2  
c.C110T p.A37V 
nonsynonymous 
SNV 
het Novel 0.17 0.003 5.37 Unknown function  
RECQL RecQ protein-like  ENST0000044412
9.2 exon6  
c.G644T p.R215L 
nonsynonymous 
SNV 
het Novel 0.03 0.37 4.21 DNA helicase that may play a 
role in the repair of DNA that 
is damaged by ultraviolet light 
or other mutagens 
THOP1 thimet 
oligopeptidase 1 
ENST0000030774
1.5 exon5  
c.C557T p.T186M 
nonsynonymous 
SNV 
het 0.001461 0.04 0.001 2.81 Involved in the metabolism of 
neuropeptides <20 amino acid 
residues long. Involved in 
cytoplasmic peptide 
degradation. Able to degrade 
the beta-amyloid precursor 
protein 
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TMOD1 tropomodulin 1 ENST0000025936
5.3 exon2  c.G14A 
p.R5Q 
nonsynonymous 
SNV 
het 0.000846 0.07 0.027 4.91 Is an actin-capping protein 
that regulates 
tropomyosin, inhibiting 
depolymerization and 
elongation of the pointed end 
of actin 
filaments and thereby 
influencing the structure of the 
erythrocyte membrane 
skeleton 
TTC23L tetratricopeptide 
repeat domain 
23-like 
ENST0000050562
4.1 exon3  
c.C218T p.S73F 
nonsynonymous 
SNV 
het Novel 0.05 NA NA Not known 
ZNF462 zinc finger 
protein 462 
ENST0000044114
7.2 exon1  
c.C1819T 
p.R607W 
nonsynonymous 
SNV 
het Novel 0 0.997 3.05 May be involved in 
transcriptional regulation 
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Table 5.10: Variants remaining after filtering in linkage regions in individual II:5 
Gene Gene Name Amino acid 
change 
Exonic Function Call Highest 
Frequency 
in 
Publically 
Available 
databases 
SIFT 
Score 
Poly 
Phen2 
Score 
GERP 
Score 
Comments 
CARD6 caspase 
recruitment 
domain 
family, 
member 6 
ENST00000254
691.5 exon3 
c.C1016T 
p.T339I 
nonsynonymous 
SNV 
het Novel 0 0.988 2.79 Microtubule-associated protein that 
interacts with receptor-interacting 
protein kinases and positively 
modulate signal transduction 
pathways converging on activation 
of the inducible transcription factor 
NF-kB. May be involved in 
apoptosis 
CDKN1B cyclin-
dependent 
kinase 
inhibitor 1B  
ENST00000228
872.4 exon1 
c.C277T 
p.R93W 
 
nonsynonymous 
SNV 
het 5.00E-04 0 1 5.05 Important regulator of cell cycle 
progression. Involved in G1 arrest. 
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CLEC4E C-type lectin 
domain family 
4, member E 
ENST00000299
663.3 exon2 
c.G83T p.G28V 
nonsynonymous 
SNV 
het 7.70E-05 0.28 0.861 2.23 C-type lectin that functions as cell-
surface receptor for a wide variety of 
ligands such as damaged cells, fungi 
and mycobacteria. 
DAP death-
associated 
protein 
ENST00000230
895.6 exon1 
c.A44C p.H15P 
nonsynonymous 
SNV 
het Novel 0 0.998 3.38 Negative regulator of autophagy. 
Involved in mediating interferon-
gamma-induced cell death 
DNAJC22 DnaJ (Hsp40) 
homolog, 
subfamily C, 
member 22 
ENST00000395
069.2 exon2 
c.G742A 
p.G248R 
nonsynonymous 
SNV 
het 0.000769 0 0.995 3.52 May function as a co-chaperone 
GOLGA6L2 golgin A6 
family-like 2 
ENST00000567
107.1 exon8 
c.1788_1790del 
p.596_597del 
nonframeshift 
deletion 
het Novel NA NA NA Not known 
GZMK granzyme K 
(granzyme 3; 
tryptase II) 
ENST00000231
009.2 exon2 
c.G212A 
p.R71Q 
nonsynonymous 
SNV 
het Novel 0.27 0.137 -3.56 Serine protease from the cytoplasmic 
granules of cytotoxic lymphocyte. 
Poorly conserved. 
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KRT2 keratin 2 ENST00000309
680.3 exon1 
c.286_287insTT
TGGAGGCGG
CAGCGGC 
p.F96delinsFG
GGSGF 
nonframeshift 
insertion 
het Novel NA NA NA Probably contributes to terminal 
cornification. Associated with 
keratinocyte activation, proliferation 
and 
keratinization 
KRT72 keratin 72 ENST00000354
310.4 exon6 
c.G1045C 
p.E349Q 
nonsynonymous 
SNV 
het Novel 0.03 0.011 1.97 Has a role in hair formation 
LRRK2 leucine-rich 
repeat kinase 2 
ENST00000298
910.7 exon47 
c.C6974T 
p.S2325F 
nonsynonymous 
SNV 
het Novel 0 0.544 5.38 Gene in which mutations are known 
to cause autosomal dominant 
Parkinson's disease 
PKP2 plakophilin 2 ENST00000340
811.4 exon11 
c.A2233G 
p.I745V 
nonsynonymous 
SNV 
het Novel 0.29 0.022 2.64 May play a role in junctional plaques 
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PLEKHA5 pleckstrin 
homology 
domain 
containing, 
family A 
member 5 
ENST00000424
268.1 exon8 
c.G791A 
p.S264Nn11 
c.G1133A 
p.S378N 
nonsynonymous 
SNV 
het Novel 0.77 0 2.55 Unknown function  
PRB3 proline-rich 
protein BstNI 
subfamily 3 
ENST00000381
842.3 exon5 
c.605-2A>G  
Splicing hom Novel NA NA NA Major constituent of parotid saliva. 
Proposed to act as a bacterial 
receptor.  
PRDM9 PR domain 
containing 9 
ENST00000296
682.3 exon11 
c.C2042G 
p.T681S 
nonsynonymous 
SNV 
hom Novel 1 0.1099
52 
-4.57 Likely to be involved in 
transcriptional regulation 
RAI14 retinoic acid 
induced 14 
ENST00000397
449.1 exon2 
c.C110T 
p.A37V 
nonsynonymous 
SNV 
het Novel 0.17 0.003 5.37 Unknown function  
RECQL RecQ protein-
like  
ENST00000444
129.2 exon6 
c.G644T 
nonsynonymous 
SNV 
het Novel 0.03 0.37 4.21 DNA helicase that may play a role in 
the repair of DNA that is damaged 
by ultraviolet light or other 
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p.R215L mutagens 
SIGLEC1 sialic acid 
binding Ig-like 
lectin 1, 
sialoadhesin 
NASIGLEC1 splicing het Novel NA NA NA Acts as an endocytic receptor 
mediating clathrin dependent 
endocytosis. 
TAS2R31 taste receptor, 
type 2, 
member 31 
ENST00000390
675.2 exon1 
c.G259A 
p.V87I 
nonsynonymous 
SNV 
het present in 
dbSNP 
but MAF 
not 
available 
NA NA NA Receptor that may play a role in the 
perception of bitterness. Unlikely 
candidate 
 
 
 
 
TMOD1 tropomodulin 
1 
ENST00000259
365.3 exon2 
c.G14A p.R5Q 
nonsynonymous 
SNV 
het 0.000846 0.07 0.027 4.91 Actin-capping protein that regulates 
tropomyosin by binding to its N-
terminus, inhibiting 
depolymerization and elongation of 
the pointed end of actin 
filaments and thereby influencing 
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the structure of the erythrocyte 
membrane skeleton. 
 
TTC23L tetratricopepti
de repeat 
domain 23-like 
ENST00000505
624.1 exon3 
c.C218T p.S73F 
nonsynonymous 
SNV 
het Novel 0.05 NA NA Not known 
ZNF462 zinc finger 
protein 462 
ENST00000441
147.2 exon1 
c.C1819T 
p.R607W 
nonsynonymous 
SNV 
het Novel 0 0.997 3.05 May be involved in transcriptional 
regulation 
 
 149 
 
Review of the variants in both individual II:1 and II:5 revealed there was no gene 
which had a compound heterozygous or homozygous variant in. This remained 
the case even when synonymous variants were included in the analysis. A copy 
number analysis was performed across the exome using ‘Exome depth’ (as 
described in chapter 2), however this did not reveal any homozygous copy 
number variants within the linkage region, nor did it reveal any heterozygous 
copy number variants in genes which already had a splicing, nonsynonymous or 
indel variant ascertained from exome sequencing. The coverage of ascertained 
variants within the linkage regions in II:1 was checked in II:5 (and vice versa) to 
confirm that variants that were not shared between the two individuals were 
sufficiently covered in the other individual.   
 
Next, I considered only shared variants between individuals II:1 and II:5 (Table 
5.11). Of interest, there is a novel, nonsynonymous variant in LRRK2 
(ENST00000298910.7 exon47 c.C6974T p.S2325F), at a highly conserved residue 
(GERP score 5.38), within the WD40 domain of the protein. Mutations in LRRK2 
are an established cause of autosomal dominant PD. Sanger sequencing 
confirmed that this variant was present in the four affected individuals and not in 
the unaffected individual.  
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Table 5.11: Shared rare variants between individual II:1 and II:5. 
 
Gene Gene Name Amino acid 
change 
Exonic Function Call Highest 
Frequency 
in 
Publically 
Available 
databases 
SIFT 
Score 
Poly 
Phen2 
Score 
GERP 
Score 
Comments 
CARD6 caspase 
recruitment 
domain 
family, 
member 6 
ENST0000025
4691.5 exon3 
c.C1016T 
p.T339I 
nonsynonymous 
SNV 
het Novel 0 0.988 2.79 Microtubule-associated protein that interacts 
with receptor-interacting protein kinases 
and positively modulate signal transduction 
pathways converging on activation of the 
inducible transcription factor NF-kB. May be 
involved in apoptosis 
CDKN1B cyclin-
dependent 
kinase 
inhibitor 1B  
ENST0000022
8872.4 exon1 
c.C277T 
p.R93W 
nonsynonymous 
SNV 
het 5.00E-04 0 1 5.05 Important regulator of cell cycle 
progression. Involved in G1 arrest. 
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CLEC4E C-type 
lectin 
domain 
family 4, 
member E 
ENST0000029
9663.3 exon2 
c.G83T 
p.G28V 
nonsynonymous 
SNV 
het 7.70E-05 0.28 0.861 2.23 C-type lectin that functions as cell-surface 
receptor for a wide variety of ligands such 
as damaged cells, fungi and mycobacteria. 
DNAJC22 DnaJ 
(Hsp40) 
homolog, 
subfamily 
C, member 
22 
ENST0000039
5069.2 exon2 
c.G742A 
p.G248R 
nonsynonymous 
SNV 
het 0.000769 0 0.995 3.52 May function as a co-chaperone 
GZMK granzyme K 
(granzyme 
3; tryptase 
II) 
ENST0000023
1009.2 exon2 
c.G212A 
p.R71Q 
nonsynonymous 
SNV 
het Novel 0.27 0.137 -3.56 Serine protease from the cytoplasmic 
granules of cytotoxic lymphocyte. Poorly 
conserved. 
LRRK2 leucine-rich 
repeat 
kinase 2 
ENST0000029
8910.7 exon47 
c.C6974T 
p.S2325F 
nonsynonymous 
SNV 
het Novel 0 0.544 5.38 Gene in which mutations are known to 
cause autosomal dominant Parkinson's 
disease 
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PKP2 plakophilin 
2 
ENST0000034
0811.4 exon11 
c.A2233G 
p.I745V 
nonsynonymous 
SNV 
het Novel 0.29 0.022 2.64 May play a role in junctional plaques 
PLEKHA5 pleckstrin 
homology 
domain 
containing, 
family A 
member 5 
ENST0000042
4268.1 exon8 
c.G791A 
p.S264Nn11 
c.G1133A 
p.S378N 
nonsynonymous 
SNV 
het Novel 0.77 0 2.55 Unknown function  
RAI14 retinoic acid 
induced 14 
ENST0000039
7449.1 exon2 
c.C110T 
p.A37V 
nonsynonymous 
SNV 
het Novel 0.17 0.003 5.37 Unknown function  
RECQL RecQ 
protein-like  
ENST0000044
4129.2 exon6 
c.G644T 
p.R215L 
nonsynonymous 
SNV 
het Novel 0.03 0.37 4.21 DNA helicase that may play a role in the 
repair of DNA that is damaged by 
ultraviolet light or other 
mutagens 
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TTC23L tetratricope
ptide repeat 
domain 23-
like 
ENST0000050
5624.1 exon3 
c.C218T 
p.S73F 
nonsynonymous 
SNV 
het Novel 0.05 NA NA Not known 
ZNF462 zinc finger 
protein 462 
ENST0000044
1147.2 exon1 
c.C1819T 
p.R607W 
nonsynonymous 
SNV 
het Novel 0 0.997 3.05 May be involved in transcriptional 
regulation 
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Parametric genome-wide linkage analysis was also performed using Merlin with 
an autosomal dominant model of inheritance (see materials and methods, chapter 
2). This revealed 71 linkage regions (Table 5.12). When variant filtering was 
repeated for these linkage regions only, after synonymous and homozygous 
variants were excluded, and those variants with a frequency of 0.1%, 38 shared 
variants between II:1 and II:5 remained (table 5.13). Once again, the novel, highly 
conserved, variant in the LRRK2 gene is in one of the linkage regions with the 
highest Lod score of 1.12. 
 
Table 5.12: Parametric Linkage regions and Lod scores for autosomal dominant 
inheritance. 
Chromosome Position from Position to Max lod score 
1 20,056,631 22,674,370 0.8 
1 117,845,032 180,543,539 0.82 
1 201,883,199 205,418,134 0.82 
1 244,930,726 245,474,078 0.82 
2 6,418,557 11,753,697 0.83 
2 21,586,117 29,229,806 0.82 
2 30,860,007 30902939  0.82 
2 34,672,921 40,341,388 0.82 
2 45,905,946 65,892,430 0.82 
2 69,126,125 73,857,002 0.82 
2 78,307,412 78,755,686 0.82 
2 82,410,462 86,376,474 0.82 
2 101,911,385 115,730,919 0.82 
2 123,818,973 137,179,433 0.82 
2 173,369,231 210,330,754 0.82 
2 231,976,460 238,294,434 0.82 
3 9,877,481 15,935,841 0.77 
3 25,212,878 29,258,177 0.82 
3 34,822,886 35,278,145 0.82 
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3 45,828,586 59,625,877 0.82 
3 151,507,750 172,321,434 0.82 
4 3,454,304 23,962,061 1.12 
4 159,876,379 180,472,339 0.82 
5 1,529,358 14,776,897 1.1 
5 73,030,942 73330562  0.82 
5 76,171,063 77,284,789 0.82 
5 90,858,258 100,567,453 0.82 
5 110,708,854 116,080,067 0.82 
5 135,978,129 152,797,679 0.82 
5 173,684,581 178950814  0.82 
6 20,274,321 33,753,673 0.82 
6 41,941,980 46,914,760 0.82 
6 53,489,402 68,921,177 0.82 
6 109,410,569 119,903,523 0.82 
6 126,029,043 152,624,699 0.82 
7 39,285,620 96,519,876 1.12 
7 152,162,209 157,600,780 0.82 
8 176,818 6,471,526 0.82 
8 13,174,945 14,489,024 0.82 
8 141,727,310 144,163,378 0.82 
9 2,267,871 8,215,609 0.82 
9 19,386,565 38,214,047 0.82 
10 1,276,186 14,332,431 0.82 
10 89,175,636 95,101,480 0.82 
10 124,931,515 133,441,851 0.82 
11 20,989,375 22,475,813 0.82 
11 27,401,190 32,226,445 0.82 
11 78,698,287 101,470,545 1.12 
11 128,371,441 134,617,321 0.82 
12 3,647,268 59,850,416 1.12 
12 68,617,219 75,500,790 0.81 
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12 80,580,111 96,447,847 0.82 
13 21,745,977 23,900,652 0.82 
13 44482204  57,064,916 0.3 
13 63,644,364 83,837,607 0.82 
13 108,403,984 109,865,139 0.82 
14 23,596,320 34,199,638 0.82 
14 88,275,924 93,796,411 0.82 
15 22,759,438 34,574,330 0.82 
15 46158407  47,246,651 0.82 
15 61,124,220 101,862,970 1.12 
16 442,805 6,144,648 0.82 
16 13,803,064 17,722,115 0.82 
16 23,888,840 30,154,740 0.82 
16 73,421,001 81,427,483 0.82 
17 1,943,888 6,733,672 0.82 
18 6,653,590 8,546,911 0.61 
18 72,845,315 5,426,449 0.82 
20 191,797 18,889,562 1.12 
21 15,659,254 40,935,773 0.82 
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Table 5.13: Showing variants shared between II:1 and II:5 within Linkage regions (autosomal dominant model of inheritance) 
Gene Gene Name Amino acid change Exonic Function Call Frequency 
in 
publically 
available 
databases 
SIFT 
score 
Poly 
Phen2 
Score 
GERP 
score 
Comment 
RECQL RecQ protein-
like 
RECQL 
ENST00000444129.2 
exon6 c.G644T 
p.R215L 
nonsynonymous 
SNV 
het Novel 0.03 0.37 4.21 DNA repair 
PKP2 plakophilin 2 PKP2 
ENST00000340811.4 
exon11 c.A2233G 
p.I745V 
nonsynonymous 
SNV 
het Novel 0.29 0.022 2.64 May play a role in junctional plaques 
LRRK2 leucine-rich 
repeat kinase 2 
LRRK2 
ENST00000298910.7 
exon47 c.C6974T 
p.S2325F 
nonsynonymous 
SNV 
het Novel 0 0.544 5.38 Gene in which mutations are known 
to cause autosomal dominant 
Parkinson's disease 
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ARHGEF11 Rho guanine 
nucleotide 
exchange 
factor 11 
ARHGEF11 
ENST00000361409.2 
exon6 c.C416T 
p.A139V 
nonsynonymous 
SNV 
het Novel 0.14 0.006 1.4 Play a fundamental role in cellular 
processes that are initiated by 
extracellular stimuli that work 
through G protein coupled receptors 
TTC30A tetratricopepti
de repeat 
domain 30A 
TTC30A 
ENST00000355689.4 
exon1 c.G274A 
p.A92T 
nonsynonymous 
SNV 
het Novel 0.01 0.503 5.68 Plays a role in anterograde 
intraflagellar transport, the process 
by which cilia precursors are 
transported from the base of the 
cilium to the site of their 
incorporation at the tip 
RAPH1 Ras association 
and pleckstrin 
homology 
domains 1 
RAPH1 
ENST00000319170.5 
exon14 c.2570_2578del 
p.857_860del 
nonframeshift 
deletion 
het Novel NA NA NA Mediator of localized membrane 
signals. Implicated in the regulation 
of lamellipodial dynamics. 
Negatively regulates cell adhesion 
PLXNB1 plexin B1 PLXNB1 
ENST00000456774.1 
exon19 c.G3265A 
p.V1089I 
nonsynonymous 
SNV 
het Novel 0 0.984 4.8 Receptor for SEMA4D. Plays a role 
in RHOA activation and subsequent 
changes of the actin cytoskeleton. 
Plays a role in axon guidance, 
invasive growth and cell migration 
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ZNF518B zinc finger 
protein 518B 
ZNF518B 
ENST00000326756.3 
exon3 c.G2758A 
p.A920T 
nonsynonymous 
SNV 
het Novel 0 0.889 1.72 Transcriptional regulation 
TKTL2 transketolase-
like 2 
TKTL2 
ENST00000280605.3 
exon1 c.G617C 
p.C206S 
nonsynonymous 
SNV 
het Novel 0 0.907 2.66 Plays a pivotal role in carcinogenesis 
PAPD7 PAP associated 
domain 
containing 7 
PAPD7 
ENST00000230859.6 
exon13 c.A1621C 
p.S541R 
nonsynonymous 
SNV 
het Novel 0 0.906 4.83 DNA polymerase that is likely 
involved in DNA repair. 
ST8SIA4 ST8 alpha-N-
acetyl-
neuraminide 
alpha-2,8-
sialyltransferas
e 4 
ST8SIA4 
ENST00000231461.4 
exon4 c.G619T 
p.D207Y 
nonsynonymous 
SNV 
het Novel 0.02 0.418 4.97 Catalyzes the polycondensation of 
alpha-2,8-linked sialic acid required 
for the synthesis of polysialic acid, 
which is present on the embryonic 
neural cell adhesion molecule, 
necessary for plasticity of neural 
cells 
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APC adenomatous 
polyposis coli 
APC 
ENST00000257430.4 
exon16 c.G4919A 
p.R1640Q 
nonsynonymous 
SNV 
het Novel 0.31 1 5.81 Tumor suppressor gene. Mutations 
in this cause a familial cancer 
syndrome. Unlikely candidate 
OR14J1 olfactory 
receptor, 
family 14, 
subfamily J, 
member 1 
OR14J1 
ENST00000377160.2 
exon1 c.G56A p.R19H 
nonsynonymous 
SNV 
het Novel 0.24 0.01 -4.29 Odorant receptor 
VARS valyl-tRNA 
synthetase 
VARS 
ENST00000375663.3 
exon7 c.G881C 
p.G294A 
nonsynonymous 
SNV 
het submitted 
to dbSNP 
0.34 0.038 2.91 Aminoacyl-tRNA synthetases 
catalyze the aminoacylation of tRNA 
by their cognate amino acid. Many 
tRNA synthetases are linkaed to 
neurological diseases 
PRPH2 peripherin 2  PRPH2 
ENST00000230381.5 
exon2 c.G616T 
nonsynonymous 
SNV 
het Novel 0.28 0.005 4.66 Involved in disk morphogenesis 
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p.V206L 
 
 
HCRTR2 hypocretin 
(orexin) 
receptor 2 
HCRTR2 
ENST00000370862.3 
exon7 c.G1211A 
p.R404Q 
nonsynonymous 
SNV 
het Novel 0.07 0.293 4.99 G-protein coupled receptor involved 
in the regulation of feeding 
behaviour.  
C7orf10 chromosome 7 
open reading 
frame 10 
C7orf10 
ENST00000309930.5 
exon3 c.G242A 
p.R81K 
nonsynonymous 
SNV 
het Novel 0.36 NA NA Mutations in this gene are associated 
with glutaric aciduria type III, an 
autosomal recessive inborn error of 
metabolism 
HTR5A 5-
hydroxytrypta
mine receptor 
5A 
HTR5A 
ENST00000287907.2 
exon2 c.G817T 
p.D273Y 
nonsynonymous 
SNV 
het Novel 0 0.964 4.51 Receptors for serotonin, a biogenic 
hormone that functions as a 
neurotransmitter, a hormone, and a 
mitogen 
INSL6 insulin-like 6 INSL6 
ENST00000381641.3 
exon2 c.329_337del 
p.110_113del 
nonframeshift 
deletion 
het Novel NA NA NA May have a role in sperm 
development and fertilization. 
Unlikely candidate gene 
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SEC61A2 Sec61 alpha 2 
subunit (S. 
cerevisiae) 
SEC61A2 
ENST00000304267.8 
exon12 c.A1249G 
p.K417E 
nonsynonymous 
SNV 
het Novel 0.02 NA NA Appears to play a crucial role in the 
insertion of secretory and membrane 
polypeptides into the ER. 
ESPL1 extra spindle 
pole bodies 
homolog 1  
ESPL1 
ENST00000257934.4 
exon3 c.A937G 
p.K313E 
nonsynonymous 
SNV 
het Novel 0.64 0 -2.85 Caspase-like protease, which plays a 
central role in the chromosome 
segregation. Unlikely candidate as 
poorly conserved 
SGCG sarcoglycan, 
gamma 
SGCG 
ENST00000218867.3 
exon5 c.T479C 
p.V160A 
nonsynonymous 
SNV 
het Novel 0 0.551 5.06 Component of the sarcoglycan 
complex 
TRIM13 tripartite motif 
containing 13 
TRIM13 
ENST00000298772.5 
exon2 c.G137A 
p.R46Q 
nonsynonymous 
SNV 
het Novel 0.04 0.999 5.17 E3 ubiquitin ligase. Candidate 
variant.  
LMO7 LIM domain 7 LMO7 
ENST00000341547.4 
exon3 c.254_255del 
p.85_85del 
frameshift 
deletion 
het Novel NA NA NA Involved in protein-protein 
interactions 
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AKAP6 A kinase 
(PRKA) anchor 
protein 6 
AKAP6 
ENST00000280979.4 
exon4 c.G809A 
p.R270Q 
nonsynonymous 
SNV 
het Novel 0.17 0.954 4.56 Binds to type II regulatory subunits 
of protein kinase A and 
anchors/targets them to the nuclear 
membrane or sarcoplasmic 
reticulum 
BTBD7 BTB (POZ) 
domain 
containing 7 
BTBD7 
ENST00000393170.2 
exon5 c.G811A 
p.G271S 
nonsynonymous 
SNV 
het Novel 0.02 0.98 5.46 Unknown function. Highly 
conserved 
PKM2 pyruvate 
kinase, muscle 
PKM2 
ENST00000449901.2 
exon3 c.T62C p.I21T 
nonsynonymous 
SNV 
het Novel 0 NA NA Involved in glycolysis 
CHRNB4 cholinergic 
receptor, 
nicotinic, beta 
4 
CHRNB4 
ENST00000412074.2 
exon5 c.G595A 
p.D199N 
nonsynonymous 
SNV 
het Novel 0 NA NA Subunit of Nicotinic receptor, 
ligand-gated ion channels that 
modulate cell membrane potentials 
ZNF592 zinc finger 
protein 592 
ZNF592 
ENST00000299927.3 
exon1 c.T1762A 
p.C588S 
nonsynonymous 
SNV 
het Novel 0.3 0.408 4.8 Involved in cerebellar development. 
Mutations in this gene cause 
autosomal recessive spinocerebellar 
ataxia. 
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ACAN aggrecan ACAN 
ENST00000561243.1 
exon11 c.G4150A 
p.A1384T 
nonsynonymous 
SNV 
het submitted 
to dbSNP 
0.24 NA NA Integral part of the extracellular 
matrix in cartilagenous tissue. 
Mutations in this gene may be 
involved in skeletal dysplasia and 
spinal degeneration. 
FBXL16 F-box and 
leucine-rich 
repeat protein 
16 
FBXL16 
ENST00000397621.1 
exon2 c.G19A p.D7N 
nonsynonymous 
SNV 
het Novel 0.66 0 -1.26 Substrate-recognition component of 
the SKP1-CUL1-F-box protein-type 
E3 ubiquitin ligase complex. Poorly 
conserved, unlikely candidate 
IGFALS insulin-like 
growth factor 
binding 
protein, acid 
labile subunit 
IGFALS 
ENST00000215539.3 
exon2 c.G1406A 
p.R469H 
nonsynonymous 
SNV 
het Novel 0.08 0.003 -4.36 Involved in protein-protein 
interactions. Poorly conserved, 
unlikely candidate 
NTN3 netrin 3 NTN3 
ENST00000293973.1 
exon1 c.G620A 
p.S207N 
nonsynonymous 
SNV 
het Novel 1 0 -0.617 Control guidance of CNS 
commissural axons and peripheral 
motor axons. Unlikely candidate as 
poorly conserved 
NTN3 netrin 3 NTN3 
ENST00000293973.1 
nonsynonymous 
SNV 
het Novel 0.01 0.288 2.28 Control guidance of CNS 
commissural axons and peripheral 
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exon1 c.C621A 
p.S207R 
motor axons. Unlikely candidate as 
poorly conserved 
ADCY9 adenylate 
cyclase 9 
ADCY9 
ENST00000294016.3 
exon2 c.A1609G 
p.K537E 
nonsynonymous 
SNV 
het Novel 0.28 0.015 3.98 Adenylate cyclase is a membrane 
bound enzyme that catalyses the 
formation of cyclic AMP from ATP.  
C17orf85 chromosome 
17 open 
reading frame 
85 
C17orf85 
ENST00000389005.4 
exon10 c.G1192A 
p.D398N 
nonsynonymous 
SNV 
het Novel 0.01 0.97 5.5 Unknown function 
PCDHGA8 protocadherin 
gamma 
subfamily A, 8 
PCDHGA8 
ENST00000398604.2 
exon1 c.G2063A 
p.S688N 
nonsynonymous 
SNV 
het Novel 0.34 NA NA Potential calcium-dependent cell-
adhesion protein. May be involved 
in the establishment and 
maintenance of specific neuronal 
connections in the brain 
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5.5.5 DISCUSSION 
The genetic aetiology was investigated in a small non-consanguineous family with 
parkinsonism-dystonia using linkage analysis and WES of two affected 
individuals. The mode of inheritance was thought to be autosomal recessive, 
however, we could not exclude autosomal dominant inheritance.  
 
For the analysis using an autosomal recessive model of inheritance, no compound 
heterozygous or homozygous variants were found within the linkage regions, even 
when widening filtering to include synonymous and copy number variants. 
However, a variant was found in the LRRK2 gene (ENST00000298910.7 exon47 
c.C6974T p.S2325F), at a very highly conserved residue in the WD40 domain 
(GERP score 5.38). The variant generates high scores for in-silico analysis of 
deleteriousness, SIFT predicts that the variant is damaging, whilst Polyphen2 
predicts the variant is possibly damaging (SIFT score 0.05, Polyphen 2 score 0.57). 
The variant is absent from all current control databases. Mutations in LRRK2 are a 
known cause of autosomal dominant PD. The p.S2325F LRRK2 variant has not been 
reported previously in association with PD.  As discussed in the introduction 
(chapter 1), no unequivocally pathogenic mutations have been reported in the 
WD40 domain to-date, however there at least nine variants in the WD40 domain 
have been described in association with PD (http://www.molgen.vib-
ua.be/PDmutDB).120, 121 In particular, the T2356I variant in the WD40 domain, has 
been reported several times in association with PD,329-331 suggesting mutations in 
this domain might cause PD. 
 
All affected individuals in this family developed an arm tremor in the first decade, 
however they were not examined at this time, therefore it is not clear whether the 
tremor is part of their Parkinson’s disease or a separate condition. The age of onset 
of parkinsonism in this family ranges from 26-46 years. Early age of onset has been 
described in LRRK2-related PD,332 however it is rare, a large study examining age 
related penetrance of LRRK2 mutations, calculated the penetrance of non-G2019S 
LRRK2 mutations to be less than 5% before the age of 35 years.115 Many of the 
affected individuals in this family have dystonia as part of their clinical symptoms 
after L-dopa treatment. Dystonia is commoner in LRRK2-related PD than in 
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idiopathic parkinsonism and most often occurs after dopamine replacement.115 
Dystonia preceding L-dopa treatment is generally a feature of autosomal recessive 
parkinsonism (Parkin, PINK1, DJ1). 
 
There are a number of factors that suggest that this LRRK2 variant might be causal. 
The in-silico prediction suggests the variant is deleterious, the codon is highly 
conserved and other mutations in LRRK2 are associated with genetic forms of PD. 
However, there are a number of considerations which are suggest that this may not 
be the causal variant. Asian individuals have more genetic variability than 
Caucasian individuals,16 therefore this may represent a previously undescribed 
benign polymorphism in the LRRK2 gene that is not present in control databases as 
genetic data from individuals of Asian ancestry are underrepresented in these 
databases. As the common mutations in LRRK2 are clustered in the Roc, Cor and 
Kinase domain, typically most laboratories will only sequence these hot-spots in 
families with autosomal dominant PD. With the advent of next-generation 
sequencing all exons of the LRRK2 gene will be screened in patients and it is likely 
to become clear whether mutations in other domains can cause PD. Additionally, 
other families may be identified with the p.S2325F LRRK2 variant thus helping 
clarify whether or not it is pathogenic. Lastly, the mode of inheritance will become 
clearer as the affected individuals children reach adulthood.   
 
The work on this family demonstrates the difficulties in WES data analysis in small 
families where the affected individuals are in a single generation. One of the 
simplest ways to determine a candidate variants pathogenicity is to show it 
segregates with disease in other families/patients. When the variant is novel and 
absent from both control cohort databases and patient replication cohorts 
functional work is needed to explore further the pathogenicity. If the causal variant 
in this family is not the p.S2325F LRRK2 variant, it may have been ascertained 
through WES and be present in the candidate variants lists Table 5.9-5.11 and 5.13, 
or it may not have been ascertained due to the limitations of WES (discussed in 
section 5.3.3). 
 
Chapter Conclusion 
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In summary the 3 families presented herein in this chapter illustrate a number of 
important points about the use of WES in autosomal recessive PD. Family 1 
demonstrates that in small consanguineous families, WES and autozygosity 
mapping may produce candidate lists of variants/genes, but in order to confirm or 
refute the pathogenicity of such variants, replication studies in a large number of 
PD patients may be necessary. It is likely this will necessitate sharing of data 
amongst large research consortia. Family 2 demonstrate that WES and 
autozygosity mapping may be a very powerful tool even in singleton cases where 
the gene is already known to be associated with PD. Family 3 demonstrate that in 
small kindreds if the mode of inheritance is not be confidently known this can 
significantly hamper the data interpretation.  
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CHAPTER 6. WHOLE EXOME 
SEQUENCING IN AUTOSOMAL 
RECESSIVE GENERALISED 
DYSTONIA 
 
6.1 STATEMENT OF CONTRIBUTION TO THIS 
RESEARCH 
Unless otherwise indicated I performed autozygosity mapping and analysed the 
WES data. I performed confirmatory Sanger sequencing and segregation analysis. I 
examined all family members. 
 
6.2 BACKGROUND 
I identified 3 consanguineous families on the departmental neurogenetics database 
who had generalised dystonia where the genetic cause was unknown. Although 
these families were small I decided to perform WES in combination with 
autozygosity mapping or linkage analysis to try and determine the genetic cause. 
 
6.3 FAMILY 4: AUTOZYGOSITY MAPPING AND 
EXOME SEQUENCING IN A CONSANGUINEOUS 
KINDRED WITH GENERALISED DYSTONIA AND 
SPASTIC PARAPARESIS 
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6.3.1 Background 
A Pakistani family with generalised dystonia, parkinsonism, and a spastic 
paraparesis was identified by Prof Bhatia, though the movement disorders clinic at 
the NHNN. Parental consanguinity and the young age at onset suggested an 
autosomal recessive mode of inheritance. The pedigree for the family is shown in 
figure 6.1. WES and linkage analysis was used to try and identify the genetic cause.  
 
Figure 6.1: Pedigree of family 4 
 
6.3.2 MATERIALS AND METHODS 
6.3.2.1 Samples 
Genomic DNA samples were obtained from peripheral blood lymphocytes, for 
individuals III:1, III:3, IV:1, IV:2, IV:3, IV:4 and IV:5 using standard protocols. 
Participants gave written consent, and the study met with the local ethic boards 
approval. 
6.3.2.2 Phenotypic characterization of the affected individuals 
IV:2 was examined by both Prof. Kailash Bhatia (a Movement Disorders Specialist) 
and myself, IV:4 was examined by Dr. Lucinda Carr (Paediatric Neurologist) and 
was deceased at the time this research study commenced. IV:1, IV:3 and IV:5 were 
examined by myself.  
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6.3.2.3 Whole Exome Sequencing  
Individual IV:2 was selected for WES, being the most severely affected living 
individual. WES was performed as described in the Materials and Methods chapter 
(chapter 2).  
 
6.3.2.4 Genome wide Linkage Analysis 
Multipoint parametric linkage utilizing ~30,000 equally spaced markers was 
performed using the computer program Allegro. This work was performed by Prof 
Robert Kleta, Dr. Dr. Horia Stanescu and Mehmet Tekman at UCL.  
 
6.3.2.5 Variant filtering 
Only variants within regions of linkage were used for filtering. Synonymous 
variants and any variant present in a range of publically available databases of 
sequence variation (dbSNP, 1000 Genomes, Complete Genomic 69 Database and 
NHLBI Exome Sequencing Project database) with a frequency greater than 1% 
were filtered out.  
 
6.3.3 RESULTS 
6.3.3.1 Phenotypic Characterisation of patients 
Individual IV:4 was born at term by normal delivery. Motor milestones were 
normal up until the age of 12 months. She had been able to walk with support at 
the age of 12 months however from the age of 18 months she had become less 
steady on her feet and never achieved independent mobility. Her speech was 
delayed only being able to speak single words at the age of 2 years. Examination 
aged 2 revealed an unsteady high steppage gait requiring assistance. In the lower 
limbs there was pathologically brisk reflexes and extensor plantars. There was fine 
nystagmus in the primary position and slight pallor of the optic discs and fine 
pendular nystagmus on pursuit eye movement with poor optokinetic nystagmus. 
Over a period of 10 years her condition rapidly progressed. She developed 
spasticity in both upper and lower limbs with generalised dystonia and torticollis, 
which left her wheelchair bound. She also had severe learning difficulties. Surgery 
was required for a severe rapidly progressive scoliosis. She was dependent for all 
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activities of daily living and was fed via a gastrostomy. A trial of L-dopa was 
thought to be of some help. Baclofen and botulinum toxin injections were used for 
management of spasticity and dystonia. The patient died aged 20 years as a result 
of an intercurrent chest infection. Investigations showed normal routine bloods, 
karyotype, EEG, visual evoked potentials, auditory evoked potentials and nerve 
conduction studies. A CT brain showed mild cerebellar atrophy.  
 
Individual IV:3 had normal motor milestones and early development. She first 
developed symptoms aged 17 with stiffness of the legs when walking. Examination 
aged 29 years revealed brisk upper limb reflexes. In the lower limbs there was a 
spastic paraparesis with pathologically brisk reflexes and extensor plantar 
responses. There were no features of dystonia present on examination. 
 
Individual IV:2 developed mild walking difficulties and a tendency to fall from the 
age of 2 years at the time of a intercurrent viral illness. His speech development 
was very good up until the age of 4.5 years. At this time he had a dramatic 
worsening of his symptoms following an episode of hepatitis A and lost all 
movement including speech and swallowing. He made a partial recovery with 
regards to his walking. However later that year he had a second acute worsening 
during an intercurrent illness with tonsillitis. He was wheelchair bound thereafter. 
In the intervening period his clinical condition has remained stable. His 
examination aged 22 years revealed that he was significantly disabled due to 
generalised dystonia with bulbar involvement rendering him anarthric. He also 
has a spastic quadriparesis. Neuropsychometry demonstrated the patient has some 
degree of intellectual dysfunction. He communicates with an aid. He requires 
feeding via a percutaneous gastrostomy. His medications include Baclofen, 
Clonazepam, L-dopa and botulinum toxin injections. More recently he has had 
deep brain stimulation for management of his generalised dystonia with a good 
clinical response. MRI Brain scan showed normal basal ganglia and cerebellum 
with bifrontal atrophy – thought to be secondary to perinatal ischaemia. T2* MRI 
sequences did not reveal any mineralization.  
 
Summary of investigations in Family 
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In order to rule out known genetic causes of dystonia or parkinsonism, affected 
family members were screened for mutations in the following genes as part of their 
diagnostic work-up: DYT1, PANK2, PLA2G6. Copper studies, CSF, white cell 
enzymes, amino acids, and lactate were normal in individual IV:1. 
6.3.3.2 Genome Wide Linkage Analysis 
Review of the genotyping data revealed clustered genotyping errors in 2 samples 
(IV:4 and IV:5), which remained when fresh samples were obtained and chipped 
for a second time. The additional genotype was highly suggestive of non-paternity, 
but from an individual who was very closely related to III:1 e.g., a brother. 
Multipoint parametric linkage analysis was performed which revealed only 2 
regions of linkage (table 6.1). Autozygosity mapping confirmed there were no 
other regions of homozygosity outside of these 2 linkage regions shared only by 
affected siblings. 
 
Table 6.1: regions of linkage in Family 4  
 
6.3.3.3 Exome Sequencing in Individual IV:2 
WES metrics indicated good coverage in IV:2 (Table 6.2) 
 
Table 6.2: WES metrics in IV:2 
 IV:2  Family 4 
Total number of reads 34,992,914 
Reads aligned to target 27,150,170 
Mean Target Coverage 26% 
% Target covered by 2 reads 92% 
Chromosome SNP  
from 
SNP 
To 
Physical 
position 
(hg19) From 
Physical 
position 
(hg19) To 
LOD 
score 
6 rs6912426 rs707542 25,409,785 
 
36,924,102 
 
2.958600 
13 rs943782 rs7320510 27,575,037 
 
30,997,831 
 
2.958700 
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% Target covered by 10 reads 80% 
% Target covered by 20 reads 57% 
Total number of variants 21,308 
6.3.3.4 Variant filtering 
First the linkage regions established from the analysis taking into account the non-
paternity were used. Only variants within these regions were used for filtering. 
Variants were filtered out if they were present in publically available databases at a 
frequency of more than 1%. The variants that remained after filtering are detailed 
in table 6.3.
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Table 6.3: Variants remaining within linkage regions following filtering 
Gene Gene Name Amino acid 
Change 
Exonic Function Call Allele 
frequency 
in 
publically 
available 
databases 
SIFT Polyphen 
2 
Comments 
HLA-A Major 
histocompatib
ility complex, 
class I, A 
ENST00000376
802.2: 
exon4:c.751del
G: p.D251fs 
frameshift 
deletion 
het recorded 
once in 
dbSNP 
NA NA HLA-A is involved in the presentation of 
foreign antigens to the immune system 
unlikely candidate for a complex dystonia 
syndrome 
TNXB tenascin XB ENST00000375
244.3: 
exon3:c.T1388
C: p.V463A 
Nonsynonymous 
SNV 
het novel 0.19 0.95 TNXB mediates interactions between cells 
and the extracellular matrix. Mutations in 
this only present in heterozygous state 
and mainly expressed in connective tissue 
HLA-
DRB1 
major 
histocompatib
ility complex, 
class II, DR 
beta 1 
ENST00000360
004.5: 
exon3:c.A379C
: p.K127Q 
Nonsynonymous 
SNV 
het recorded 
once in 
dbSNP 
0.11 0.015 HLA-DRB1 is involved in the presentation 
of foreign antigens to the immune system 
unlikely candidate for a complex dystonia 
syndrome 
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HLA Human leucocyte antigen system 
Two rare heterozygous variants in the HLA locus were present in IV:4. The HLA 
locus is one of the most complex regions in the human genome due to the extreme 
levels of polymorphism and linkage disequilibrium. The region contains more than 
200 protein-coding genes that play key roles in immune function and defense. The 
genes encode cell-surface antigen-presenting proteins among other functions.  
 
HLA-A 
HLA-A belongs to the HLA class I heavy chain molecule in the major 
histocompatibility complex (MHC). This class I molecule is a heterodimer 
consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy 
chain is anchored in the membrane. Class I molecules play a central role in the 
immune system by presenting peptides derived from the endoplasmic reticulum 
lumen. They are expressed in nearly all cells.  
 
HLA-DRB1  
HLA-DRB1 is a HLA class II molecule in the major histocompatibility complex 
(MHC). It encodes a cell surface alpha/beta heterodimeric protein whose function 
is to present processed foreign antigens to T cells. HLA-DRB1 is highly 
polymorphic with 58 known alleles in humans. For the two variants in the HLA 
region review of coverage data did not reveal any uncovered regions for these 
genes where a second variant might be present. In any event, the HLA genes were 
felt to be an unlikely cause of autosomal recessive dystonia.  
 
TNXB 
This gene encodes a member of the tenascin family of extracellular matrix 
glycoproteins. The tenascins have anti-adhesive effects, as opposed to fibronectin, 
which is adhesive. This protein is thought to function in matrix maturation during 
wound healing. TNXB is expressed in brain, most highly in the cerebellum. Defects 
in TNXB are the cause of tenascin-X deficiency (MIM 606408). Tenascin-X 
deficiency leads to an Ehlers-Danlos-like syndrome characterized by 
hyperextensible skin, hypermobile joints, and tissue fragility. Review of the 
coverage of TNXB revealed it was complete.  
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No new variants were revealed when synonymous variants were considered in the 
regions of linkage, or when the linkage regions for the model ignoring the non-
paternity.  
 
6.3.3.5 Sanger sequencing of uncovered regions 
A custom script was used to identify exons with a coverage of less than 4 reads 
within the chromosome 6 and 13 linkage regions which take into account the non-
paternity. All coding exons and their flanking intronic region identified by this 
were sanger sequenced in IV:2. However this did not reveal any rare or novel 
variants. 
 
6.3.3.6 Copy number variant analysis 
Inspection of the OmniExpress data for the affected individuals did not reveal any 
copy number variation within the regions of linkage. ExomeDepth275 (Chapter 2) 
was used to detect CNV calls from exome sequence data, however it did not reveal 
any rare or novel CNVs within regions of linkage. 
 
6.3.3.7 Exploring the possibility of two diseases in the family 
There is a wide clinical spectrum between affected family members. IV:2 and IV:4 
both present with severe generalised dystonia and spastic paraparesis. However, 
IV:3 has only a mild spastic paraparesis. Intra-familial phenotypic variability is 
readily recognized in many Neurogenetic disorders. However, in this family it is 
likely that there are multiple loops of consanguinity in preceding generations that 
are not known about. Therefore, it is possible that the spastic paraparesis and 
generalised dystonia are separate conditions and result from autosomal recessive 
mutations in different genes. The occurrence of more than one genetic condition in 
individuals has been reported several times by WES.33  
 
To explore whether a autosomal recessive mutations in another gene has resulted 
in the generalised dystonia phenotype, regions of homozygosity shared only by 
IV:2 and IV:4 were identified: Hg19 chr1:216,649,667-223,209,450; chr6:36,725,464-
41,527,065, chr7:43,140,000-49,850,666; chr12:50:453,641-51,575,615; 
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chr15:43,589,078-33,912,633. WES filtering was performed as before however this 
did not reveal any novel or rare homozygous variants.  
 
6.3.4 Discussion 
In this consanguineous kindred with generalised dystonia and spastic paraparesis 
linkage analysis has identified a ~11.5Mb region on chromosome 6 and a ~3.5Mb 
region on chromosome 13, in which the causal variant is likely to be located. 
Neither of these regions has been associated with autosomal recessive generalised 
dystonia before, suggesting this family has a novel cause for this phenotype.  
 
WES and linkage analysis has identified 3 heterozygous variants within these 
linkage regions. The function of each of these 3 genes has been well studied. Two 
of the genes lie in the human major histocompatibility complex (MHC). HLA-A is a 
class I HLA gene and interacts with T-cell receptor molecules, as well as killer 
immunoglobulin-like receptors expressed on natural killer cells and some T-cells.333  
HLA subtypes are associated with susceptibility to HIV-1,334 birdshot 
chorioretinopathy,335 haemochromatosis,336 early-onset Alzheimer disease,337 
Stevens Johnson Syndrome,338 infectious mononucleosis,339 type 1 diabetes340 and 
multiple sclerosis.341 HLA-DRB1 a cell surface alpha/beta heterodimeric protein 
that presents processed foreign antigens to T cells. It is associated with 
susceptibility to severe malaria,342 bullous pemphigoid,343 acute graft-versus-host 
disease,344, hepatitis C,345 HIV-1,334 multiple sclerosis341, 346 amongst other diseases. 
Currently, the two main disease associations with the HLA genes are response to 
infectious disease and autoimmune diseases. There are rare reports of autoimmune 
disease in association with sporadic forms of dystonia for e.g., antinuclear 
antibodies and orofacial-cervical dystonia347 and atypical dystonia in association 
with antibasal ganglia antibodies.348 TNXB has been established to mediate 
interactions between cells and the extracellular matrix. Loss of function mutations 
cause autosomal recessive Ehlers-Danlos like syndrome, where connective tissue 
problems resulted in hypermobility, hyperelastic skin and easy bruising.  
 
There is a diverse range of pathways implicated in the pathogenesis of primary 
dystonia: dopamine signaling (GCH1, TH, SPR, GNAL, TOR1A), regulation of gene 
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expression and cell cycle dynamics (THAP1 and TAF3), cell structure (TUBB4A, 
SGCE), synaptic dysfunction (PRRT2) and neuronal excitability (ANO3). Pathways 
involved in heredodegenerative dystonias include neurometabolic pathways 
(HPRT in Lesch-Nyan disease), mitochondrial metabolism (TIMM8A in dystonia 
deafness syndrome), DNA repair (AOA1, AOA2, ATM in autosomal recessive 
ataxias with dystonia). Although it is possible that a novel gene for 
heredodegenerative dystonia could implicate a novel pathway, the putative 
function of HLA-A, HLA-DRB1 and TNXB still seem unlikely candidates based on 
their function. Additionally, in this consanguineous family, the overwhelming 
likelihood is that the variant is likely to be identical by state and therefore 
homozygous.  
 
Therefore, WES and linkage analysis has failed to identify the causal variant in this 
family. Sanger sequencing of uncovered/poorly covered coding exons in the 
linked regions has not identified the causal variant. The general technical and 
analytical reasons for failure of WES and mapping data to identify the causal 
variant in a family with a Mendelian disorder are as follows: 
 
Technical Limitations: 
1. Part or all, of the causative gene is not in the target definition (for example, 
it is not a known gene, or there is a failure in the bait design). The probes in 
sequence capture methods are designed based on the sequence information 
from gene annotation databases such as the consensus coding sequence 
(CCDS) database and Refseq database; therefore, unknown or yet-to-
annotate exons cannot be captured. There may also be a failure in bait 
design so that an exonic region is not captured. Selectively sequencing the 
exome- which is, to our knowledge, the most likely region of the genome to 
contain pathogenic mutations – also excludes noncoding regions. The 
contribution of mutations in non-coding regions to Mendelian disease has 
yet to be determined. Finally, it is recognized that microRNAs, promotors 
and ultra-conserved elements may be associated with disease, reflecting 
this, commercial kits are increasingly targeting these sequences 
2. Inadequate coverage of the region that contains a causal variant. A certain 
minimum depth of coverage is required for sufficient accuracy of variant 
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detection; that is, positions or regions in the genome of the individual that 
are different from the reference human genome sequence. Typically, a 
minimum coverage of 8-10 reads per base is required for high-confidence 
detection of a heterozygous single nucleotide variant. Regions with 
repetitive sequences are more poorly characterized, as repetitive sequences 
may have prevented inclusion of a probe, or the reads originating from 
these regions cannot easily be mapped to a single position in the reference 
genome. Additionally probes may be poorly performing in GC-rich regions. 
There may be inadequate coverage of the region that contains the causal 
variant, for example, because of poor capture or poor sequencing 
3. The causal variant is covered but not accurately called, for example, in the 
presence of a small but complex indel. Furthermore, exome sequencing is 
unable to detect structural variants or chromosomal rearrangements, which 
are believed to be important for Mendelian disorders.   
Analytical Limitations: 
4. There may be more than one disease in the family e.g. autosomal recessive 
spastic paraparesis and autosomal recessive generalised dystonia.  
5. A variant may have been excluded from a homozygous region as it is 
present in a publically available database at an appreciable frequency 
because it is a false positive variant in that database. Currently, more than 
17 million SNPs in the human genome have been documented in dbSNP 
with a false positive rate of ~15-17%.59  
6. The causal variant could be synonymous and have been excluded in the 
variant filtering process. 
 
Future work 
As the likely position of the causal variant has been narrowed down to two 
genomic regions, this family have been submitted for whole-genome sequencing. 
A fibroblast cell line has been established to facilitate future studies if the causal 
gene is identified.  
 
 
 181 
6.4 FAMILY 5: WHOLE EXOME SEQUENCING IN A 
FAMILY WITH AUTOSOMAL RECESSIVE 
GENERALISED DYSTONIA, SPASTIC 
PARAPARESIS AND CEREBELLAR SIGNS. 
 
6.4.1 STATEMENT OF CONTRIBUTION TO THIS RESEARCH 
I examined all family members and performed homozygosity mapping and 
analysed WES data. I performed confirmatory Sanger sequencing and segregation 
analysis. I wrote the manuscript, which arose from this work, which was published 
in the journal of Neurology.349 
 
6.4.2 BACKGROUND 
Prof Bhatia identified a family (Family 5, figure 6.2) with an unusual phenotype 
consisting of generalised dystonia, spastic paraparesis and cerebellar signs. The 
mode of inheritance in this family was presumed to be autosomal recessive; this 
was suggested by the presence of parental consanguinity, two affected siblings 
with infantile age of onset and phenotypically normal parents. Autozygosity 
mapping and WES lead to the identification of a homozygous nonsense mutation 
in ALS2. Generalised dystonia and cerebellar signs have not been reported in 
association with ALS2-related disease, therefore this widened the recognized 
phenotype for this disorder.  
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Figure 6.2: Pedigree of family 5 
                
 
6.4.3 MATERIALS AND METHODS 
6.4.3.1 Samples 
I collected DNA samples from this family. All participants gave written informed 
consent. The study was approved by the local ethics board.  
6.4.3.2 Autozygosity Mapping 
Autozygosity mapping was performed for regions >0.5Mb in II:1, II:2 and II:3 as 
outlined in the Materials and Methods chapter (chapter 2) using 
HumanOmniExpress beadchips.  
6.4.3.3 Whole Exome Sequencing 
Individual II:2 was selected for WES in family 5 as she was the most severely 
affected individual. WES was performed at UCL Institute of Neurology as 
described in the material and Methods chapter (chapter 2). 
6.4.3.4 Variant Filtering 
Only homozygous variants within regions of homozygosity shared only by the two 
affected individuals (II:2 and II:3, figure 6.2) were used for filtering. Synonymous 
variants and any variant present at a frequency >1% in a range of publically 
I:1
I:2
II:1
II:2
II:3
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available databases of sequence variation (dbSNP, 1000 Genomes, Complete 
Genomic 69 Database and NHLBI Exome Sequencing Project database) was filtered 
out, in addition to variants present >3 times in our own in-house database of 
exome sequencing in individuals (n=200) with an unrelated non-neurological 
disease.  
6.4.3.5 Sanger Sequencing 
Sanger sequencing was performed for exon 10 of the ALS2 gene (transcript ID: 
ENST00000264276) in family 5 and described in Materials and Methods (chapter 2). 
 
6.4.4 RESULTS 
6.4.4.1 Phenotypic Characterisation  
The index case (Figure 6.2, II:2) is of Bangladeshi descent. Her early motor 
milestones were normal, however she failed to walk independently, prompting 
assessment aged 2 years. Examination at this time revealed a mild spastic diplegia 
with global developmental delay and microcephaly (below 2nd centile). She 
presented to our center aged 13 years, her examination revealed a few beats of 
nystagmus, a facetious smile and anathria. There was marked spasticity and 
contractures in the limbs with dystonic posturing of the hands.  Global muscle 
weakness was present with distal lower limb wasting suggested lower motor 
neuron involvement. She requires a motorized wheelchair. Subsequently, surgical 
intervention was required for a rapidly progressive scoliosis. A trial of L-dopa was 
not helpful.  
 
II:3 achieved normal motor milestones up until 12 months of age when he started 
toe-walking. Examination aged 7 years revealed microcephaly (2nd-9th centile), 
nystagmoid jerks and intermittent head titubation. In the upper and lower limbs 
there was spasticity with clonus and dystonic posturing of the arms and trunk. 
Gait examination showed truncal sway, suggestive of ataxia. Neck flexors were 
weak as were proximal and distal muscle groups. Reflexes were pathologically 
brisk with bilaterally extensor plantar responses. There was a mild scoliosis.  
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MRI brain imaging in II:2 showed mild lack of white matter bulk and some 
immaturity of the white matter signal. CSF and an extensive metabolic screen were 
normal. A muscle biopsy showed angular atrophic fibres with grouping of fast and 
slow fibres in keeping with a neurogenic component. 
 
6.4.4.2 Autozygosity mapping results 
5 regions of homozygosity were identified, totaling almost ~54Mb, shared only by 
the affected individuals II:2 and II:3 (Table 6.4).  
 
Table 6.4: Homozygous regions >0.5Mb concordant in II:2 and II:3 
 
6.4.4.3 Whole Exome Sequencing 
Alignment metrics for WES in II:2 revealed good coverage (table 6.5) 
 
Table 6.5: WES Metrics for II:2, Family 5 
 Family 5 II:2 
Total number of reads 47,076,032 
Non-duplicated reads 35,872,402 
Reads aligned to target 85% 
Mean Target Coverage 28 
% Target covered by 2 reads 92% 
% Target covered by 10 reads 80% 
% Target covered by 20 reads 58% 
Total number of variants 20,485 
 
Chromosome Start End Size (bp) 
2 171,210,691 189,879,843 18,669,152 
2 191,979,359 207,890,135 15,910,776 
2 223,594,372 232,343,950 8,749,578 
7 0 5,452,756 5,452,756 
12 0 5,811,469 5,811,469 
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6.4.4.4 Variant filtering in regions of shared homozygosity 
Following WES, filtering of variants within the regions of homozygosity shared 
only by II:2 and II:3, revealed a single novel nonsense homozygous variant 
remained: c.G2002T p.G668X in ALS2 (Transcript: ENST00000264276).  
6.4.4.5 Sanger sequencing confirmation of candidate variant 
Sanger sequencing confirmed the variant was present in the homozygous state in 
both affected siblings (II:2 and II:3). Their parents (I:1 and I:2) are heterozygous 
carriers and the unaffected sibling (II:1) does not carry the mutation.  
 
6.4.5 DISCUSSION 
In this small consanguineous family WES and autozygosity mapping has revealed 
a novel homozygous nonsense mutation in the gene ALS2, as the cause of the 
generalised dystonia, spastic paraparesis and cerebellar signs in this family. The 
affected individuals shared >54Mb of homozygosity meaning that Sanger 
sequencing of candidate genes in the region would not have been feasible in this 
family. This case demonstrates the power of WES applied with mapping strategies. 
Subsequently, a collaborator identified a homozygous frameshift mutation in ALS2 
in another family with generalised dystonia and a spastic paraparesis confirming 
that the phenotype of ALS2 mutations is wider than first thought and includes 
generalised dystonia.349  
 
Mutations in the ALS2 gene (OMIM 606352) cause autosomal recessive motor 
neuron diseases, including juvenile-onset amyotrophic lateral sclerosis (JALS),350 
juvenile-onset primary lateral sclerosis (JPLS) and infantile-onset ascending 
hereditary spastic paraplegia (IAHSP).351, 352  In JALS both upper and lower motor 
neurons are affected, whereas neurodegeneration only involves upper motor 
neurons in JPLS and IAHSP. Despite these differences in neuropathology, almost 
all mutations in ALS2 described to date result in a clinical phenotype of infantile 
onset limb and facial weakness, accompanied by bulbar symptoms, which 
generally progress to paraplegia during childhood. Rarely patients with JALS have 
been reported with lower motor neuron involvement.353 ALS2 mutations are 
distributed widely across the entire coding sequence and mostly result in loss of 
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protein function.353-355 No clinical diagnostic criteria exist for ALS2 related diseases. 
However, there is a significant overlap in the clinical features of both affected 
family members in family 5 with cases already described in the literature. Both 
affected family members have an infantile onset disease with clinical involvement 
of both upper and lower motor neurons and bulbar involvement, in keeping with 
JALS.  
 
The manuscript detailing Family 5 is the first report of generalised dystonia in 
association with ALS2 related disease.349 Other novel clinical findings include 
microcephaly and cerebellar signs, however currently it is not clear if these are 
features of ALS2-related disease. Interestingly, in a wild-type mice model of the 
disease, ALS2 was highly expressed in the granular and Purkinje layers of the 
cerebellum and ALS2-null mice have been found to develop an age-dependent 
slowly progressive loss of cerebellar Purkinje cells, suggesting that cerebellar signs 
may well be part of the extended phenotype.356 The ALS2 protein binds to a small 
GTPase RAB5 and functions as a guanine nucleotide exchange factor (GEF) for 
RAB5 and plays a role in intracellular endosomal trafficking,356 highlighting that 
this may be an important biological pathway or mechanism through which 
dystonia may occur. This report adds to the growing literature of widening of the 
phenotypic spectrum of genetic disorders using next-generation sequencing. We 
propose that the ALS2 gene should be screened for mutations in patients who 
present with a similar phenotype. 
  
6.5 FAMILY 6: WHOLE EXOME SEQUENCING IN A 
CONSANGUINEOUS FAMILY WITH GENERALISED 
DYSTONIA 
6.5.1 STATEMENT OF CONTRIBUTION TO THIS RESEARCH 
I examined all family members, performed autozygosity mapping and analysed 
the WES data. I performed confirmatory Sanger sequencing and segregation 
analysis. 
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6.5.2 BACKGROUND 
I identified a patient from the Neurogenetics database who had a provisional 
diagnosis of cerebral palsy. The differential diagnosis included an autosomal 
recessive generalised dystonia, a genetic disorder had been suggested by the 
presence of parental consanguinity and infantile onset of symptoms. However 
since she was the only affected family member, there was uncertainty as to the 
correct diagnosis. A combination of WES and autozygosity mapping was used to 
explore the possibility of a genetic aetiology. This identified a novel, homozygous, 
missense mutation in GCDH, mutations in which cause Glutaric-aciduria type 1. 
The patient was subsequently reviewed by the Metabolic disease team at NHNN 
and underwent metabolic tests which confirmed the diagnosis of Glutaric-aciduria 
type 1.   
 
Figure 6.3: Pedigree of family 6  
               
 
 
6.5.3 METHODS 
6.5.3.1 Samples 
I collected DNA samples from this family. All participants gave written informed 
consent. The study was approved by the local ethics board.  
 
IV:1
III:2
III:1
II:1
II:2
II:3
II:4
I:1
I:2
IV:2
IV:3
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6.5.3.2 Phenotypic Characterisation  
Family 6  (Figure 6.3) were examined by a movement disorder specialist Dr. 
Patricia Limousin and myself.  
 
6.5.3.3 Autozygosity Mapping 
Autozygosity mapping for regions >0.5Mb was performed on all siblings (IV:1-
IV:3, figure 6.3) using a Human Omni express beadchip as discussed in Materials 
and Methods (chapter 2).  
 
6.5.3.4 Whole exome sequencing 
WES was performed in IV:1 at UCL Institute of Neurology using the Illumina 
Truseq Exome Enrichment kit (62Mb target). 
 
6.5.3.5 Variant Filtering 
Only homozygous variants within regions of homozygosity were used for filtering. 
I filtered out synonymous variants and any variant present in a range of publically 
available databases of sequence variation above a frequency of 1% (dbSNP, 1000 
Genomes, Complete Genomic 69 Database and NHLBI Exome Sequencing Project 
database), as well as variants that were present more than 3 times in our own in-
house database of exome sequencing of individuals (n=200) with an unrelated non-
neurological disease.  
 
6.5.3.6 Sanger Sequencing 
Sanger sequencing was performed for exon 6 of the GCDH gene (transcript ID: 
ENST00000222214) in family 6 to confirm the putative causal variant and to 
determine segregation with the disease in the family. 
 
6.5.4 RESULTS 
6.5.4.1 Phenotypic Characterisation 
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The index case (Figure 6.3, IV:1) is of Lebanese descent. The pregnancy with IV:1 
was complicated by oligohydramnios and she was born by caesarean section 3 
months premature. She achieved normal motor milestones. She was able to stand 
whilst holding onto objects at the age of 9 months. At 10 months of age, she 
developed an ear infection followed a day or so later by an acute neurological 
deterioration. She had several seizures with eye deviation, during which she 
became rigid and unresponsive. She was admitted to intensive care for 1 month. 
On discharge from ITU, her family noticed she had lost head control and the ability 
to sit and stand and required a wheelchair. Subsequently, she developed 
prominent orolingual dystonia, which improved somewhat with Synacthen. Her 
neurological condition remained static for the next 7 years. Aged 8 years, she 
developed slowly progressive involuntary limb movements consisting of dystonia, 
chorea and ballism. The movements would keep her awake all night and she lost 
purposeful movements in the upper limbs. She was treated with Madopar 250mg 
tds, tetrabenazine 25mg bd, baclofen 25mg tds, tizanidine 2mg nocte with mild 
clinical benefit. Due to the poor response to medical therapy she had bilateral 
globus pallidus pars interna (GPi) deep brain stimulation (DBS) aged 19 years. This 
initially helped a little with ballism and painful spasms in the right arm. However 
this effect soon disappeared and the patient had a capsular response with difficulty 
swallowing. Despite several trials of adjusting the stimulator, DBS was felt to be 
exacerbating the involuntary movements and was stopped 2 years after 
implantation.  
 
Examination of IV:1 aged 18 years revealed severe mobile generalised dystonia 
with prominent bulbar and lingual involvement. She had a scoliosis and flexion 
contractures of the limbs. The involuntary movements were particularly severe in 
the left arm with dystonia, ballism and myoclonus. There was no spasticity at rest 
but she had numerous painful spasms.  Reflexes were normal, the left plantar 
response was extensor and right plantar response flexor. Currently, she is 
wheelchair bound and is anarthric.  The rest of the neurological examination was 
normal and there is no macrocephaly. MRI brain showed putaminal hyperintensity 
in the lateral aspects bilaterally indicating striatal necrosis. Routine bloods, 
ammonia, acanthocytes, copper studies, urinary and plasma organic acids, long 
chain fatty acids and white cell enzymes were normal. Genetic testing for DYT1 
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and PANK2 mutations were negative. EMG and nerve conduction studies were 
normal. 
 
Neurological examination of IV:2, IV:3, III:1 and III:2 was normal. 
 
6.5.4.2 Autozygosity Mapping Results 
33 regions of potential regions of autozygosity, shared by IV:1 alone were 
identified, totaling > 49Mb (table 6.6). 
 
Table 6.6: Homozygous regions >0.5Mb present only in IV:1 
Chromosome Start End Size (bp) 
1 190,385,304 191,424,963 1,040 
1 187,840,501 188,624,613 784 
1 113,338,649 113,914,390 576 
2 87,430,727 90,240,473 2,810 
3 41,216,488 41,822,054 606 
7 22,155,376 28,376,691 6,221 
7 139,163,463 140,254,890 1,091 
7 84,010,005 84,866,308 856 
7 145,928,429 146,516,749 588 
7 1,806,723 2,346,115 539 
8 47,757,290 49,047,878 1,291 
8 33,020,810 33,994,378 974 
10 15,629,360 18,302,192 2,673 
10 23,661,291 24,693,878 1,033 
11 46,393,757 47,303,275 910 
11 22,536,864 23,125,291 910 
11 116,518,960 117,151,412 632 
13 19,058,717 22,844,305 3,786 
13 89,510,330 90,196,888 687 
13 113,461,004 114,092,549 632 
14 88,765,833 89,438,126 672 
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14 68,208,677 68,843,605 635 
14 81,933,447 82,551,186 618 
14 75,159,007 75,750,200 591 
15 55,226,861 56,362,968 1,136 
15 52,100,215 52,712,988 613 
18 18,556,505 22,765,009 4,209 
18 13,600,497 14,381,966 781 
18 25,728,693 26,264,471 536 
20 9,077,491 16,248,453 7,171 
21 47,557,074 48,100,155 543 
22 48,281,630 49,911,182 1,630 
22 46,362,396 47,940,908 1,579 
 
6.5.4.3 Whole exome sequencing 
Alignment metrics for WES in IV:1 revealed good coverage (table 6.7) 
 
Table 6.7: Summary metrics for WES 
 Family 6B IV:1 
Total number of reads 131,717,454 
Non-duplicated reads 82,829,037 
Reads aligned to target 68,562,726 
Mean Target Coverage 65 
% Target covered by 2 reads 96 
% Target covered by 10 reads 91 
% Target covered by 20 reads 85 
Total number of variants 22,191 
 
After filtering of variants within the regions of homozygosity only present in 
individual IV:1, 7 homozygous novel variants remained (see table 6.8). The variant 
in the gene GCDH, was of immediate significance as it was associated with a 
neurometabolic disorder: autosomal recessive Glutaric Aciduria type 1. The variant 
was predicted to be pathogenic using two in-silico prediction software prediction 
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programs. The amino acid at which the substitution takes place is highly conserved 
with a GERP score of 5.14. The variant c.368A>G p.Y123C (transcript ID 
ENST00000222214) was confirmed by sanger sequencing to be homozygous in  
IV:1, IV:2 is a heterozygote carrier and IV:3 does not carry the mutation. Their 
parents (III:1 and III:2) are heterozygous carriers.  
 
In view of the genetic results, further metabolic testing was performed to explore a 
diagnosis of Glutaric aciduria type I caused by mutations in GCDH. This again 
showed a normal amino acid profile in the plasma. Urine organic acids were 
normal, glutaric acid and 3-hydroxyglutaric acid were not detected on three 
separate occasions. Plasma carnitine profile showed a low plasma carnitine at 
25umol/L (26-62) with a free carnitine of 22umol/L (22-50) and raised plasma 
glutarylcarnitine at 0.55umol/L (normal range <0.08), in keeping with a diagnosis 
of glutaric aciduria type 1. The patient was given carnitine supplementation, 
advised on a high carbohydrate and low protein diet and given details of an oral 
emergency regime, in the event of an intercurrent illness. 
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Table 6.8: showing the remaining variants following exome variant filtering 
Gene 
Symbol 
Full Gene Name Gene Function Variant 
Annotation 
Exonic Function Call Present in 
Publically 
Available 
Databases 
SIFT 
Score 
Poly 
Phen2 
Score 
GERP 
Score 
CAPN8 calpain 8 Involved in membrane trafficking in 
the gastric surface mucus cells. 
uc009xee.2:c.T16
82A:p.I561N 
nonsynonymous hom Novel 0 0.84 NA 
SULT1B1 sulfotransferase 
family, cytosolic, 
1B, member 1 
Sulfotransferase enzymes catalyze the 
sulfate conjugation of many hormones, 
neurotransmitters, drugs, and 
xenobiotic compounds.  
uc003hen.2:c.C7
72T:p.R258C 
nonsynonymous hom Novel 0 1 1.58 
AGAP8 ArfGAP with 
GTPase domain, 
ankyrin repeat 
and PH domain 8 
Putative GTPase-activating protein uc009xnv.2:c.C9
46G:p.R316G 
nonsynonymous hom Novel 0 NA NA 
C11orf82 Chromosome 11 
open reading 
frame 82 
Acts as an anti-apoptotic factor and its 
absence increases cell death under 
normal and stress conditions.  
 
 
uc010rss.1:c.C27
8T:p.S93L 
nonsynonymous hom Novel 0 0.983 4.3 
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ERCC4 Excision repair 
cross-
complementing 
rodent repair 
deficiency, 
complementation 
group 4 
This complex is a structure specific 
DNA repair endonuclease. Defects in 
this gene are a cause of Xeroderma 
Pigmentosum  
uc002dce.2:c.G3
35C:p.R112T 
nonsynonymous hom Novel 0 0.996 4.98 
BFAR bifunctional 
apoptosis 
regulator 
Apoptosis regulator. Has anti-apoptotic 
activity, both for apoptosis triggered 
via death-receptors and via 
mitochondrial factors 
uc002dcm.2:c.A
410G:p.N137S 
nonsynonymous hom Novel 0 0.309 4.78 
GCDH glutaryl-CoA 
dehydrogenase 
The protein catalyzes the oxidative 
decarboxylation of glutaryl-CoA to 
crotonyl-CoA and CO(2). Defects in 
GCDH are the cause of glutaric 
aciduria type 1, an autosomal recessive 
metabolic disorder characterized by 
progressive dystonia and athetosis due 
to gliosis and neuronal loss in the basal 
ganglia 
uc010xms.1:c.A2
69G:p.Y90C 
nonsynonymous hom Novel 0 1 5.14 
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6.10 DISCUSSION 
Mutations in GCDH cause autosomal recessive Glutaric Aciduria Type 1 (GA-1) 
(MIM 231670) an inborn error of lysine, hydroxylisine, and tryptophan metabolism 
caused by deficiency of glutaryl-CoA dehydrogenase, an enzyme found in the 
mitochondrial matrix and converts glutaryl-CoA to crotonyl-CoA. The combined 
worldwide frequency of GA-1 based on newborn screening is 1:100,000 infants.357 
The disorder is characterized by macrocephaly at birth or shortly after. Patients are 
vulnerable to striatal damage resulting in severe generalised dystonia between 6 
and 18 months of age,358 usually during an intercurrent febrile illness. It is still 
unclear what causes this selective sensitivity. Patients remain severely disabled 
after the initial decompensation and will not be able to walk. MRI imaging 
typically shows increased signal intensity on T2-weighted imaging. The metabolic 
hallmark of GA-1 is combined elevation of glutaric acid, 3-hydroxyglutaric acid 
and glutarylcarnitine (C5-DC) in urine, plasma and CSF, but in a group of patients 
(“low excreters”) metabolic screening may show (intermittently) normal results. 
This phenomenon is well demonstrated by our patient who had normal glutaric 
acid and 3-hydroxyglutaric acid, despite repeated determinations of organic acids. 
The diagnosis in our patient was confirmed by the presence of raised 
glutarylcarnitine. Identification of patients with GCDH mutations is important 
since dietary intervention (low protein diet, diet restricted in lysine/tryptophan, 
supplementation with carnitine/riboflavin) prevents neurological damage in the 
majority of patients.359 
 
The novel GCDH missense mutation (p.Y123C) in our patient, is highly likely to be 
pathogenic for a number of reasons. It is absent from publically available 
databases, it segregates with disease in the family, it is predicted to be damaging 
by 5 in-silico prediction programs (SIFT, Align GVGD, polyphen2, mutation taster 
and panther), it is a non-conservative amino acid substitution at a highly conserved 
residue within a functional domain of GCDH and there are reported pathogenic 
missense mutations at both adjacent codons.360, 361  
 
IV:1’s clinical presentation broadly fits with the phenotype described for GA-1, her 
development was normal until an intercurrent febrile illness aged 9 months after 
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which she developed acute onset seizures followed by generalised dystonia. She 
has imaging features that are consistent with a diagnosis of GA-1 and her 
metabolic investigations are also supportive. However, the progressive movement 
disorder in IV:1 is atypical in GA-1 as commonly patients with GA-1 have a static 
neurological deficit. Both IV:1 and a recently reported case demonstrate that a 
progressive movement disorder may be a manifestation of GA-1, even without 
recurrent metabolic decompensations.362 DBS has only been reported in one other 
patient with GA-1, who experienced improvement in dystonia and functionality 
following unilateral GPi DBS for dystonia.363 Our patient had little clinical 
improvement with bilateral GPi DBS, however further studies with larger numbers 
of patients will be needed to determine if GPi DBS is helpful in patients with GA-1 
related movement disorders. Early identification of GA-1 is important as dietary 
intervention and advice on preventative measures during intercurrent infections 
reduces morbidity and mortality.  Genetic testing of affected patients siblings may 
identify at risk individuals in whom neurological damage can be prevented.   
 
This case has demonstrated how a combination of autozygosity mapping and WES 
has been able to correctly identify the underlying cause of a rare dystonia 
syndrome in a patient that presented a diagnostic challenge. It has facilitated 
genetic counseling in the family, revising the initial diagnosis of athetoid cerebral 
palsy and provided an option for predictive testing in other family members, 
which is important since dietary intervention can prevent neurological damage. It 
also highlights the possible potential of exome sequencing in the genetic 
diagnostics setting, where many genes can be sequenced simultaneously and in 
genetically heterogeneous disorders such as inherited neuropathies this may be 
more cost effective than sequential Sanger sequencing of genes. Additionally, this 
case highlights that findings from exome sequencing may influence therapeutic 
management decisions. This has been reported for other families in the literature 
including giving high-dose riboflavin supplementation to a patient with mutations 
in ACAD9,364 making a definitive decision about allogenic stem-cell transplant in a 
patient with a mutation in X-linked inhibitor of apoptosis gene,365 starting patients 
with alpha-methylacyl-CoA racemase deficiency on phytanic and pristantic acid 
restricted diets,366 management of early infections and cancer screening in patients 
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with ATM mutations367 and initiation of riboflavin therapy in a patient with 
Brown-Vialetto-Van Laere syndrome.368 
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CHAPTER 7. CONCLUSIONS AND 
FUTURE DIRECTIONS 
My PhD research focused on the use of WES to dissect the aetiologies of Mendelian 
forms of Parkinson’s disease and Dystonia. Through the work on the families 
presented herein in this thesis I have been able to appreciate the strengths, pitfalls 
and challenges of WES. I have demonstrated successes in identifying the causal 
variant in autosomal dominant Parkinson’s disease (chapter 4), autosomal 
recessive generalised parkinsonism syndromes (chapter 5), and autosomal 
recessive generalised dystonia (chapter 6). I have also presented examples of 
failures of WES in autosomal recessive early-onset Parkinson’s disease (chapter 5), 
and autosomal recessive generalised dystonia (chapter 6). Additionally I used 
Sanger sequencing to confirm that mutations in VPS35 are a cause of autosomal 
dominant Parkinson’s disease (chapter 3). I will briefly summarize the major 
findings of these projects and highlight out future directions: 
 
VPS35 Screening in a Parkinson’s Disease Cohort (Chapter 3) 
VPS35 was the first Mendelian gene to be shown to cause PD using next-
generation sequencing technologies. As with all genes identified by WES, it is 
important that replication studies are performed to confirm the finding in 
ethnically diverse populations, and to determine whether other mutations that 
those reported in the initial study are pathogenic. We screened a large UK PD 
series for mutations in VPS35. We identified one large kindred with the already 
reported pathogenic VPS35 mutation. The kindred had highly penetrant autosomal 
dominant PD, which was similar to idiopathic PD.  
 
Whole Exome Sequencing in Autosomal Dominant Parkinson’s Disease (Chapter 4) 
In this family I identified a novel mutation in DCTN1 as the cause of the autosomal 
dominant Parkinson’s disease. This family serves as a good example of how WES, 
without the use of linkage analysis, was able to identify the cause of disease in a 
family with autosomal dominant neurodegenerative disease. Furthermore it 
widens the recognized phenotype associated with Perry Syndrome. 
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Whole exome Sequencing and Autozygosity Mapping in Autosomal Recessive 
Parkinsonism Disorders (Chapter 5) 
 
In family 1, I was unable to identify the causal variant for autosomal recessive 
Parkinson’s Disease in a consanguineous kindred with PD, despite the use of 
autozygosity mapping which significantly reduced the genomic regions to be 
considered. Several candidate variants were identified, however, screening of a 
large series of early-onset PD patients did not reveal another patient with 
homozygous or compound heterozygous mutations in the exon in which the 
variant occurred in the candidate genes. This family demonstrate one of the 
limitations of WES, namely that in small families WES and mapping strategies may 
still leave several candidate variants and that identifying the pathogenic variant 
may require large scale screening, which will be best done using targeted NGS 
panels. It is possible that the causal variant was not identified due to a number of 
technical or analytical reasons. 
 
In family 2, I was able to identify the cause of a complicated parkinsonian 
syndrome in a singleton case using a combination of WES and autozygosity 
mapping. This demonstrated the utility of WES as a timely method to 
simultaneously screen several genes that can cause juvenile onset complex 
parkinsonian syndromes.  
 
In family 3, the causal variant in a small non-consanguineous family with early-
onset PD was not confidently identified using WES and genome-wide linkage 
analysis. The finding of a novel, predicted pathogenic variant in LRRK2, which 
segregated with the disease in the family, brought into question the mode of 
inheritance in the family.  
 
Whole exome sequencing in autosomal recessive generalised dystonia (chapter 6) 
In family 4, two genomic regions were shown to be linked with a complex 
phenotype of autosomal recessive generalised dystonia and spastic paraparesis. 
WES several heterozygous variants within the linkage regions, however, none 
were felt to be causal. The analysis in this family was complicated by non-paternity 
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and the fact that the phenotype could result from two separate genetic aetiologies. 
The family will be a good candidate for whole genome sequencing.   
 
In family 5, WES and autozygosity mapping revealed a novel nonsense ALS2 
mutation as the cause of generalised dystonia and upper and lower motor neuron 
signs in two siblings. This work widens the known phenotypic spectrum in 
association with ALS2 related disease. 
 
In family 6, autozygosity mapping and WES in a consanguineous family revealed a 
novel GCDH mutation as the cause of progressive generalised dystonia in singleton 
case. This revised the original diagnosis in the index case and furthermore changed 
the management of the patient with institution of dietary measures to prevent 
further neurological relapse.  
 
Future Directions 
In two of the families presented in this thesis, WES has widened the known 
phenotype associated with a Mendelian genetic disorder (families with DCTN1 and 
ALS2 mutations). Other examples of widened phenotype spectrum using WES 
include the identification of VCP mutations and TDP-43 pathology in a family with 
autosomal dominantly inherited amyotrophic lateral sclerosis.34 Prior to this VCP 
mutations had only been associated with families with Inclusion body myopathy, 
Paget’s disease and Frontotemporal dementia. Mutational screening of VCP in 
additional familial ALS samples suggested that VCP mutations may account for 
~1-2% of familial ALS. This work implicated defects in the ubiquitin/protein 
degradation pathway in motor neuron degeneration for the first time. These 
examples show that broadening the phenotype associated with mutations using 
next-generation sequencing has the potential to provide information on the 
aetiological basis of disorders by uniting what is known about the biological 
underpinnings of apparently unrelated disorders into a single model.  
 
Most of the successes of WES have been in studies on rare Mendelian disorders, 
caused by variants in high penetrance segregating in families. In the near future, 
the power of WES used together with mapping strategies should enable the 
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identification of genes underlying a large fraction of Mendelian disorders that are 
currently unsolved.  
 
 
 
The work on family 1 and 3 illustrates a problem of narrowing the list of candidate 
variants from WES data in families from ethnicities that are not well represented in 
control population databases such as Exome Variant Server. Results from the 1000 
Genome project have revealed the differences in the numbers of known and novel 
variants in Europeans, Asians and Africans.369 In assessing the effects of rare 
variants, it is important to consider the allele frequency of the variant in ethnically 
matched individuals in relation to the disease frequency in that particular ethnic 
group. For patients from ethnicities underrepresented in control databases, 
filtering of candidate pathogenic variants for a rare Mendelian disorder on the 
basis of their absence from public databases is insufficient, sequencing of a 
sufficient number of unaffected individuals from the same ethnic group is needed 
to determine if a variant is a rare benign polymorphism or potentially causal. 
Expansion of these control databases to include data from different ethnic groups 
will greatly aid gene discovery.  
 
It is not clear yet what proportion of Mendelian disorders are caused by mutations 
in the non-coding part of the genome, as previous estimates are likely to have been 
skewed upward by protein-centric studies. The next challenge in Mendelian 
disease research will be to systematically study the role of variation in the non-
coding part of our genome in health and disease. Estimates of the success of WES 
are in the large part absent from the literature as negative studies tend not to be 
published, however, at a large groups working on rare Mendelian disorders have 
estimated their success rate at 60-80%.370  
 
It is likely that WGS will be able to reveal the genetic cause of families that have 
not been solved with WES. This is because WGS does not have the problem of 
‘missing exons’ as a result of incomplete capture, variants in highly conserved non-
coding regions can be readily explored for unexplained cases and WGS covers the 
non-coding genome (intronic and intergenic) and allows better detection of CNVs. 
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As the cost of next-generation sequencing continues to fall, the field will move 
from whole-exome to whole-genome sequencing. However, taking advantage of 
these more comprehensive data for disease gene discovery and molecular 
diagnostics in patients crucially depends on the development of analytical 
strategies for making sense of non-coding variation. Renewed effort in several 
areas is likely to help additional gene identification by exome and whole-genome 
sequencing. Firstly, there needs to be proper curation of phenotypes, particularly 
in the context of Mendelian disorders. Secondly, there is a need for improved 
technical, statistical and bioinformatics methods for reducing the rate of false-
positive and false negative variant calls; calling indels; prioritizing candidate 
causal variants; and predicting and annotating the potential functional impact for 
disease gene discovery or molecular diagnostics. Identifying novel genes or 
candidate genes for autosomal recessive and autosomal disorders is a realistic goal 
presently, however narrowing down candidate gene lists is likely to require 
unprecedented cooperation and coordination in Neurogenetics, with the 
development of large consortia groups for data sharing and with sophisticated 
approaches to conduct candidate prioritization and screening in replication 
cohorts.  
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